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Abstract
A large multi-gene family encodes many different phosphodiesterase (PDE) enzymes 
with alternative mRNA splicing generating additional complexity. This thesis details the 
discovery and cloning of two new PDE4A cyclic AMP specific phosphodiesterases. 
These two enzymes have been named hRDl (HSPDE4A1) and PDE4A10. hRDl is a 
PDE4A short-form and PDE4A10 is a PDE4A long-form. Previous to this study only a 
single active PDE4A short-form from rat RDI (RNPDE4A1A) had been cloned and two 
active PDE4A long-forms, namely PDE4A5 (mammalian and rat) and PDE4A8 (rat). 
Reverse transcriptase PCR analysis carried out in a previous study had indicated that 
RDI homologues were conserved across species and sequencing of the HSPDE4A gene 
revealed the existence of tlie human homologue. The sequencing study located the 5' 
exon encoding the unique N-terminal region of the human homologue of tlie rodent 
isoform RDI and also the splice jimction used to produce tliis short-form. The work 
carried out in tliis tliesis details how this information was used to clone the human short- 
form hRDl as both the sequence encoding the unique N-terminal and the position of tlie 
sphce junction had both been revealed.
The open reading frame encoding liRDl (HSPDE4A1A, GenBank U97583) was 
engineered for expression in the plasmid pcDNA3 (Invitrogen) and this was transiently 
expressed in COS-1 cells. The mature hRDl protein was detected as an 83kDa species, 
the majority of which was associated with the high-speed membrane fraction. The kinetic 
propeities of this enzyme were also investigated and hRDl displayed a Km for cAMP of 
around 3 pM, an IC50 value for inhibition by the PDE4-selective inhibitor rolipram of
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around 0.3 pM and tlie thermostability of the enzyme was found to be considerably more 
tiiermostable than rat RDI. The membrane binding capability of the enzyme was also 
investigated. Tliis was done by generating human RDI as a mature 80kDa species in an 
in vitro transcription-translation system which displayed the ability to bind to COS-1 cell 
membranes.
The data from these experiments showed that the rat and human homologues displayed 
very similar properties, particularly their intracellular location. Km for cAMP and 
sensitivity to rolipram inhibition. They displayed marked differences in their 
thermostability which may be a result of conformational differences between tlie proteins 
in regions outside of their active sites.
The human PDE4A long-form PDE4A10 was cloned initially by Graham Rena in this 
laboratory. The sequence for the unique N-terminus of this isoform was based on a rat 
cDNA containing sequence which indicated a novel N-terminus. Existence of the human 
homologue was confirmed by reverse transcriptase analysis which detected PDE4A10 in 
human cell lines. Furtlier sequencing of human cosmid clones containing HSPDE4A 
sequence confirmed the sequence and also revealed tlie position of the PDE4A10 splice 
junction.
This thesis details how PDE4A10 was engineered for expression studies. The construct 
which was originally engineered apparently contained tliree potential in-fiame initiating 
metliionines (ATG). This study defined the native AT G of PDE4A10 and a construct was 
engineered in the plasmid pSV-SPORT for expression in COS-1 cells. The mature 
PDE4A10 protein was detected as a species of around 125kDa on traditional 8% cross- 
linked SDS-polyacrylamide gels. This was very similar to the other PDE long-foim
13
PDE4A4B (PDE46) and tlie difference in molecular weight between these two proteins 
could only be resolved on a pre-cast Tris-Acetate 3-8% polyacrylamide gel system 
(Novex). Using this system the calculated molecular weight of PDE4A10 was now 
around 120kDa compared to 125kDa for PDE4A4B calculated using the same system.
The majority of PDE4A10 expressed in COS-1 cells was detected in the cytosolic 
fraction and the majority of PDE4A10 activity was also found in the cytosohc fraction. 
Kinetic studies revealed that the enzyme displayed a Km for cAMP of around 4 pM and 
an IC50 value for inhibition by the PDE4-selective inhibitor rolipram of around 0,3-1 pM 
in the membrane fractions and aroimd 0.02 pM in the cytosohc fraction.
14
CHAPTER 1
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1.1 Brief introduction to PDEs
Cyclic nucleotide phosphodiesterases (PDEs) play a key pivotal role in intracellular 
signalling as they provide the sole route for hydrolysis and tlius inactivation of the 
ubiquitous second cell messenger cAMP and cGMP. Certain PDEs can hydrolyse both 
cAMP and cGMP whüe others are specific for one or the other.
PDEs are encoded by 19 different genes in mammals (Conti and Jin 1999; Conti et a l, 
1995; Beavo 1995; Fisher et al., 1998a, Fisher et al., 1998b; Soderling et al., 1998). 
However, further complexity arises fi’om the rearrangement of the transcriptional units 
within each gene - so-called alternative mRNA splicing - giving the nmnber of PDEs 
produced around 50 (Conti and Jin 1999; Muller et a l, 1996). This gives rise to a vast 
range of similar proteins with subtle but cmcial differences in tlieir structural and 
functional properties (Beavo et al., 1994; Bentley et a l, 1992; Butt et a l, 1994).
Individual PDEs can be categorised according to tlieir properties such as their apparent 
molecular mass, substrate specificity (K m ), immunological reactivity, sensitivity to 
synthetic inhibitors (IC50) and mode of regulation (Barnett et al., 1995; Bolger, 1994; 
Charbonneau et al., 1986; Yan et a l, 1996; Yan et al, 19950). But their basic function in 
each different cell type remains the same and that is to regulate the level of cAMP or 
cGMP available in the cell which is able to activate cychc nucleotide-dependent protein 
kinases (PKA). These, in turn, initiate multiple cellular events, (Kemp et al., 1975; Walsh 
et al, 1994) by phosphorylation of target substrates.
The diagram below in figure 1 shows an overall scheme of where PDEs fit into the 
general signal transduction patliway within mammalian cells. The generation of the first
signal (cAMP) in response to extracellular stimuli at the cell surface in the form of 
neurotransmitters, hormones, phospholipids, photons, odorants, certain taste ligands and 
growth factors (Gutkind, 1998; Ji et a l, 1998) will be discussed in the next section.
our
IN ADENYLYL CYCLASE
ATP
S’-AMP ^ cAMP
Hydrolysis by PDEs
f
+ve feedback
cyclic nucleotide 
gntcd ion channels EPAOGEF\
Raplb
/  \
T
Phosphorylation of target proteins
Figure 1. Intracellular regulation o f cAMP by phosphodiesterases. This figure 
outlines the way in which PDEs interact with intracellular signalling once a signal has 
been detected at the cell surface and transduced via G-protein-coupled receptors 
resulting in the formation o f cyclic AMP. cAMP is able to exert its effect on cAMP- 
dependent protein kinase A, as well as EPAC, cAMP-GEF and cyclic nucleotide gated
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ion channels, which then triggers many events within the cell. The hydrolysis o f cAMP by 
PDEs is the mechanism by which these events are regulated and the cAMP signal is 
attenuated or switched off.
1.2 Generation of the second messenger cyclic nucleotide (cAMP)
The molecule 3', 5'-cychc monophosphate (cAMP) was discovered in the 1950s by 
Sutherland and his co-workers (Sutherland and Rail 1957). Generation of cAMP is the 
ubiquitous intracellular response to many stimuli at the cell surface. These stimuli are 
detected by a vast range of receptor molecules which span the cellular membrane. These 
receptors generally consist of seven transmembrane domains and are referred to as 7TM 
receptors or GPCRs, G-protein coupled receptors (Houslay and Milligan 1997; Mitzobe 
et al. 1996).
Stimuli in the form of certain neurotransmitters or honnones are able to activate specific 
members of the 7TM receptor family and this triggers an interaction between the receptor 
and the G-protein linked to it on the intracellular surface of the membrane (Gutkind 
1998). In the case of ligands that increase cAMP levels their occupied receptors 
specifically interact with the guanine nucleotide regulatory protein Gs and allow this G- 
protein to exchange GDP witli GTP. This causes a conformational change in the G- 
protein that results in the dissociation of the GTP-bound a - G s  subunit and also release of 
the py complexes. The GTP-bound fonn of a-Gs then stimulates the transmembrane 
enzyme adenylyl cyclase. It is adenylyl cyclase that generates cAMP fi’ora ATP (Cooper
18
1998; Hanoime et a l, 1997; Simahara et al., 1996; Tang and Hurley 1998; Xia and Storm
1997).
The formation of cAMP requires various changes in the molecule ATP. Specifically the 
3-hydroxyl group on ATP must be deprotonated in order to be activated. This makes it 
susceptible to nucleophihc attack which stabilises the transition state at the a-phosphate. 
This also confers stabilisation of increased negative charge on tlie leaving group 
pyrophosphate (Hurley 1999).
The structure and function of the ATP binding site of adenylyl cyclase has been revealed 
by P-site (phosphorylation site) inhibitor complex studies. Tliese showed that a single 
Mg^^ ion was capable o f interacting with botli phosphate moieties of pyrophosphate and 
the ATP binding site was found to be made up of two Asp residues which are 
mutationally sensitive (Liu et al. 1997; Tang et al. 1995; Tesmer et al. 1997; Yan et al.
1997). This provides evidence for a two ion mechanism (Pieroni et al. 1995; 
Zimmermann et al. 1998) whereby one ion acts kinetically as free Mg^^ and the other 
binds in a complex with ATP.
There is a model for tliis interaction based on a similar situation in the DNA polymerase 
family. In Üiis case two ions bind to DNA polymerase-primer-template-nucleotide 
complexes (Kiefer et a l 1998; Steitz 1998) showing how tlie two ions may be 
coordinated in the adenylyl cyclase active site. The ion observed in the adenylyl cyclase 
active site corresponds to the "B" metal ion in the polymerase and it binds all three 
nucleotide phosphates with tight interactions (S away a et a l  1997) which strongly 
suggests that this ion acts as the kinetically active ATP complex.
The metal ion A is less tightly boimd in the adenylyl cyclase structure (Doubhe et a l
19
1998) and interacts with die 3'-hydroxyl group and the nucleotide a-phosphate and both 
ions share in transition state stabihsation. Both of these metal ions are coordinated by 
Asps in the Mg^^ binding site and it is possible that the Asp-354 in the adenylyl cyclase 
or its equivalent in DNA polymerase may in these reactions act as a general base.
1.3 G-protein coupled receptors (GPCRs)
GPCRs are membrane-spanning proteins consisting of seven transmembrane domains. 
They have also been referred to as 7TM receptors (Baldwin et al. 1997; Unger et al.
1997). A vast anay of these receptors exist, widi more than 2000 GPCRs documented 
since 1986 (Dixon et al. 1986). They can be broadly classified by the type of molecule 
which they are able to bind and detect. They are also classified into more than 100 
subfamihes based on their receptor fiinction, ligand structure and sequence homology.
As mentioned above, GPCRs bind and detect the presence of many different molecules. 
These include biogenic amines, nucleosides, eicosanoids, and moieties of lipids 
(lysophosphatidic acid and spliingosine 1-phosphate), glycoprotein hormones, LSH, FSH, 
human CG, and TSH plus small neurotransmitters like Ca^^, glutamate and GAB A (Ji et 
al. 1998), as well as protease ligands such as thrombin.
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N-Terminal Segment
Exoloop 2
Exoloop 3Exoloop 1
Cytoloo | | 4
Cytoloop 2
Cytoloop 3
Cytoloop 1
C-Terminal Segment
Figure 2. Basic structure o f GPCRs showing the N-terminal segment, seven TM 
domains, which form the TM core, three exoloops, four cytoloops and a C-termmal 
segment. Signals can he generated by cleavage o f the N-terminal segment, the remainder 
o f which then interacts with exoloops to generate a signal. Other molecules bind to the N- 
terminal segment and the liganded N-terminal segment interacts with exoloops to 
generate a signal. Smaller molecules hind to the N-terminal segment and the liganded N- 
terminal segment interacts with the membrane-associated domain, generating a signal. A 
fourth cytoloop is formed when the C-terminal segment is palmitoylated at Cys. Adapted 
from Ji et al. 1998.
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Figure 2 shows the basic structuie of GPCRs. This consists of an extracellular N-terminal 
segment, seven transmembrane domains forming the TM core, three exoloops, four 
cytoloops and a C-terminal segment. The seven transmembrane sections are each made 
up of around 20-27 amino acids. However, the various loop and N- and C-terminal 
sections of the receptors vary widely in their size. It has been proposed that the length of 
the N-terminal segment correlates to the size of hgand which it can bind (Ji et al. 1995).
All GPCRs adopt the same basic seven TM structure, with N- and C-terminal segments 
on opposite sides of the membrane, allowing glycosylation and ligand binding at the N- 
terminal segment and phosphorylation and palmitoylation at the C-terminal segment, 
which allows for desensitisation and internalisation of the receptor (Lefkowitz 1998).
GPCR agonists are capable of conformational changes which are part of the mechanism 
by which signals are transduced and are able to be relayed to the G-proteins which are 
coupled to the receptors. Recently GPCRs have been shown to be capable of activating 
G-proteins in the absence of agonist and this capability is enlianced by mutations in 
structural domains of the receptor, presumably acting in the same way as but instead of 
conformational changes normally triggered by agonist binding (Altenbach et al. 1996; 
Chidiac 1994; Farrens et al. 1996; Samama et al. 1993; Wess 1997).
The seven TM domains are able to orientate themselves in different ways in the 
membrane so as to offer maximal diversity for ligand binding. Tliis also provides 
different mechanisms for binding. One example concerns the binding of lysophosphatidic 
acid wliich has a fatty chain associates with it. If TM domain 7, which is normally 
apposed to TMs 1 and 2 (Sealfon et al. 1997), is orientated more closely to TM 2 than
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TM 1 then this opens up a long crevice between TMs 1 and 7 which creates a binding site 
for such a molecule.
Other types of agonists bind to the receptor in a similar way, using various regions of the 
different TM domains. Receptor activation can be tliouglit of a three step process. The 
first step is signal generation, then TM signal transduction and finally signal transfer to 
signalling molecules (G-proteins) at the cytosol surface of the plasma membrane (Ji et al.
1995). TM domain hydrogen bonds play the major part in this process. In this way the 
ligand binds and generates a signal which is transduced through the TM core (Ji et al.
1998).
One example of this involvement of hydrogen bonds in the TM domains is the way in 
which photoactivation of retinal affects configuration of tlie receptor. This causes the 
kinked conformation to straighten which in turn changes the packing of TMs 3 and 5-7 
through rearrangement of the hydrogen bonds. In the case of some receptors it has been 
fairly easy to establish that ligand binding and signal generation are separate occuirences 
taking place at different TM domains. For example in biogenic amine receptors TM3 is 
thought to be tlie primary site for ligand binding with signal generation occurring 
primarily at a different locations on TMs 5 and 6, although tliese processes in other 
receptors can be difficult to distinguish (Ji et al. 1998).
Another group of agonists which trigger signalling in a different way using different parts 
of the GPCR structure are the glycoprotein hormones, LH, FSH, CG and TSH which are 
the largest and most complex of the GPCR agonists. They bind firstly only to the N- 
terminal domain with high affinity which then undergoes a conformational change (Ji et 
al. 1995) and a signal is generated through secondary interactions with the membrane-
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associated domain. The first high affinity interaction involves both the common a- 
subimit and the hormone-specific p-subimit of the glycoprotein coming into contact with 
the N-terminal segment of the receptor (Dias et al. 1998; Grossmann et al. 1997). Signal 
generation, however, takes place at the exoloops as secondary binding occurs between the 
liganded N-terminal segment and exoloops 1-3 (Remy et al. 1996; Ryu et al. 1998). 
Interestingly it has been shown that mutations occurring in these exoloops can actually 
lead to constitutive activation of the receptor confirming their role in receptor activation 
(Parma et al. 1995).
There is a basic model for GPCR agonist activation which is called the ternary complex 
model (Gether and Kobilka 1998). This helps to explain why so many different classes of 
agonists (full, partial, neutral and inverse) are able to have an effect on the receptor 
signalling through GPCR interactions with the G-protein. The model proposes that the 
receptor exists in a state of equilibrium between the inactive (R) and active (R*) state and 
the agonist effect depends on its abihty to alter this state (Kenakin 1997). The active state 
R* is also the conformational state in which tlie receptor is capable of activating G- 
proteins.
The ways in which conformational changes can be induced are various. For several non- 
GPCR receptor families, including receptor tyrosine kinases and the growth hormone 
receptor family, agonist-induced receptor dimérisation is required for signal transduction 
(Wells, 1996). In the case of GPCRs recent evidence has suggested that they can also 
form dimers which indicates tliat dimérisation may also be a part of the activation process 
(Cvejic and Devi 1997; Herbert et al. 1996; Romano et al. 1996). Protonation also plays a 
role in receptor activation. In tlie case of the rhodopsin GPCR family they have a highly
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conserved DRY motif at the cytoplasmic side of TM3 (Probst et al. 1992). The arginine 
in this motif (ArgIII:26) is usually conserved and is held in a hydrophilic pocket by polar 
residues conserved in TMs 1, 2 and 7. Receptor activation may occur through protonation 
of AspIII:25 vyhich causes ArgIII:26 to become exposed to the cytoplasm as it moves out 
of the polar pocket.
Previously hidden sequences in the second and third intracellular loops are now exposed. 
The mechanisms above lend support to the theory of the active (R*) state of the enzyme, 
in which its conformation has changed causing activation. This also implies that the 
GPCRs must have stable intramolecular interactions in order to remain in an inactive (R) 
state. Indeed small mutations such as one in the C-teiminal region of the third 
intracellular loop can lead to a large increase in agonist-independent receptor activity 
(Lefkowitz et al. 1993).
A startling array of complexity and adaptation is displayed by the GPCRs and this is only 
the first level of cellular signalling, the detection stage. The next section will discuss the 
second stage in signal transduction where signals received by the GPCRs are relayed onto 
the G-protein, die first stage of signalhng within the cell.
1.4 G-proteins
As seen in die previous section, signals arriving at the exterior of the cell are detected by 
receptors coupled to G-proteins. These proteins are heterotrimeric and they relay signals 
from the receptors and transform them into intracellular responses.
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G-proteins are made up of several subunits, a , p and y and many gene products are 
known to encode each subunit. The G-proteins fall into three distinct classes based on 
their activities within the cell and these are; Gg, which activates adenylyl cyclase, Gi, 
which inhibits adenylyl cyclase and Gq, which activates phospholipase C. Two other G- 
protein groups are known to exist (G12 and G n) but their functions are not known (Hamm
1998).
When G-proteins are in Üieir inactive heterotrimeric state tliey bind GDP. They become 
activated when the receptor catalyses a reaction involving guanine nucleotide exchange 
which leads to GTP binding to the a  subunit. GTP binding causes the dissociation of the 
a  submit (with the GTP bound to it) from the rest of the G-protein molecule, the p and y 
subunits (Lambright et al. 1994; Lambright et al. 1996). These two separate units, the 
GaGTP and the Gpy, are now both able to exert downstream effects. The G a has 
intrinsic GTPase activity and hydrolyses tlie GTP back to GDP causing desensitisation. 
The speed of this reaction becomes the rate limiting step in attenuating cellular responses 
to G-proteins.
G a subunits consist of two domains. The G domain is structurally identical to the 
superfamily of GTPases including small G-proteins, and is involved in binding and 
hydrolysing GTP and tlie imique helical domain buries tlie GTP in the core of the protein 
(Hamm et al. 1998). The core of the a  submit contains tlie catalytic core that contains the 
gaunine nucleotide-binding site which is able to bind and hydrolyse GTP to GDP. It 
consists of 5 a  hehces surrounding a 6 -stranded p-sheet and contains the consensus 
sequences involved in GTP binding that bind the phosphate group and guanine ring of 
GTP. The core also contains a binding consensus site for Mg^ "^  which is essential for
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catalysis (Sprang 1997).
The p-subunit of G-proteins has an N-terminal helix followed by a repeating 7-membered 
p-propeller stmcture based on its 7 WD repeats (Lambriglit et al. 1996; Sondek et al.
1996). Each of the seven similar p-sheets consist of four antiparallel strands which make 
up one propeller. The y-subunit is made up of two a  helical structures witli no inherent 
tertiary structure. Interaction with the P-subunit occurs through die N-terminal helix of 
the y-subunit which forms a coiled-coil with the N-terminal helix of the P-subunit. The 
remainder of the y-subunit makes extensive contacts all along the base of the P-subunit 
(Lambright et al. 1996; Sondek et al. 1996).
The P- and y-subiuiits together form a fimctional unit that only becomes dissociated by 
dénaturation. When the G-protein is activated by receptors this causes GTP binding on 
the Ga-subunit to occur. There is a GTP-mediated switch on the Ga-subimit whose 
structural nature causes a conformational change of three flexible regions, referred to as 
Switches I, II and III to a well ordered, GTP-bound activated confonnation. This has a 
lower affinity for the Gpy-subunit (Lambright et al. 1994). The GaGTP now has 
increased affinity for effectors and subunit dissociation which leads to the generation of 
free Gpy which is now able to activate effectors.
Many studies have focussed on determining which parts of the G-protein interact witii the 
receptor. Two possible sites of membrane interaction have been discovered in the N- 
teiminal region of the a-subunit and the C-terminal region of the y-subimit. These regions 
are lipidated (Resh 1996) and relatively close together in the heterotrhner and evidence 
exists tliat all tliree subunits possess good receptor contact areas.
The C-terminal region of the Ga-subimit has been particularly well studied and
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mutagenic analyses have shown that the C-terminus of the tliird extracellular loop of 
receptors is capable of binding to the C-terminus of the Ga-subunits (Martin et al. 1996; 
Sprang, 1997).
Mutational analysis of the p-subunit has shown that mutations in residues tliat make 
contact with the a-subunit causes a block in receptor-mediated GDP-GTP exchange. This 
provides evidence that the py-subunits of the heterotrimeric G-protein are required to 
enhance receptor interaction with the a-subunit and suggests that the y-subunit must be 
holding the a-subunit in place for GDP release to occur. Indeed one particular region of 
tlie G-protein, the C-terminal region of the y-subunit has been shown to be involved in 
receptor coupling and specificity (Kiesselev et al. 1995; Yasuda et al. 1996).
When the three subunits, the a-subunit (1) and the Py-subunit (2 and 3), of the 
heterotrimeric G-protein dissociate upon GTP binding to the a-subunit the G-protein is 
now in its active state and a new surface becomes available on die Ga-subimit (Skiba et 
al. 1996). These submits are now able to interact with effectors with a gready increased 
affinity (20-100 fold higher) througli these particular surfaces than in their GDP-bound 
state. These surfaces on die Ga-subunits also display remarkable specificity for effector 
interaction (Skiba et al. 1996).
The Gpy once separated fi"om the GaGTP is capable of activating many proteins 
(Clapham and Neer 1997). These include some isoforms of second messenger enzymes 
such as PLCp2 and -p3 (Morris and Scarlata 1997) and adenylyl cyclase, certain G- 
protein-responsive K^, Ca^^ and some Na^ charnels (Sclmeider et al. 1997), more than 
one phosphatidylinositol 3-kinase isoform (Tang and Downes, 1997) and has also been 
reported to bind to members of the Rho family of GTPases, Rho and Rac (Harhammer et
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al. 1996).
There is evidence that Gpy interactions with effectors may occur through the G a binding 
site as the Gpy conformation when free is die same as it is in the G-protein heterodimer 
(Sondek et al. 1996). This also imphes that G a is able to inhibit the action of free GPy 
through binding to the G a binding site on Gp (Chen et al. 1995; Chen et al. 1997). Other 
regions that may be involved in effector interactions include die N-terminal coiled coil 
(Pellegrino et al. 1997) and blades 1 and 7 of the p-propeller of Gp (Bliiml et al. 1997).
1.5 Adenylyl cyclase
Adenylyl cyclase is the molecule which is able to generate cAMP from ATP. There are 
nine isoforms of adenylyl cyclase, two of these have splice variants. The various adenylyl 
cyclase famihes and the effects of various regulators on them can be seen in figure 3.
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Adenylyl cyclase Sphce Variants Chromosomal location
AC-I 7pl2-7pl3
AC-II 5pl5.3
AC-in 2p22-2p24
AC-IV 14qll.2
AC-V 2 3ql3.2-3q21
AC-VI 2 12ql2-12ql3
AC-VII 16ql2-16ql3
A C -vni 8q24.2
AC-IX unknown
Figure 3. The different isoforms o f adenylyl cyclase and the two splice variants 
which belong to families V and VI. Also shown are the chromosomal locations o f  each 
adenylyl cyclase isoform.
All adenylyl cyclase molecules share a basic primary structure. This consists of two 
transmembrane regions named Mi and M2 and there are two cytoplasmic regions C] and 
C2 (Hurley 1999; Knipinski et al. 1989; Taussig and Gilman 1995). Figure 4 below, 
shows a diagi'ammatic representation of these subunits which make up adenylyl cyclase 
and their position witliin the cell membrane.
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First transmembrane cluster Second transmembrane cluster
Major giycosylation site
ExtraccUulai*
Intracellular
First intracellular 
loop
BY-syiiergisiiig site (AC-II)
CaM kinase II 
Regulatory site (AC-III)
Second intracellular loop
Forskolin 
binding sites
Figure 4. Relative positions o f  the subunits making up the basic structure o f 
adenylyl cyclase. There are two transmembrane subunits, Mj and M 2 which are each 
made up o f six helices, and two cytoplasmic regions Cj and Cj. The active site is 
contained within the cytoplasmic regions. The regulatory elements are also situated in 
this region including the CaM (Calmodulin) regidatory region which is situated next to 
the cytoplasmic domains. Diagram adaptedfrom Houslay and Milligan 1997.
The transmembrane regions are each made up of six membrane-spanning hehces and
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their function, other than to locate the molecule in the membrane, is unknown. They do, 
however, show similar topology to some membrane transporters although none of the 
mammahan isoforms of adenylyl cyclase have been shown to display this type of activity 
(Sunahara et al. 1996).
There is a high degree of homology shown in the cytoplasmic regions between tlie family 
members and more variation is seen in the transmembrane helices between families 
(Houslay and Milligan 1997). The active sites of the enzyme are contained within the 
cytoplasmic domains. These two regions Ci and C2 are botli subdivided into two units, a 
and b (Cia, Cib and C2a, C2b). The subunits Cu and C2a are highly homologous to each 
other, contain all of the catalytic domain and are able to heterodimerise with each other in 
solution (Tang and Gilman 1995; Whisnaut et al. 1996; Yan et al. 1996) leading to 
reconstitution of tlie enzyme activity.
The region Cib is faiily large, aroimd 15kDa, and is thought to contain several regulatory 
domains, whereas the C2b region is extremely small and has no identified function to date. 
Structural analysis of adenylyl cyclase type II has revealed that the C2 region is formed of 
two C2 monomers making a homodimer of a circular shape with ventral groove between 
the two monomers. There are two forskolin binding sites witliin tliis ventral groove of the 
homodimer (Zhang et al. 1997). Forskolin can bind to and activate all forms of adenylyl 
cyclase except type IX. Many mutagenesis studies have shown that tlie adenylyl cyclase 
active site, i.e. the ATP binding site, must be located within this ventral groove and two 
particular residues (Asnl025 and Asn 1029) have been shown to be critical for enzyme 
activity (Tang et al. 1995; Yan et al. 1997; Tucker et al. 1998).
Another region of the adenylyl cyclase molecule which has been implicated as playing a
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role in ATP binding is the carboxyl terminal. It may be that this region has a regulatory 
influence on the binding. It was not possible to deduce the crystal structure of this region 
at the same time as the C2 structure was resolved but this suggested that the C-terminal 
region was disordered and became more ordered upon ATP binding to the catalytic site 
(Zhang et al. 1997). It has been proposed tliat the C-terminal region forms a flap or a Ud 
when it is bound in the catalytic site and in this position it is able to exert a regulatory 
influence on catalysis.
Other molecules are known to play a role in regulation of mammalian adenylyl cyclase 
activity. They are strongly activated by Mn^^ and inliibited by very low (millimolar) 
concentrations of Ca^^. The activation of many enzymes is dependent on Mg^^ and this 
can often be replaced with Mn^^ resulting in the same effect. In tlie case of adenylyl 
cyclase tlie effects of the Mn^^ and Ca^^ ions are unlikely to have distinct physiological 
significance or reflect particular binding sites for these ions. A possible physiological 
inhibition of type V and VI adenylyl cyclase has been reported when Ca^^ is present at 
higher concentrations. In this case the free Ca^^ is binding competitively to the Mg^^ sites 
on the enzyme but does not activate it catalytically in the same way (Yoshimura and 
Cooper 1992).
Forskolin has also been shown to be a very strong activator of adenylyl cyclase. It binds 
to the catalytic core of the enzyme in tlie ventral cleft that also contains tlie active site but 
at the opposite end. It acts as glue using hydrophobic and hydrogen bonding to bind these 
two regions in tlie core together and activating the enzyme. Particular residues have been 
implicated in this binding as type IX adenylyl cyclase is unresponsive to forskolin. It was 
found to have a Ser to Ala and a Leu to Tyr change in the binding pocket. Wlien these
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sites were reversed by site-directed mutagenesis the resulting mutant of type IX is now 
activated by forskolin (Yan et al. 1998). It is also possible that an equivalent endogenous 
activator to forskolin exists but has so far not been discovered.
The GTP-bound G-protein a-subunit Gga is able to potently activate aU of the adenylyl 
cyclases and acts m the same way as forskolin does to bind the two regions Cl and C2 
together. This subunit must also have another function and studies have shown that it 
must be capable of inducing a conformational change stimulating catalysis (Yan et al. 
1997; Zimmermann 1998).
Ca^Vcalmoduin is also capable of activating type I adenylyl cyclase and is thought to 
bind to a helical region on tlie Cjb region. The specific mechanism is unknown but it may 
be interfering witli an autoinhibitory interaction in the catalytic core between the Cia and 
Cz domains (Vorherr et al. 1993; Wu et al. 1993).
Adenylyl cyclase can also be regulated by protein phosphorylation and protein kinase C 
has been shown to activate type II by phosphorylation at Tlir-1057. This particular region 
is known to contain a site which is required for protein kinase C activation. This 
phosphorylation site is at the edge of the carboxyl tenninal tail wliich upon ATP binding 
to tlie active site folds over it. It is thougli that phosphorylation may help tliis region to 
adopt die correct conformation for tiiis action (Bol et al. 1997; Levin and Reed 1995).
A region on the outer edge of the active site is phosphorylated by CaM kinase II at Ser- 
1076 and inhibits type III adenylyl cyclase by interfering directly with catalysis (Wei et 
al. 1996). Protein kinase A phosphorylates Ser-674 in the C ib region of type VI and may 
be regulating a low affinity secondary binding site for Gga (Chen et al. 1997). Type I 
adenylyl cyclase is phosphorylated by CaM kinase IV in the Cib domain which interferes
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with calmodulin binding sites therefore disabling the Ca^Vcahnodulin activation of the 
enzyme (Wayman et al. 1996). Figure 5 summarises the information above concerning 
which elements regulate which isofoims of adenylyl cyclase and the effects they have on 
them, whether they are positively or negatively influential on activation.
Adenylyl
Cyclase
Regulators Ca2+ G-prot
Py
G-prot
aGi
PKC PKA
AC-I + “ - ?
AC-II nc +(+aGs) nc + ?
AC-III +(+aGs) Nc ? + ?
AC-IV nc +(+aGs) nc nc/“ ?
AC-V - Nc - nc/+ -
AC-VI - Nc - nc/+ -
AC-VII nc + ? +(?) 7
AC-VIII + - ? ?
AC-IX - Nc ? ? ?
Figure 5. The effects o f  various regulators on the activity o f  different adenylyl 
cyclase isoforms. +, signifies increase in activity; - signifies decrease in activity; nc 
signifies no change and (+aGs) signifies synergy seen with aGs  ^ Table adapted from  
Houslay and Milligan 1997.
The resolution of tlie precise structure of the other adenylyl cyclase subunits will enable
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further mutational experiments to determine the exact nature of the various regulatory 
elements in the context of various stimulatory pathways.
The last few sections have looked at the many different elements which are influential in 
the production of cychc AMP by adenylyl cyclase. There aie many ways in which its 
activity can be regulated either directly or indirectly as a result of agonist binding to the 
GPCR and the effects of this on the G-protein which brings the ATP molecule into 
contact with the adenylyl cyclase. The next section will focus on the effects that the 
molecule cAMP has within the cell, the molecule wliich it is able to activate, and the 
resulting effects of signal transduction from the exterior cell surface.
1.6 Protein kinase A
Nearly all of the effects within the cell in response to extracellular signals which lead to 
tlie generation of cAMP are mediated through protein kinase A (PKA). Indeed the 
primary action of cAMP in eukaryotic cells is to activate PKA which is often described 
as being cAMP dependent. These proteins are tlie mediators of the actions of honnones 
and neurotransmitters which are detected at the cell surface by the GPCRs (Beebe and 
Corbin 1986; Edelman et al. 1987; Francis and Corbin 1994; Taylor et al. 1990). 
Fundamentally important physiological processes in cells which are regulated by PKA 
include synaptic transmission, ion channel and transporter activities, carbohydrate and 
lipid metabolism, cell growth and differentiation and gene transcription (Rubin 1994).
More than 300 protein kinases are now known to play cmcial roles in various aspects of
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cellular control (Walsh et a l 1994). Diversity within the protein kinase A group is created 
by the existence of tliree C subunit isoforms, a , p and y. The PKA holoenzymes 
containing the predominant C a and Cy isofonns show very slight differences in their 
kinetic profile with regards to cAMP sensitivity and very httle difference in their 
substrate speeificities and interactions with the cAMP binding R subunits of which there 
are two forms, RI and RII (Gamm et al. 1996; Scott et al. 1991; Taylor et al. 1990). It is 
the homodimeric R subunits which display greater variation with regards to cAMP 
binding affinity and locahsation within cells (Corbin et al. 1975).
PKAs, once activated, are able to phosphoiylate a wide range of cellular substrates wliich 
display serine or threonine residues in a particular context. These residues either have to 
be presented in the sequence context of Arg-Arg-Xaa-Ser/Thr or Lys-Arg-Xaa-Xaa- 
Ser/Thr (Dell'Acqua and Scott 1997; Kemp et al. 1977; Kemp and Pearson 1990). Many 
proteins display these particular sequence motifs so several regulatory mechanisms are in 
place to prevent indiscriminate phosphorylation and to ensure that botli cAMP levels and 
kinase activity are tightly controlled (Adams et al. 1991; Bacskai et al. 1993; Barsony and 
Marks 1990; Paws on and Scott 1997). Intracellular cAMP levels are conti'olled by a 
balance of adenylyl cyclases and degradation by cAMP phosphodiesterases. The cAMP 
concentration is further regulated in localised areas by signal-terminating mechanisms 
such as de sensitisation of adenylyl cyclase and compartmentahsed activation of cAMP 
phosphodiesterases (DellAcqua and Scott 1997).
PKA isofoims are heterotetramers composed of two regulatory subunits (R) and two 
catalytic subunits (C). The regulatory subimits maintain the catalytic units in an inactive 
state and it is also the regulatory subunits which bind cAMP (Corbin et al. 1973; Corbin
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and Keeley 1977; Potter et al. 1978; Potter and Taylor 1979).
Wlien the cAMP levels rise in response to extracellulai’ stimuli from hormones and 
neurotransmitters each R subunit binds two cAMP molecules. The previously inactive 
PKA holoenzyme dissociates upon cAMP binding (Su et al 1993, 1995) into an Rz- 
CAMP4 complex and active C monomers. The C subunits become active as dissociation 
from the R subunits alleviates an autoinhibitory contact (Gibbs et al. 1992; Wang et al. 
1991). Once the C subunit are activated the kinase is free to phosphorylate any residues 
which are presented in the protein sequence context mentioned earlier. When substrates 
are phosphorylated either their functional and / or structural properties are altered.
The active C subunits phosphorylate target proteins in the plasma membrane, cytoplasm, 
nucleus and other specialised aieas within tlie cell. From previous studies it has been 
shown tliat tlie se kinases were cytosolic enzymes as tlie majority of PKA activity is 
usually found to be associated with the soluble (cytosolic) fraction of cell and tissue 
homogenates. However, one particular protein, the rra«5 -acting, nuclear protein CREB is 
also dependent on phosphorylation by PKA C-subimits in order to elicit gene 
transcription (Gonzalez and Montminy 1984), but the PKA holoenzyme is not found in 
the nucleus. A mechanism involving rapid diffusion of activated C-subimits of PKA into 
intracellular compartments demonstrated how it was able to gain access to the nucleus 
(Gonzalez and Montminy 1984).
Both the active and inactive forms of CREB are boimd constitutively to DNA in 
chromatin so translocation of active C-subunits of PKA from the cytoplasm to the 
nucleus is an essential step in cAMP-controlled transcriptional activation (Hagiwara et al. 
1993). This was demonstrated by injecting C and R subunits, which had been coupled to
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fluorophores, into tlie cytoplasm of intact fibroblasts or neurons. Accumulation of the 
dissociated C subunits was observed in die nucleus whereas R subunits and holoenzyme 
remained in the cytoplasm (Adams et al. 1991; Backscai et al. 1993; Fantozzi et al. 1992; 
Meinkoth et al. 1990).
There are several ways in which the activity of PKAs is controlled. It is necessary to limit 
their activity as the motifs which they phosphorylate occiu relatively frequently in many 
proteins within the cell and inappropriate and unlimited responses would occur if no 
control mechanisms were in place. Control of PKA action starts widi factors relating to 
the level of second messenger available in the cell which is able to activate PKA in die 
first place. Adenylyl cyclase activity is controlled, for example dirough desensitisation, 
and the action of cAMP phosphodiesterases generates concentration gradients of cAMP 
within cells (Beavo et al. 1994; Tang and Gilman 1992). Otiier ways in wliich cAMP 
gradients are determined in cells are due to localisation of both phosphodiesterases 
(PDEs) and the PKAs themselves. PDEs are found to be localised to discrete areas of the 
cell and so are able to establish localised cAMP gradients within the cell (Cooper et al. 
1995; Mons et al. 1995; Shakiu et al. 1993; Smith et al. 1996).
The idea that PKAs may be localised and able to sample cAMP gradients at distinct 
points was fust shown when Lohman and co-workers discovered a novel protein from 
neurons which binds RII isoforms witli high affinity in the early 1980s (Lohmann et al. 
1984). The binding proteins copurified with RII after affinity chromatography on cAMP 
sepharose and were thought to be contaminating proteins until many of them were shown 
to retain their ability to bind RII after irmnobilisation on nitrocellulose filters (Lohmann 
et al. 1984). A slight variation of this technique became the standard method for
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identifying PKA binding proteins using RII subunit as the probe (Hausken et a l 1997). 
The diagram in figure 6 below shows a schematic representation of the RII dimer binding 
to the anchoring protein. Studies mapping the sites on RII which are required for 
interactions witli AKAPs (A kinase anchoring proteins) firstly concluded that RII 
dimérisation is a prerequisite for anchoring and then foimd that the first 45 residues of 
RII were involved in AKAP binding (Hausken et a l 1994; Luo et a l 1990; Scott et al. 
1990). Site-directed mutagenesis analyses defined isoleucines at positions 3 and 5 within 
this region of RII as essential determinants for association of RII with AKAPs (Hausken 
et al. 1994, 1996). It has also been discovered that leucines and iosleucines are crucial 
factors on the reciprocal binding surface of the AKAP (Glantz et al. 1993) althougli 
additional AKAP-binding determinants have been mapped between residues 11 to 25 of 
each RII molecule (Li and Rubin 1995).
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RII Dimer
V l U ' l u H ' l l l
I Jiriifliii
TARGETING EOCUS
Figure 6. This diagram represents how the RII dimer hinds to the A Kinase 
Anchoring protein (AKAP) anchoring it in place. The regions where the PKA associates 
with the binding protein (Anchoring) and the area interacting with subcellular organelles 
or structures (Targeting) are both indicated. The anchoring domain highlights the 
isoleucines (lie) at positions 3 and 5 within the first 45 residues o f the RII binding 
domain which are essential determinants fo r  association with AKAPs. Adapted from  
[)elTAcqua and Scott 1997.
It was then proposed that the co-purified protein and other related RII binding proteins 
are able to bind PKAII at specific intracellular locations (Bregman et al. 1989; Bregman 
et al. 1991 ; Leiser et al. 1986; Sarkar et al. 1984) . This would place kinases in close
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proximity with certain substrate proteins leading to rapid reception and propagation of tlie 
original signal carried by the second messenger cAMP. These RII binding proteins were 
named A Kinase Anchor Proteins and abbreviated to AKAPs (Glantz et a l 1992; Hirsch 
et a l 1992). Following the discovery of RII binding proteins further investigation 
revealed other proteins capable of binding RII in Golgi membranes, the nucleus, 
centrosomes and tlie cortical actin cytoskeleton and which tlierefore may be involved in 
the functional modification or localisation of PKAII isoenzymes. Subsequent studies 
have identified many other AKAPs that are associated with particular organelles (Scott et 
al. 2000). Most of these have been discovered using a combination of subcellular 
fractionation and immunochemical techniques such as the RII overlay assay. The diagram 
in figure 7 gives an idea of where these different AKAPs are located and indicates just 
how PKA activity can be directed to very specific areas of the cell through binding to 
AKAPs.
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Figure 7. Approximate location o f various known AKAPs indicating how they bring 
about targeting o f various PKAs within the cell. Adapted from Scott et al. 2000.
1.7 Phosphodiesterases
Phosphodiesterases make up a multi-gene family to supply the activity to convert 3', 5' 
cAMP to 5-AMP (Beavo et al. 1994; Conti and Jin 1999, Manganiello 1995b; Torphy et 
al. 1993). PDEs were discovered aroimd the same time as cAMP in the 1960's and very 
shortly afterwards the level of diversity witliin this group of enzymes became apparent as 
distinct types, or isoforms as we now know, of PDE were separated and partially purified
43
from various different tissues (Manganiello et al. 1995). To begin with PDEs could only 
be identified using basic biochemical criteria and were classified according to 
fractionation using ion-exchange cliromatography (Beavo et al. 1971; Thompson et al. 
1992; Thompson and Appleman 1971). The first PDEs to be discovered were tlie 
calmodulin regulated PDEs and were classed as type I simply because they were usually 
the first PDE activity to be eluted from a standard dietiiylaminoethyl (DEAE) ion- 
exchange column. Only since the advent of molecular biology techniques has it been 
possible to classify the PDEs more fuUy and relate their DNA sequence to their structure 
and possible function (Beavo and Reifsnyder 1990).
1.7.1 Structural organisation of PDEs
Most PDEs characterised so far fall into two main categories based on their specificity for 
and sensitivity to substrate. Some are able to hydrolyse cAMP or cGMP and some are 
able to hydrolyse botli. Some are inhibited by cGMP (Beltman, et al. 1995). Despite these 
fimctional differences many studies have shown tliat most PDEs characterised so far 
share a structurally conserved region of around 300 amino acids (see figure 8.).
This conservation was revealed after it had been noticed that segments of the protein 
kinases which bind and are regulated by cyclic nucleotides appear to be homologous with 
each other (Takio et al. 1984) and with the Escherichia coli catabolite gene activator 
protein (CAP), a protein which allows regulation of gene expression by cAMP in E. coli 
(Weber et al. 1982). It was also noted that there is a 7-residue segment of identity
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between the dnc+ -encoded PDEs and a cAMP binding site from the regulatory subunit of 
the cAMP-dependent protein kinase (Chen et al. 1986).
One particular study had revealed partial amino acid sequences from a Ca^Vcalmodulin- 
stimulated PDE from bovine brain and a cGMP-stimulated PDE from bovine heart 
(Charbonneau et al. 1986). These sequences were compared with the nucleotide 
sequences of two distantly related PDEs, one a yeast PDE2 gene and the other the 
Drosophila dunce+ gene (Chen et al. 1986; Sass et al. 1986). This comparison showed a 
region of homology consisting of between 200 to 270 amino acids which was shared 
between all of these PDEs. Even though the molecular weights of these proteins varied 
from 40 to 150 kDa the region of homology seemed to be restricted to one specific 
segment of each protein. These related segments were proposed to represent the catalytic 
site of the enzymes and tlie lack of total homology between the sequences showed that 
they must be unique gene products (Charbonneau et al. 1986).
Further studies have supported this hypothesis by using controlled proteolysis of PDEl 
(Kincaid et al. 1985; Tucker et al. 1981) and PDE2 (Stroop et al. 1989) or deletion 
mutagenesis of PDE3 (Pillai et al. 1994; Cheung et al. 1996) and PDE4 (Jin et al. 1992; 
Pillai et al. 1993; Jacobwitz et al. 1996; Kovala et al. 1997; Owens et al. 1997). These 
experiments showed the direct link between the conserved amino acid regions in these 
PDE sequences and tlie domain in the proteins which were involved in substrate 
recognition and catalysis (Conti and Jin 1999).
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N-tenrinai R e ^ a to ry  Ddmain Catalytic R eg ^
(Targedng?)
C-teminal Regon 
(RegMatory?)
Figure 8. The general structural domain organisation o f PDEs. The particular 
function o f each domain is derived from either sequence similarities, deletion and site- 
directed mutagenesis and controlled proteolysis (in the case o f the catalytic domain) or 
biochemically and from mutagenesis in the case o f the regulatory domains specific for  
each PDE. The properties o f  the targeting domains are inferred from the behaviour o f 
native or recombinant proteins and from deletion mutagenesis.
1.7.2 PDE families
There are currently 19 genes which have been identified as encoding PDEs. These 
enzymes share a certain amount o f sequence homology in the core catalytic domain but 
they vary widely outside o f this, reflecting different properties. They differ with regard to 
molecular mass, chromatographic qualities, substrate specificity, immunological
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reactivity, sensitivity to inhibitors, modes of regulation and Üieir distribution within 
different areas of the cell and tissue types. Multiple PDE forms can be found in the same 
tissue and even within the same cell (Beavo et al. 1982; Strada et al. 1984; Wells and 
Hardman 1977), however, distinct ceU-type specific expression patterns are evident.
The different PDE are now classified numerically on the basis of sequence as this 
determines their distinct functional properties. The naming of these various PDEs is, 
however, dependent upon their substrate specificity and regulatory properties (Beavo 
1988). They can be broadly classified based upon their substrate specificity into tlie 
following groups; i) the PDEl, Ca^Vcalmodulin-dependent PDEs, ii) the PDE2 cGMP- 
stimulated PDEs, iii) the PDE3 cGMP-inhibited PDEs, iv) tlie PDE4, PDE7 and PDE8 
cAMP-specific PDEs, and v) the PDE5, PDE6, PDE9 and PDE 10 cGMP-specific PDEs 
(Conti et al. 1991; Torphy et al. 1993). PDE 10 and PDEl 1 are, however, thought to 
hydrolyse both cAMP and cGMP.
1.8 PDEl
PDEl enzymes were among the first PDEs discovered and are encoded for by tliree 
separate genes PDEl A, PDE IB and PDEIC. Added complexity is provided by 
alternative mRNA splicing (Bentley et al. 1992; Borisy et al. 1992; Charbonneau et al. 
1991; Rossi et al. 1988; Shenolikar et al. 1985). They are known as tlie Ca^Vcalmodulin- 
dependent PDEs (CaM-PDEs) as they are ail activated by calmodulin in the presence of 
calcium. They also serve to hydrolyse both cAMP and cGMP.
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Particularly high levels of PDEIC mRNAs have been found in olfactory epithelium, 
testis, and regions of mouse brain.
The various PDEl splice variants all tend to exhibit a higher affinity for cGMP than for 
cAMP (Butt et al. 1994) but respond differently to Ca^^ stimulation and respond 
differently to inhibitors. A study using substrate competition assays interestingly revealed 
that there appeared to be only one catalytic site for both die substrates cAMP and cGMP 
(Yan et al. 1996).
The Ca^^/calmodulin binding region of these enzymes is found on the N-terminal side of 
the catalytic unit, as seen in figure 9, (Charbonneau et ai. 1991) and splice variants with 
similar Ca^^ sensitivities share similar N termini. The CaM-binding is also found in a 
region which displays similarities to the cGMP-binding regions in PDE2 and the UCR 
domains in PDE4.
Wliere N-terminal sequence divergence occurs between isoenzymes, differences in 
affinities for CaM are also observed. This implies that a role for alternative splicing at the 
N-terminus of PDEl A is to generate isoforms with different affinities for CaM. This will 
have a direct effect on PDE activity as binding of CaM to the CaM-binding domain is 
able to stimulate PDE activity (Charbonneau et al. 1991). To support this theory it has 
been proposed that in die absence of Ca^VCaM, the CaM-binding domain binds the 
catalytic domain and is able to suppress activity. Once Ca^^/CaM binding to the CaM- 
binding site occurs this results in a conformational change which exposes the active site 
in the catalytic domain (Charbonneau et al. 1991).
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Figure 9. Schematic representation o f  the organisation o f  the various domains (with 
function attributed i f  known) within type PDEl isoforms.
1.9 PDE2
PDE type 2 enzymes are similar to PDEl in tliat they too are able to bind and hydrolyse 
both cAMP and cGMP. They are stimulated by cGMP and appeai* to have a lower Km for 
cGMP than for cAMP. In the case of PDE2 there are two allosteric cGMP binding sites 
known as GAP domains (Fawcett et al. 2000; Soderling et al. 1999) found on the N- 
terminal side of the catalytic imit. Thus when cGMP binds to tliis site the enzyme is 
stimulated to hydrolyse cAMP. Tliis occurs due to positive cooperative kinetics and tlie 
effect of the cGMP binding is to increase the affinity of the enzyme for cAMP (Beavo
1988). In the case of both PDEl and PDE2 families the N-terminal regions are able to act
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as regulatory domains capable of exerting an influence over the catalytic activity 
presumably by triggering a confoimational change in the catalytic domain.
So far the PDE2 enzymes have all been shown to derive from a single gene. Alternative 
mRNA splicing results in three known isoforms; PDE2A1, PDE2A2 and PDE2A3. Once 
again within this group of enzymes sequence analysis has shown tliat the different 
isoforms shared the same C-terminal sequences but they have different N-terminal 
sequences which could determine their localisation within the cell as some of these N- 
terminal sequences have been shown to associate witli membranes (Yang et al. 1994). 
Comparison of sequences from PDE2A1 and two other PDE types, PDE5 which is 
cGMP-specific, and the photoreceptor PDE6 has shown a second region of homology 
shared by all of these isofonns. This region is distinct from tlie consei’ved catalytic 
domain and is located near the middle of PDE2A1. Experiments have shown tliat this 
region binds cGMP with liigh affinity and is also involved m allosteric regulation of the 
PDE2 enzymes (Stroop et al. 1989; Stroop and Beavo 1991). Multiple-sequence 
alignment of tliese regions has shown two intemally-homologous repeat sequences within 
the cGMP binding or GAP domains (see figure 10) of all tliree of these PDEs (Trong et 
al. 1990; McAllister-Lucas 1993) although the significance of this is unclear.
50
N-tenrinal
Region
(targeting?)
GAF
Domain
GAF
Domain
Catalytic
Region
(-terminal
Domain
Figure 10. Schematic representation o f the organisation o f the various domains 
which make up PDE2 isoforms and the function o f the domain where known.
1.10 PDE3
There are two genes, A and B, which encode for the two known PDE3 family members. 
In contrast to PDE2, these are all potently inhibited by low concentrations o f cGMP. 
They are also different from members the PDE2 family in that they specifically hydrolyse 
cAM P and not cGMP. In fact cGM P acts as a very potent competitive inhibitor binding to 
the catalytic site o f these isoforms rather than binding to a regulatory region. Interestingly 
PDE3 enzymes contain a unique insert foimd within the catalytic domain o f this enzyme 
family that has been suggested to explain the high cGM P binding o f this enzyme.
Early research using biochemical methods identified two distinct PDE3 enzymes, one 
found in both platelets and heart (M cPhee et al. 1986; Harrison et al. 1986) and the other 
in adipose tissue (Degerman et al. 1988). These initial findings were later confirmed
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using cDNA cloning techniques. This showed that there are two PDE3 genes wliich 
allow distinct expression patterns. PDE3A is expressed in heart and platelets (Meacci et 
al. 1992) wlule PDE3B is expressed in adipocytes (Taira et al. 1993).
Additional data suggests that multiple promoters in tlie PDE3A gene are responsible for 
producing at least two different mRNAs that encode proteins which differ at their N 
termini (Kayusa et al. 1995).
1.11 PDE4
This PDE family is encoded for by four genes, PDE4A, PDE4B, PDE4C and PDE4D. 
Their sequences show the highest degree of homology to the Drosophila melanogaster 
dune PDE. This particular PDE was discovered due to several mutants of D. 
melanogaster which were defective in learning and memory processes and showed 
lesions at the dunce {dnc) locus (Aceves-Pina et al. 1984; Dudai et al. 1976; Gailey et al. 
1982; Tempel et al. 1983). These dnc flies were shown to have a deficiency in the activity 
of one form of cAMP PDE compared to normal (Byers et al. 1981; Davis and Kauvar 
1984). The dnc locus generates numerous alternatively spliced mRNAs and many of 
these are produced from independent transcriptional start sites (Engels et al. 1994; 
Obemotle et al. 1993).
Based on this information and the fact that most of the PDE4 isoforms can be inhibited 
by rolipram (interestingly the dnc PDE4 is rolipram insensitive), a compound with anti­
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depressant effects in humans (Nemoz et al. 1985), linkage studies have tried to reveal 
their involvement in psychiatric and behavioural disorders (Milatovich et al. 1994). 
Enzymes of this family are characterised by their high affinity for cAMP and a low 
affinity for cGMP which it neither hydrolyses nor is inliibited by. PDE4s are able to 
hydrolyse 3',5' cyclic AMP to the inactive form 5 -AMP (Bentley and Beavo 1992; Chen 
et al., 1986). The products of each particular PDE4 gene share a region in their C- 
terminai domains tliat are identical and this can be exploited to produce antisera which 
distinguish between isoforms generated from otlier PDE4 genes (Huston et al. 1996; 
Lobban 1994; Shakur 1995).
PDE4 enzymes are also insensitive to inhibition by cGMP and imaffected by tlie presence 
of Ca^^/calmodulin. This very large family of enzymes comprised of many different 
isoforms aU of which are imiquely sensitive to inhibition by rolipram. They have been 
particulaiiy well studied due to the fact that selective inhibitors for these enzymes have 
proved to be particularly useful as anti-inflammatoiy agents.
1.11.1 Discovery of PDE4
This cAMP-specific and rohpram-inhibited PDE was first described in heart extracts 
(Reeves et al. 1987) and separated out from other PDEs by ion exchange 
cluomatography. The next leap in understanding type 4 PDEs came when a rolipram 
inhibited, cAMP-specific PDE, named RDI, was cloned from rat brain (Davis et al.
1989). Although the dune PDE is not sensitive to rolipram it was used as a probe to
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screen a rat brain cDNA library (Henkel-Tigges and Davies 1990). This was underlined 
by tlie cloning of other rodent forms and the idea that PDE4s were tlie products of four 
different genes with extra diversity created through alternative mRNA splicing became 
accepted. This idea was supported by the existence of many human PDE4 isoforms and 
tlie mapping of the genes encoding them to separate chromosomes (Bolger et al. 1993; 
Horton et al. 1995; Swinnen et al. 1989; Szpirer et al. 1995). The notion that diversity 
within each subtype is generated by alternative mRNA splicing is supported by 
comparisons of human and rat PDE4D isoforms (for which 5 sphcing variants have been 
reported) which all show a similar splicing pattern indicating that this is a conserved 
feature (Bolger et al. 1997; Sette et al. 1994; Nemoz et al. 1996). In tlie case of PDE4 
enzymes all of tlie genes encoding the various isoforms in this family have been mapped 
to particular chromosomes. These can be seen in figure 11.
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Subtype Chrom osom al location
PDE4A 19(pl3.2)
PDE4 B 1 p31
PDE4 C 19 (pl3.1)
PDE4 D 5 ql2
Figure 11. The chromosomes to which the various genes encoding the type 4 family 
isoforms A, B, C and D have been assigned through mapping. Localisation is usually 
accomplished using fluorescence in-situ hybridisation (FISH) (Gordon et al. 1995). Fine 
mapping in the case ofPDE4A and PDE4C has been accomplished through sequencing.
1.11.2 PDE4 domain organisation
1.11.2.1 The catalytic domain
It has long been established that PDEs contain a core domain which contains the catalytic 
activity (Charbonneau et al. 1986), Indeed, proteolysis experiments have confirmed the 
link between this conserved region and the domain involved in substrate recognition and
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catalysis. However, the homology is not uniform and this is one feature that can help 
distinguish between various PDE families and sublypes. The identification of these 
regions of homology was estabhshed using ahgnment of sequences from various PDE 
isoforms. This highlighted a common region of 30-40% similarity that appeared to be 
around 300 residues in length and provided the catalytic domain of these enzymes 
(Charbonneau 1990). The catalytic region (see figure 12) of the PDE4 isoenzymes forms 
a unit of around 357 residues (332 to 689 in PDE4A) and this region shows around 84% 
homology between the four PDE4 family members as well as the dunce PDE. The active 
isoenzymes from each particular PDE class aU have identical sequence at their extreme 
C-tennini.
In the case of PDE4 enzymes the region of catalytic activity has also been defined using 
mutational studies. These studies have identified individual residues, witliin this central 
region, tliat once mutated lead to either complete or substantial loss of catalytic activity 
(Jacobitz et al. 1997; Jin et al. 1992; Shabb and Corbin 1992; Woodford et al. 1989). 
Several regions in the conserved region are invariant but they are interspersed witli 
regions of considerable diversity. These regions are likely to be major determinants of the 
structure of die catalytic core, directly effecting the substrate recognition or being 
involved in maintaining die tertiary structure of die region. The regions of diversity are 
likely to confer sub-family specific properties on the function of the enzyme.
Several studies have attempted to define the minimum catalytic core. The discovery of a 
catalyticaUy inactive PDE4A species called 2EL (Horton et al. 1995) containing 278 
residues from within the catalytic core demonstrated that the sequences outwith this 
segment are essential to maintain catalytic activity. It is possible to restore the catalytic
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activity of this enzyme by constructing a chimera which replaces the C-terminal region 
but replacing the N-terminal portion has no effect. This shows that the functional 
catalytic unit extends beyond residue 643 in PDE4A4B and others studies have shown 
that C-terminal truncations from residue 772 are active, placing the functional core 
between 643 and 722.
These studies, however, can become difficult to interpret because of the influence of 
other regulatory domains and the N-terminal on catalytic activity. Deletions witliin the N- 
tenninal regions produce confusing results reflecting the influence of different sub- 
regions on the catalytic domain (Jacobitz et al. 1996; Owens et al. 1997).
1.11.2.2 UCRl and UCR2, Upstream Conserved Regions
These regions are shown in tlie diagram in figure 12. They were identified as regions of 
particular homology by sequence alignment of PDE4s and are not present in any other 
form of PDE (Bolger et al. 1994). The 60-residue UCRl region is foimd N-terminal to 
the 80-residue UCR2 region and is separated from UCR2 by a linker region named L R l. 
Similarly, UCR2 is joined to the catalytic imit by another tinker region named LR2. LRl 
and LR2 are distinct for each of the various PDE4 classes and are respectively around 33 
and 10 to 28 residues in lengtli. The linker regions may confer a regulatory role on the 
UCRs giving them more isoform specific properties. These two regions are quite 
different in structure, LRl has both hydrophilic and hydrophobic domains whereas LR2 
regions are all hydrophobic. LRl sequences in particular display a large degree of
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heterogeneity between the various long-foiin PDE4 isofonns. This could give rise to 
structural differences between isofonns produced by the vaiious PDE4 genes.
It is possible that the LR2 regions may be acting to hold UCRl and UCR2 in particular 
positions relative to one another and also relative to the catalytic region of the enzyme. 
The orientation of the extreme N-terminal regions unique to each splice variant would 
also be controlled by the position of these sections. In this way UCRl and UCR2 are 
likely to play a pivotal role in determining the effects of each unique N-terminal region 
on the catalytic unit. The regulatory effects of these regions on tlie catalytic activity may 
be isoform specific due to the linker regions LRl and 2. This may be resolved tlirough 
fiufher structural studies.
Structural analysis has shown the first half of UCRl is very polar and that this region is 
likely to be highly flexible. The C-terminal half of UCRl in contiast is very hydrophobic 
and helical wheel analysis suggests that this region forms an ainphipathic helix with some 
charged groups to one side. There is evidence to suggest tliat changes in the conformation 
of UCRl can cause major functional changes. A serine in the motif RRESW (Ser^ "*) of 
PDE4D3 has been shown to be phosphorylated by PKA (Alvarez et al. 1995; Hoffman et 
al. 1998; Sette and Conti 1996). This action is believed to alter the conformation of this 
region and leads to an increase in catalytic activity of the enzyme (Alvarez et al. 1995; 
Sette and Conti 1996; Sette et al. 1994). Interestingly, this motif (RRESW) is conserved 
in all the long-form PDEs and also the Drosophila melanogaster dune PDE, indicating its 
functional significance.
It has been suggested that the phosphorylation of Ser^ "^  causes a change in overall charge 
(from positive to neutral) in this region which may disrupt of modify tlie putative
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interaction between the UCRl and UCR2 regions. This may in turn transmit a 
conformational change to the catalytic unit altering catalytic activity. There is already 
evidence (for PDE4 A) tliat the structure of N-terminal sphce regions or their interaction 
with membrane and cytoskeletal components can lead to altered enzyme activity 
(Houslay 1996; Houslay et al. 1995).
UCR2 has a markedly different primary structure to UCRl. It is exti'emely hydrophilic 
and secondary structure plots suggest that it forms a series of tliree helical regions 
(Houslay et al. 1998). These regions may form amphipatliic hehces as tlie first and last 
helical regions are anionic whereas the central region appears to be cationic overall.
1.11.2.3 Alternative mRNA splicing
PDE4 genes generate a family of active isoenzymes through alternative mRNA splicing. 
Tliree 5' splice junctions have been identified, giving rise to isoenzymes witli different N- 
terminal regions. The first splicing junction produces RNAs which encode tlie long-form 
PDE isofonns and the second and third splice junctions produce the short-fonn PDE4 
isoforms. A catalyticaUy inactive fonn is also generated from the 4A gene tlirough both 5' 
and 3' splicing. These sptice junctions can be seen in the diagram in figure 12.
The alternative sphcing seen in PDEs is very similar to that seen in tlie dune gene of D. 
melanogaster and the same pattern of transcripts being created from alternative 
transcriptional start sites within the genes (Qui and Davis 1993). The gene structure 
enabling production of a large number of mRNA transcripts is likely to be complex.
59
Genomic studies have already revealed tlie full genomic sequences for PDE4A and 
PDE4C and partial genomic sequences for rat PDEB and D genes but these have so far 
only described the short-form PDEs (Monaco et al. 1994). The upstream 5' sequence in 
which any additional transcriptional start sites and promoters are likely to be located but 
these were not included in the study.
However, recently the gene locus encoding PDE4A was cloned and this was investigated 
for the presence of both short and long-forms and the cDNAs encoding them. Tliis study 
was also able to determine the number of separate exons in each cDNA. The existence of 
a number of PDEs including PDE46, TM3 and 2EL was also confirmed and the exons 
encoding botli the initiating codon for tlie PDE46 ORE and its unique N-tenninal were 
identified. The exons encoding UCRs, 1 and 2 were also identified and found to each be 
encoded by three whereas the catalytic domain is encoded for by six exons (Sullivan et al. 
1998).
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PDE4D
Figure 12. mRNAs encoded by the mammalian cAMP-specific PDE genes PDE4A, 
PDE4B, PDE4C and PDE4D. Also shown are the transcripts o f the dune gene from  
Drosophila melanogaster. The hatched areas show the sequences with the highest level o f  
homology (UCRl, UCR2 and catalytic). The individual splice variants are shown by the 
thinner solid lines and the arrows marked I, 2 or 3 showing where the three splice 
junctions exist. Splice junction I creates long-form PDE4s; splice Junction 2 creates 
short-forms in PDE4B (4B2) and PDE4D (4DI), and .splice junction 3 creates short-
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forms in PDE4A (PDE4A1) and PDE4D (4D2) which both have a truncated UCR2. 
Adapted from Houslay et al. 1998.
1.11.2.4 Unique N-terminal domains created by alternative mRNA splicing
Alternative inRNA splicing generates unique regions of N-tenninal sequence which 
confer distinct functional properties on specific isofonns. There are two major sphce 
jimctions that give rise to alternative splicing in both human and Drosophila dunce PDE 
genes. A third has been described in the genes for PDE4A and PDE4D. The location of 
these splice jimction can be seen in figure 12. Characterisation of the HSPDE4A gene 
locus revealed an explanation for the difference in between the point of divergence used 
to create either the PDE4A and one PDE4D (4D2) short-foims or the PDE4B and other 
PDE4D short-fonn cDNAs. The "short" isoforms from the PDE4B and PDE4D genes 
(except 4D2) encode proteins that possess a complete UCR2 whereas the active PDE4A 
and PDE4D2 "super" short-form cDNAs only possess 2 of the three exons that encode 
UCR2. These PDEs lack the N-terminal part of UCR2.
Analyses of the HSPDE4A gene also revealed a sequence of 55bp that encodes the 
unique N-terminal of RDI. This region is situated in the intron that separates two of tlie 
three exons that encode UCR2. The location of this 5' exon explains why the PDE4A 
short-foim RDI has a disnipted UCR2. The short-forms PDE4B and PDE4D (except
62
4D2) have intact UCR2 regions as their unique 5' exons aie located between exons 5 and 
6 (Sullivan et al. 1998).
The presence of these unique N-terminal regions appear to confer particular functional 
properties on the various PDE4 isoforms. These properties include susceptibility for 
membrane association and intracellular targeting, regulation of the Vmax of the enzyme 
activity, influencing the thermostabiUty, conferring susceptibility to regulation by 
phosphorylation and tlie ability to bind SH3 domains.
The ability of unique N-terminal regions to confer susceptibility for membrane 
association and intracellular targeting has been particularly well studied. PDE4 activity is 
found not only in the cell cytosol but also in the particulate fractions that contain the cell 
membranes and cytoskeleton. It was first proposed PDE4 might have a paiticular ability 
to associate with membranes by binding to an anchor protein for the PPM-PDE4 enzyme 
from hepatocytes (Houslay and Maichmont 1981).
Studies carried out on the rodent short-form PDE4A, RDI, provided the first definitive 
evidence that alternative splicing could yield a membrane targeted isofonn (Scotland and 
Houslay 1995; Shakur et al. 1993). This isofonn is found to be associated with the (high­
speed) membrane fraction when expressed in COS cells and the first 25 residues of the 
unique extreme N-terminal splice region of RDI were shown to determine tlie membrane 
targeting of this splice variant. This was demonstrated by the generation of an in-frame 
chimera formed between this region of RDI and tlie normally soluble bacterial protein 
cliloramphenicol acetyl transferase (CAT). Plasmids encoding either 1-25 RDI-CAT or 
1-100 RD I-CAT were transfected into COS cells and these chimeras showed subcellular
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distribution identical to that seen with RDI. However, the truncated chimera species 26- 
100 RDI-CAT was found to be located exclusively in tlie cytosol.
Structural analyses of the N-terminal splice region of RDI revealed that it is formed of 
two folding helical regions separated by a mobile hinge region. One region in particular 
forms a polar helical region and it is unlikely that the overall structure of the RDI N- 
terminal domain would be able to insert into biological membranes. It has therefore been 
suggested that RDI becomes membrane-associated through protein-protein interactions, 
either directly with an integral membrane protein or indirectly through an adaptor protein. 
This interaction would appear to be hydrophobic, involving the tryptophan-rich Pro '^ -^ 
Trp^ *^  domain, as RDI membrane association is disrupted by veiy low concentrations of 
the non-ionic detergent Triton X-100 but not by high ionic strength.
The unique N-terminal domain of RPDE6 (RNPDE4A5) and its human homologue 
PDE46 (HSPDE4A4B) whüe found in the cell cytosol are also foimd to be associated 
with the membrane fractions. In contrast to RDI, RPDE6 is not readily solubihsed by the 
non-ionic detergent Triton X-100 or by repeated waslhng with high ionic strengtli 
solutions. Tliis imphes RPDE6 forms strong associations witli cytoskeletal components 
(McPhee et al. 1995). The same observations were made for the human homologue 
PDE4A4B (Huston et al. 1996). Laser scanning confocal microscopy studies showed that 
both PDE4A4B and RPDE6 immunoreactivity in transfected COS cells was localised to 
the margins of the cell where specialised cytoskeletal structures such as cortactin and 
fodrin associate witli actin. Cortactin and fodrin botli exhibit Src Homology 3 (SH3) 
domains. Tliey are found in many proteins that have important signalling structures and
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allow them to recruit interacting proteins to specific locations within the cell (Sparks et 
al. 1996; Wu and Parsons 1993).
SH3 domains interact with binding proteins through proline (and arginine)-rich motifs in 
the form of PXXPXXR found in the binding protein. Both RPDE6 and PDE4A4B 
possess such motifs in their unique N-terminal splice regions. Indeed RPDE6 was shown 
to interact with certain SH3 domains expressed as a GST fusion protein indicating 
specificity (O'Connell et al. 1996). RPDE6 interacted strongly with SH3 domains of the 
tyrosyl kinases fyn, lyn and src and also those from the cytoskeletal proteins fodrin and 
cortactin. Neither the long-form PDEA isoform RPDE39 or tlie core rodent PDE4A 
species met^^RDl displayed any interaction with SH3 domains. This indicates that motifs 
within the unique extreme N-terminal 110 residue splice region of RPDE6 confer this 
ability.
1.11.2.5 Distribution of PDE4 subfamilies
1.11.2.5.1 Distribution of PDE4A
The human PDE4A gene encodes for at least four long-form isoenzymes (PDE4A4B, 
PDE4A4A (truncated), PDE4A4C (truncated), PDE4A5 and PDE4A8A) and two short- 
forms (PDE4A1A and PDE4A10) as shown in figure 12. The rat PDE4A gene has so far 
been shown to encode six long-forms and one short-foim.
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The molecular weights of the human isoforms range from aroimd 76 to 125 kDa and tlieir 
Km for cAMP varies from 2-6 jiiM. They all have an IC50 value for the inliibitor rolipram 
in the pM range.
The intracellular localisation of the rodent short-form PDE4A RDI and the rodent long- 
from PDE4A RPDE6 were discussed in the previous section. Another rodent long-form 
PDE4A, RNPDE39 (RNPDE4A8) has a unique N-terminal splice region of 21 residues 
(compared to 112 unique to RPDE6) which is followed by the "common" long-form 
splice region of around 154 residues that is also seen in RPDE6. RPDE39, like RPDE6, is 
found to be associated witli both membrane and cytosolic fractions but has very different 
expression patterns to RPDE6.
RPDE39 appears to have a restricted distribution, being found in testis and hepatocytes. 
This suggests that RPDE39 may have a frmctional role distinct to that of RPDE6.
The targeting of RDI may also suggest a distinct frmctional role for the rodent short-fonn 
RDI, as it is found to be expressed in the CNS, in paiticular synaptosomes especially 
those enriched in postsynaptic densities. Wlien tliese cells were examined at the 
subcellular level the distribution of RDI showed a similar pattern to that observed in 
transfected COS cells. RDI was predominantly associated with plasma membrane and 
Golgi bodies. It has been suggested that RDI may play a role in the control of 
neurotransmitter release and the expression of PDE4A species in the CNS which is 
consistent with the PDE4 inhibitor rohpram having anti-depressant effects (Wachtel 
1983).
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1.11.2.5.2 Distribution of PDE4B
The human PDE4B gene encodes two long-forms (PDE4B1, PDE4B3) and one short- 
form isoenzymes (PDE4B2) as shown in the diagram in figure 12. Foiu rodent PDE4B 
isoforms have also been cloned. The human long-form PDE4B isoenzymes both have 
molecular weiglits of around 104 kDa whereas tlie human short-form is around 80 kDa.
All of these isoenzymes are found in both tlie cytosohc and membrane fr actions of COS 
cells and an I C 5 0  value for tlie inliibitor rolipram which is generally one tenth to one 
hundredtli lower than that of the PDE4A isoenzymes (around 0.05 to 0.2 juM).
The subcellular locahsation of PDE4B isoforms has not been studied in great detail. Data 
obtained for the distribution of two long and one short human PDE4B isoforms expressed 
in COS cells indicated that they all displayed similar distribution between particulate 
(around 20%) and cytosolic fractions.
1.11.2.5.3 Distribution of PDE4C
Only one human PDEC "long" isoform has been studied in detail (see figure 12) altliough 
eight human PDEC isoforms have been cloned, and two rodent isoforms. So far no 
human short-form PDE4C has been cloned. HSPDE4C2 has a molecular weight of 
around 80 kDa and an IC50 value for the inlhbitor rolipram in a concentration range 
similar to that of PDE4B isoforms (aiound 0.08 pM).
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Relatively little analysis of the subcellular localisation of PDE4C isoforms has been 
carried out and distribution studies have so far shown PDE4C to have restricted 
expression. RT-PCR analysis have detected PDE4C transcripts in brain, lung and kidney 
whereas all the otlier PDE4 sub-families have so far been shown to have a fairly wide 
distribution in tissues. Studies investigating die involvement of PDE4 isoenzymes in 
inflammatory diseases have also suggested that PDE4C isoforms may play a role in 
regulating the fimctioning of immime cells.
1.11.2.5.4 Distribution of PDE4D
The PDE4D gene encodes three long isofonns (PDE4D3, PDE4D4 and PDE4D5) and 
two short-forms (PDE4D1 and PDE4D2) also shown in figure 12. Five rodent forms have 
also been cloned. Characterisation of the human PDE4D isoenzymes has shown that the 
short-forms have a molecular weight of around 68 kDa while die long-fonns range from 
95-119 kDa. They aU have a Km for cAMP of around IpM. The short-fonn PDE4D 
isoforms are found to be cytosolic and have an IC50 value for inhibition by rolipram at 
concentrations of aroimd 0.05pM.
The long-fonn PDE4Ds are found both in die cytosol ( I C 5 0  value for inhibition by 
rohpram also around 0.05pM) and to be associated with the membrane jfraction. The 
membrane associated PDE4Ds have a higher I C 5 0  value for inliibition by rolipram of up 
to 0.59pM although PDE4D4 has an I C 5 0  value equal to diat of the isoforms located in
the cytosol. RT-PCR analysis has detected PDE4D transcripts in a wide range of tissues 
and their expression does not appear to be restricted.
Studies have shown that the long-form PDE4D isoforms have the potential for targeting 
to distinct intracellular compartments and these associations may be cell-specific 
depending on the means through which they are anchored. The expression of the short 
PDE4D isoforms in COS cells has so far shown them to be cytosolic although this does 
not exclude the possibility of theii* being targeted to intracellular sites when they are 
expressed natively.
Interestingly all three of tlie long-form PDE4D isoforms were solubilised by detergent 
and high NaCl concentrations although treatment witli detergent alone only partially 
solubilised PDE4D3 and PDE4D5 but not PDE4D4. Treatment with Iiigh NaCl 
concentrations alone to release isoforms binding via electrostatic interactions only 
partially solubilised PDE4D5 and had little effect on either PDE4D3 or PDE4D4. These 
findings highlight differences in modes of anchorage between these isoforms which are 
likely to be distinct properties of their imique extreme N-terminal regions.
1.12 PDE5
This family of PDEs have a higli specificity for cGMP. Sequence analysis showed that 
they contain a region homologous to that found in all of tlie other PDEs which is tlie 
conserved catalytic domain but also a second region of homology. They contain two 
high-affinity binding sites for cGMP which are non-catalytic. These were discovered by
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comparing this region of PDE5 A l sequence to the same region of sequence in PDE2 and 
PDE6 which had been previously described as a putative cGMP-binding domain. This 
region from residues 142-526 contains two homologous repeat sequences. These have 
been named repeat 'a' which runs from residues 228-311 and repeat 'b' which runs from 
residues 410-500 (McAllister-Lucas et al. 1993; Thomas et al. 1990). Evidence from 
analyses of tlie cGMP binding and dissociation kinetics has shown that there are two 
frmctionally and structurally distinct cGMP binding sites on PDE5A1 which appear to 
have different affinities for cGMP (McAllister-Lucas et al. 1995).
There is anotlier site on PDE5A1, distinct from the two cGMP binding sites in the 
homologous repeat sequences, which contains a serine residue (Ser92) that can be 
phosphoiylated by cGMP-dependent protein kinase. Phosphorylation in this case requires 
binding of cGMP to the allosteric site on tlie enzyme and is thought to effect the enzyme 
by causing an increase in catalytic activity (Loclihead et al. 1997; Thomas et al. 1990; 
Wyatt et al. 1998).
Protein kinase A has also been shown to activate PDE5 (Bums et al. 1992) and in tliis 
case does not require prior binding of cGMP to the PDE (Bums and Pyne 1992). In 
addition, the phosphoiylation of PDE5 by protein kinase A that triggers an increase in 
phosphodiesterase activity, also severely decreases inhibition of the enzyme by Zaprinast 
(Bums et al. 1992). This suggests that protein kinase A can alter the inhibitory effect of 
Zaprinast througli alterations to a non-catalytic binding site (Bums and Pyne 1992). 
Activation by protein kinase A can be blocked by recombinant PDE6 y-subunit and a 
peptide corresponding to amino acids 24-46 in this protein (Lochead et al. 1997). Further 
investigations using a specific antibody against amino acids 24-46 of the PDE6 y-subunit
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revealed two small proteins (p i4 and p i8) which appeared to fonn a complex with PDE5. 
It has been suggested that these proteins may interact with PDE5 to prevent its activation 
by PKA (Lochead et al. 1997).
1.13 PDE6
PDE6 enzymes are known as photoreceptor PDEs as tliey are effector enzymes in 
photoreceptor signal transduction. They are found in the mammalian rod and cone 
photoreceptor cells. PDE6 is activated by the retinal G-protein transducin which in turn is 
activated by rhodopsin. The activation of PDE6 leads to a decrease in intracellular cGMP 
concentrations and results in closure of the cGMP-gated cationic channels of the 
photoreceptor plasma membrane (Beavo et al. 1994).
Like PDE5 and PDE2 enzymes PDE6 family members are cGMP specific. They also 
possess a high-affinity non-catalytic cGMP-binding region. Distinct isofonns of PDE6 
are found in the two types of photoreceptor cells. Stnictural details of these isofonns have 
come from studies carried out on bovine foims of these PDEs. The PDE holoenzyme in 
bovine rods is composed of tliree basic subunits a , [3, and y. The two subunits a  and (3 are 
similar in size (around 88kDa and 84kDa respectively) and contain the catalytic activity 
(Li et al. 1990; Lipkin et al. 1990; Ovchinnikov et al. 1987). They associate witli two 
smaller y subunits (of around 13 kDa) which act as internal enzyme inliibitors (Detene et 
al. 1988). PDE6 found in bovine rod cells consists of two a ' subunits, which are identical, 
and these are associated with tliree smaller subunits of 15, 13 and 11 kDa. Each type of
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subunit is encoded for by a different gene, a  subunits are encoded by the gene PDE6A, p 
subunits by PDE6B and the a ' subunits by PDE6C (Gillespie and Beavo 1988). Sequence 
analyses of the subunits have revealed 72% identity between the rod a  and p subunits and 
63% identity between the rod PDE a  or p subunit and the cone-PDE a ' subunit 
equivalents.
The a  and P subunits also possess the high-affinity noncatalytic cGMP-binding site 
which is located in the N-terminal half of the subunit. When compared to the cGMP- 
binding regions in tlie PDE2 and PDE5 enzymes the sequence for this region in PDE6 
was also found to contain the two internal homologous repeats 'a' and 'b' seen in 2 and 5 
(Baelir et al. 1991; Khramtsov et al. 1993).
1.14 PDE7
PDE7 enzymes were discovered several years ago. PDE7 was recognised as a distinct 
PDE isoform when an DBMX-insensitive species was found in hepatocyte and liver tissue 
preparations (Lavan et al. 1989) although it has now been shown to be IBMX sensitive.
A novel PDE witli such properties was first cloned from human T cells. PDE7 enzymes 
hydrolyse and have a high affinity for cAMP but the first clone encoding tliis isoform 
was derived jfrom complementation in yeast which were deficient in PDE activity 
(Ichimura and Kase 1993; Michaeh et al. (1993). This clone was expressed in yeast and 
displayed a liigh affinity for cAMP and as well as an insensitivity to IBMX it was also 
insensitive to type 3 and type 4 PDE inhibitors. Since then at least two splice variants
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have been shown to exist, PDE7A1 and PDE7A2 which are encoded for by tlie same 
gene (Bloom and Beavo 1996; Han et al. 1997).
The main differences between the two isoforms are that PDE7A1 has a N-terminal region 
that is rich in proline, serine and positively charged amino acids whereas the N-tenninus 
of PDE7A2 is mostly hydrophobic with possible palmitoylation and myristolylation sites 
(Bloom and Beavo 1996; Han et al. 1997). PDE7A2 may also possess a targeting motif in 
its N-terminus as a species with similar electrophoretic mobility is found to be associated 
with tlie membrane fraction of human foetal skeletal muscle and heart extracts. PDE7A1, 
however, is usually found in tlie cytosolic fraction or distributed between the membrane 
and cytosolic fractions (Bloom and Beavo 1996; Han et al. 1997). 
One interesting feature of PDE7A1 is that it was found to contain a cAMP-dependent 
protein kinase pseudosubstrate motif (RRGAIS) but a functional significance has yet to 
be established although it could mean that the PDE is regulated in some way by PKA 
(Han etal. 1997).
1.15 The discovery of new PDE enzymes (FDE8, 9,10 and 11)
After the discovery of the involvement of a cAMP PDE in tlie dnc locus of D. 
melanogaster tliis gene was cloned and used as a probe to find novel human and rat 
PDEs in cDNA libraries. This was complemented by another approach which used a 
strain of yeast {S. cerevisiae) which had elevated cAMP levels resulting from mutations 
which lead to constitutive activation of adenylyl cyclase. This strain of yeast is also
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particularly sensitive to heat shock, a phenotype which is rescued by overexpression of 
proteins wliich interfere witli cAMP signalling (Colicelli et al. 1991). Other mammalian 
PDEs have been discovered through the use of PDE 1 and 2 wliich are both more sensitive 
to heat shock and by disruption of the yeast PDE4 gene which lowers yeast protease 
activity and resulted in increased expression of human recombinant PDE4 (McHale et al. 
1991; Michaeli et al. 1993; Sulhvan et al. 1994).
Other approaches focus on more molecular techniques such as using known genetic 
sequences (already known clones) as probes in low-stringency hybridisation experiments, 
using RACE technology (Huston et al. 1997) or PGR using known conserved sequence to 
design primers which then act as probes for new PDEs in cDNA hbraries (Engels et al. 
1995; Livi et al. 1990; McLauglilin et al. 1993).
With the advent of Bioinformatics and developments in the Human Genome Project 
which have resulted in an acceleration in genetic information becoming available it is 
now possible to probe databases to look for new genes. This has occurred through the 
technique of cloning short expressed sequences (ESTs) of unknown fiinction, a scatter- 
gun approach which never-the-less cuts out intronic sequence and therefore saves time 
and generates many novel sequences. The EST databases can be searched using known 
sequence from a similar gene and the level of homology required can be controlled in a 
BLAST (Basic Local Alignment Search Tool) search (Altschul et al. 1990) which is 
available at the National Centre for Bioteclinology Information (NCBl). If a positive liit 
is found and the EST sequence does not represent part of a sequence which is already 
deposited in GenBank then a clone containing the EST sequence can be ordered. This 
approach has recently been used to clone several new PDEs including four new PDE
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families 8 ,9 , 10 and 11. One major difference witli the cloning of PDE 11 was that the 
research group were able to search the commercial EST database, the Incyte LifeSeq 
database, which contains many sequences not yet publicly available.
So far any search for ESTs containing novel PDE4 sequence have only found parts of 
clones which have already been isolated and documented. Indeed I recently carried out a 
search using parts of conseived PDE4A sequence flanking more variable regions to probe 
for new PDE4A sequence in the database but did not generate any hits.
PDEs 8 ,9 , 10 and 11 have only been discovered very recently and have rapidly expanded 
the list of known PDE families. PDES is encoded for by two genes, A and B, and shows 
specificity for cAMP and PDE8B. It is not inliibited by most PDE inhibitors, including 
IBMX, with the exception of dipyridamole for which it has a fairly high IC50 value 
(Hayashi et al. 1998).
PDE9 is highly specific for cGMP with the lowest Km reported for a cGMP specific 
PDE. It is also not inhibited by the nonselective PDE inhibitor IBMX or the PDE5 
inhibitor sildenafil but is inliibited by a PDE 1/5 inliibitor compoimd known as SCH51866 
(Soderhng et al. 1998). This PDE also shows higher homology to tlie PDE recently found 
ill Dictyostelium discoideum than to any of the otlier known inammahan PDEs (Shaulsky 
etal. 1996).
PDE 10 and PDE 11 are different in that they appear to hydrolyse both cAMP and cGMP. 
In tlie case of PDE 10 a fiill-lengtli clone was identified and named PDElOAl but anotlier 
incomplete cDNA was also found (PDE10A2) and identified as such due to a divergent 
N-terminal sequence (Loughney et al. 1999). The carboxy terminal of these two PDEs 
showed homology to the catalytic regions of other mammalian PDEs and tlie N-terminal
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domain contained sequence that shared partial homology with the cGMP-binding 
domains of PDE2, 5 and 6. PDE 10 was insensitive to all PDE inhibitors tested except the 
nonselective inhibitor IBMX.
PDE 11 is most closely related to PDE5 and shows 50% homology to PDE5 in tlie 
sequence encoding the catalytic domain. PDE 11 is similar to PDE 10 in tliat it is able to 
hydrolyse both cGMP and cAMP and is inhibited by the nonselective PDE inhibitor 
IBMX. It diverges in the fact that it has a different sequence encoding the region of the 
tandem repeat in the cGMP-binding domain which is also found in PDE2, 5 and 6 
(Fawcett et al. 2000). This enzyme also differs from PDE 10 in that it is inhibited by 
several PDE inhibitors which are normally selective for the cGMP-specific PDEs. These 
inhibitors include zaprinast and dipyridamole.
1.16 PDE4 inhibitors: Potential therapeutic roles
PDE4 isoenzymes have a very wide distribution in tissues and their inhibitors have 
therefore been suggested as having potential therapeutic use in many disease states. The 
discovery that multiple PDE4 isoforms exist, some with tissue-specific patters of 
expression, indicated that inhibitors specifically targeted to one particular isoform could 
be developed. Two main therapeutic areas have been the focus of PDE4 inliibitor 
development. These include disorders of the central nervous system and also immune 
system disorders, particularly astlima. The use of PDE4 inhibitors in the treatment of 
vascular disorders such as pulmonary hypertension has also recently been investigated.
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Rolipram was identified as an antidepressant even before its mode of action had been 
identified (Canizzaro et al. 1989). At tlierapeutic doses it inhibits all known PDE4 
isoenzymes to a more or less equal extent (Muller et al. 1996). This lack of selectivity 
may account for some of the side-effects such as nausea and somnolence which were 
major side-effects seen in some Phase I and Phase II clinical tiials (Krause et al. 1990; 
Scott et al. 1991). These are common side-effects seen in clinical trials of PDE4 
inhibitors and therefore few are currently available for general clinical use. Nevertheless 
PDE4 inhibitor studies provide valuable insights into the modulation of disease states 
and improved specificity may reduce side-effects.
The use of PDE4 inhibitors may be of therapeutic use in the treatment of pulmonary 
arterial hypertension. Prohferation of smooth muscle cells is just one of the elements of 
the pathophysiology of this disease. PDE4 inliibitors have been shown not only to alter 
PDE4 ftmction in vascular smooth muscle but also to inhibit injury-induced proliferation 
of smooth muscle cells in rats (Pan et al. 1994; Poison and Strada 1996).
The majority of PDE4 inhibitor studies have focussed on tlieir use as anti-inflammatory 
or immunomodulatory agents. The presence of PDE4 enzyme activity, protein and or 
mRNA has been detected in many immime cells including monocytes, basophils, 
neutrophils, eosinophils, lymphocytes and polymorphonuclear leukocytes (Obemotle et 
al. 1993). However, the precise isoform present in a particular cell type has not been 
defined. Raising levels of cAMP in immune cells can have effects such as inhibiting 
chemotaxis, cytotoxicity and cell aggregation (Torphy and Undem 1991).
Asthma is characterised by both acute and chronic inflammatory processes and also 
increased tone of airways smooth muscle cells. PDE4 inhibitors may therefore be useflil
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in the treatment of astlima due to tlieir anti-inflammatory effects and tlieir ability to 
reduce aiiway smooth muscle tone (Banner and Page, 1995; Giembycz 1996; Torphy et 
al. 1994).
Rolipram has been shown to stereospecifically suppress the production of TNFa, 
lymphotoxin a  and to a lesser extent IFN-y in human autoreactive T cells (Sommer et al. 
1995; Genain et al. 1995). These mediators are of central pathogenic importance in 
experimental autoimmune encephalomyehtis (EAE) which is an animal model of 
multiple sclerosis(MS) (Sommer et al. 1995). Rolipram has been shown to be an effective 
treatment for EAE which suggests that PDE inhibitors may have a role to play in the 
therapy of MS (Raine, 1995).
Recent studies have also shown PDE4 inhibitors to have the potential to suppress the 
actions of inflammatory cells such as neutrophils, macrophages and CD8^ T cells that are 
associated with the progression of chronic obstructive puhnonary disease (COPD) 
(Torphy and Page 2000). The novel PDE4 inhibitor compound Ariflo™ (SB207499) has 
produced encouraging data in Phase II clinical trials into its use in the treatment of 
COPD.
Another novel PDE4 inhibitor, piclamilast (RP73401), has also been used in the 
treatment of rheumatoid arthritis (RA) with patients reporting improved symptom relief 
but higher dosage levels could not be increased due to nausea and vomiting in trial 
patients. Recent studies to develop PDE4 inliibitors with improved tlierapeutic ratios and 
fewer side-effects have revealed a novel PDE4 inhibitor PD189659. This inhibitor 
produces a broad-spectrum of anti-inflammatory effects and so far does not induce 
vomiting in dogs or ferrets (Torphy and Page 2000).
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1.17 Conclusion
PDEs play a central and crucial role in controlling the effects of signals received at the 
cell surface. Their complex gene structure means that many different type of PDEs exist 
with distinct functional differences between families and very subtle changes from 
isoform to isoform. This means that their expression is tailored to a particular cell and a 
particular ar ea of the cell and their rates of catalysis may be different.
The implications for tins are that signals disseminated in the cell through cAMP may be 
localised due to the position of the PDE. If they are positioned nearer to adenylyl cyclase 
tlien they are able to lower the concentration of cAMP nearer the cell membrane so 
effects of cAMP will be less in other areas of the cell. Perhaps the most interesting 
development in die stoiy of cell signalling is the discovery of the AKAPs anchoring 
PKAs to distinct locations in the cell. If PDEs are also located in this manner, through 
various anchoring metiiods, then they can effect the PKA activity in very specific areas of 
the cell. In this way all of the different PDEs expressed in one cell are able to create both 
local and general differences in cAMP concentration and this has implications for both 
the sensitivity of PKA to cAMP and the timing of various cellular events due to signals 
from outside of the cell.
The very specific nature of the characteristics of each PDE means that they must each 
have very discrete roles widiin the cell. cAMP is a ubiquitous second messenger therefore 
without a very sophisticated method of controlling and attenuating its effects on 
particular eflfectors, cellular events would happen in a random and inappropriate manner.
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Of course the vast range of PDEs and tlie subtle differences between isoforms makes it 
very difficult to produce inhibitors which are specific enough not to have effects on more 
than one PDE. This situation is made more comphcated by the fact that interactions with 
other proteins in the cell or modifications due to phosphorylation change the 
conformation of the PDE and can effect inhibitor binding. New approaches, however, 
may be able to focus on disrupting protein-protein interactions therefore removing a 
particular PDE fi*om its functional locus. Further studies into the structural conformation 
of PDEs and the interactions between domains within the enzyme will aid the design of 
new inliibitors. For example the effects of the Linker Regions on UCRl and UCR2 will 
aid the understanding of how conformational changes in these regions effect the catalytic 
activity.
The last few yeais has seen a sudden surge in the discovery of new PDEs. The 
availabihty of new ESTs along witli the completion of tlie Human Genome Project will 
add to this trend and we can expect further isofonns and perhaps new PDE families to be 
discovered which were previously very hard to detect using standard techniques.
PDE4 enzymes are therapeutically of considerable importance. Their selective inliibitors 
have been of use in the treatment of central nervous system (CNS) disorders such as 
depression, immune and inflammatory system diseases, particularly astlima and also in 
the treatment of vascular disorders including pulmonary hypertension. However, to 
achieve more higWy specific inhibition with minimal side-effects it is crucial to identify 
the full range of PDE4 enzymes. In this thesis I describe the cloning and characterisation 
of two new PDE4 isoforms. These may provide novel therapeutic targets in the future.
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CHAPTER 2
Methods
2.1 Advantage-GC cDNA PCR Kit (including GC-Melt) Clontech
For each sample of cDNA four different GC-Melt concentrations must be used in order to 
optimise the reaction. PCR mixtures are as follows:
Final GC-Melt Cone. (M) 0 0.5 1.0 1.5
PCR grade H2O 35 30 25 20
5X Klen Taq GC reaction buffer 10 10 10 10
GC-Melt (5M) 0 5 10 15
DNA Template 1 1 1 1
Primer Mix (lOmM each) 2 2 2 2
5 OX dNTP mix (lOmM each) 1 1 1 1
Advantage Klen Taq polymerase mix (50X) 1 1 1 1
Total Volume (pi) 50 50 50 50
Cycling parameters: One cycle of 94°C for 1 minute tlien 25 cycles of 94°C for 
SOseconds, 55°C for 3 minutes, 68°C for 3 minutes and then the reaction should be 
cooled to 4°C.
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Advantage Genomic PCR Kit using the Advantage Tth polymerase Kit (Clontech).
PCR reaction mix.
Component Volume required (pi)
PCR grade H2O 33.8
lOX Tth PCR reaction buffer 5
25mMMg(Oac)2 l.lm M final 2.2
DNA template 5
Primer mix 2
50X dNTP mix 1
Advantage Tth polymerase mix (5 OX) 1
Total reaction voliune 50
If the target size is under 5Kb tlien the following cycling parameters should be used:
One cycle at 94°C for 1 minute and then 25 cycles of 94°C for 30 seconds then 68°C for 
3 minutes. Finally one cycle at 68°C for 3 minutes then the reaction should be cooled to 
4^C.
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2.2 Agarose Gels
Analytical grade Agarose was melted in IX TAE buffer (to 1 litre H2O add 4.84g Tris 
Base, 1.142ml Glacial Acetic Acid, 2ml 0.5M EDTA at pH8.0) depending on the 
percentage of Agarose gel and volume required. The percentage of gel required depends 
on the size of DNA fragments to be visualised later using Etliidium Bromide. The smaller 
the fragments the higher the percentage of Agarose in the gel. Usually a 0.8-1% gel 
would be required for DNA fragments of around l-2Kb in size or larger.
The molten gel is cooled to around hand heat and Ipl of Ethidium bromide is added 
before being poiued into the mould. Wlien the gel is solid, samples (suspended in DNA 
loading dye: 30% Glycerol, 0.25% Bromophenol Blue and 0.25% Xylene Cylanol FF in 
H2O) are loaded into the wells and the gel is also rim suspended in IX TAE buffer at 50- 
100 Volts.
2.3 Bradford Assay
1. Make a stock solution of BSA at Img/ml.
2. A range of standard protein concentrations are required to construct a standard
curve. A reasonable range is 0 ,1 , 2, 5, 10, 15, 20pg.
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3. Pipette the BSA into Eppendorfs (e.g. Ipi for Ipg) and make up to SOOpl with 
water. Note it is easier to add the water first.
4. Add 200pl of Bradford reagent and vortex.
5. Measure the absorbance at 595nm, blanked against Opg BSA.
6. Perform identically for samples. Note these will usually have to be diluted to give
a reading within range of the assay. Try to keep the volume of the sample added
low i.e. less than lOpl.
7. Read the protein concentration from the standard plot which should be a straight
line.
2.4 Competent Cells (Electrocompetent E.coH)
1. Inoculate 50ml L-Broth in a 250ml conical flask with a single colony of E. coli cells. 
Grow with shaking (200 rpm) at 37°C overnight.
2. At the same time pre-aerate IL L-Broth at 37°C overnight.
3. Inoculate the pre-aerated IL L-Broth with 50ml of the overnight cultur e.
4. Incubate with shaking at 37°C for 2-3 hours imtil it reaches an optical density of 
A600nm=0.6-0.7.
5. Divide the IL culture equally into 4 pre-chilled (on ice) centrifuge bottles (250ml 
capacity) and incubate on ice for 20 minutes.
6. Centrifuge at 3500rpm for 15 minutes at 4°C.
7. Resuspend the cell peUets with 250ml cold sterile water per centrifuge bottle.
8. Centrifiige as above.
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9. Resuspend the cell pellets witlr 125ml cold sterile water per centrifuge bottle. Pool the 
contents of two bottles.
10. Centrifuge as above.
11. Resuspend the cell pellets with 20ml cold 100% glycerol per bottle or (7% DMSO).
12. Transfer to pre-chilled small centrifuge tubes and centrifiige as above.
13. Resuspend the cell pellets with 2ml cold 10% glycerol.
14. Dispense into 50ml aliquots and snap-freeze on dry-ice. Store at -80°C.
15. NB: It is vital that all washing steps are performed ON ICE.
2.5 Ethanol Precipitation of DNA
A general guide to precipitating DNA to rid the solution of excess salt or other 
contamination is to add 1/10^ volume of 3M Sodium Acetate and then 2.5X volume of 
75% Etlianol. Vortex to mix and then incubate at -80°C for at least 20 minutes. DNA can 
also be stored tliis way. Centrifiige the sample at maximum speed in a bench top 
microcentrifoge and carefiilly remove tlie liquid and leave the DNA to air dry.
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2.6 ELISA
1. Dilute tlie bait protein in TBS or carbonate over a range of concentrations in a 
final volume of lOOpl.
2. Plate out in triplicate and leave for one hour at room temp.
3. Wash 3 times with 1% Tween TBS (200pl per well).
4. Block with 5% marvel, lOOpl per well and leave for Ihr at room temp.
5. Wash 3 times witli 1% tween TBS as before.
6. Dilute the Py Ab 1 in 10,000 in 1% marvel and add lOOpl per well. Leave at room
temperature for Ihr.
7. Wash as before.
8. Dilute the alkaline phosphatase conjugated 2nd Ab in 1 % marvel as before and
add lOOjil per well. Leave for Ihr at room temp.
9. Wash 3X as before.
10. Detect witli Blue-phos (mix 50:50). Add lOOpl per well and develop for 10
minutes. Stop with lOOpl 2% EDTA.
11. Read at 590nm in plate reader.
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2.7 First Strand cDNA Synthesis
Using the Pharmacia Kit
To a sterile 0.5ml microcentrifuge tube add:
5pg (l-5pg) of total RNA 
DEPCHzOtototalofZOpl
Heat to 65°C in PCR machine for 10 mins then chill on ice.
Gently pipette the "Bulk strand cDNA mix" up and down to mix and give a brief spin. 
To a second sterile 0.5ml microcentrifuge tube add:
11 pi of "Bulk 1 strand cDNA mix"
Ipl "DTT" solution
Ipl of "Notl-d(T)18" (0.2pg/pl) primer 
20 pi heat-denatured RNA from tube
Pipette up and down to mix and Incubate at 37°C for 1 hour.
Tliis can be stored at -70°C.
2.8 Glycerol stocks
Pipette SOOpl of culture to be frozen into a sterile cryotube and add 200pl sterile glycerol. 
Mix well and store at -80 °C.
2.9 LDH Assay
Pyruvate + NADH gives LDH plus Lactate + NAD
Rate of decrease of OD @340nm is proportional to tlie LDH activity.
96 well plate format, note: reaction starts very quickly so do 1 row at a time and do not 
setup on ice.
Free LDH 186pl 0.15M Tris pH7.4
(Cytosolic) 7 pi lOmMNa pyruvate
7 pi sample
Mix by pipetting. To start add lOpl 2mM beta NADH and READ IMMEDIATELY.
TOTAL LDH 172pl 0.15M Tris pH 7.4 
7 pi 1 OmM Na pyruvate
7 pi sample
ADD 14pl 30% Triton X-100
Mix by pipetting. To start add lOpl 2mM beta NADH and READ IMMEDIATELY. 
%age contamination
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% lysis of PI fraction or whole cell lysate (lysis is normally aroimd 98%)
FREE LDH / total LDH X 100 = %age lysis 
To calculate cytosol contamination of PI 
FREE LDH PI / total free LDH P1+P2+S2 X 100
Slope of the curve in the linear range = rate so the higher the rate the more LDH tliere is. 
14pg sample per well should be adequate.
2.10 Ligation of DNA fragments
As a general guide a 10:1 molar insert to vector ratio should be used and no more than 
5pi of a PCR reaction if being used.
The following reaction mix should be set up:
Ipl Linearised Vector (25ng)
1 to 5 pi PCR product with appropriate 3' and 5' overhangs
Ipl lOX hgation buffer
9pl Sterile water to a total volume of 9pl
Ipl T4DNALigase (4U/pl)
lOpI Total volume
Incubate at 16°C for at least 1 horn* or overnight. Place tlie reaction on ice for 
ti ans formation or store at -20°C until ready to transform cells.
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2.11 Lysis o f COS Cells
1. Wash 100mm confluent plate of cells witli 10ml ice-cold PBS.
2. Remove all PBS and add 500ml of lysis buffer (55mM Tris/HCl, pH7.4, 132mM 
NaCl, 22mM sodium fluoride, llm M  sodium pyrophosphate, 1.1 mM EDTA, 5.5 
mM EGTA) containing protease inhibitor cocktail.
3. Scrape cells, transfer to 1.5ml eppendorf and lyse with 8 strokes of 261/2G 
needle.
4. A post-nucleai' supernatant was prepared by centrifuging the cell homogenate for 
5min at 2000 rev./min (350 gav) at 4°C in a refrigerated Biofuge bench top 
centrifuge. Retain pellet and supernatant. Wash pellet twice with lysis buffer.
5. This produced the PI pellet and the resulting supernatant was centrifuged for 30 
minutes at 100,000 gav at 4°C which produced the P2 fraction and the resulting 
high speed supernatant the S2 fraction. Wash pellet twice with lysis buffer.
6. All fractions were resuspended to the same final volume in complete KHEM.
7. Assay PI, P2 and S/N fractions for protein content (Bradford assay) and subject 
50mg of each fraction to gel electrophoresis and Western blot with 4A common 
antisera.
A more detailed protocol for COS cell fractionation is described below
1. COS-7 cells were transfected as above and incubates for up to 72 before being
prepared for homogenisation as follows:
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2. the growth medium was removed and the cells incubated in cold complete KHEM 
buffer (50mM KCl, lOmM EGTA, 50mM Hepes pH 7.2, 1.92 mM MgC12, ImM 
DTT and protease inhibitor cocktail (used in tablet form, 1 per 50ml solution, 
from Boehringer Mannheim).
3. This was carried out at 4°C and the plates were rocked every few minutes.
4. The complete KHEM was then removed and the cells were washed with lOmM 
triethanolamine/0.15M KCl (pH 7.2) for 10 minutes at 4°C.
5. Tliis was removed after 10 minutes and the cells were washed witli KHEM (no 
additions).
6. After aspirating tlie KHEM the cells were then washed in complete KHEM for 2 
minutes before tlie buffer was drained off.
7. The cells were then scraped from the culture plate and a final volume of approx. 
lOOpl per lOOcm  ^ was transferred to a glass/glass Dounce homogeniser and 
subjected to 20 passes of the pestle.
8. Mock transfected cells were prepared in exactly tlie same way.
2.12 M axiprep/M iniprep DNA
This was carried out according to the manufacturers instructions depending on the 
amount of DNA required. For sequencing the DNA would be prepared using a Miniprep 
kit as the DNA tends to contain less contamination and will provide better data after 
sequencing. Botli Promega and Qiagen DNA preparation kits were used.
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2.13 M ultiple Choice cDNA Screening
TMs was carried out using Multiple Choice™ cDNAs from OriGene Technologies Inc. 
according to the manufacturers instruction manual. Each kit included First Strand cDNA 
from six tissues from either human, rat or mouse (human in two different kits in this case) 
and control primers for p-Actin and a tissue specific gene (Cyclophüin in this case).
2.14 Membrane Association Assay
1. The Promega T7-coupled cell free transcription translation system (TNT) was 
used in order to produce mature cell free hRDl protein.
2. Ipg hRDl DNA was added to the reaction mix to a final volume of 50pl using 
rabbit reticulocyte lysate and other components from Promega according to the 
manufacturer's instructions.
3. [35S] methionine was included to a final concentration of 0.8 mCi/ml. The 
reaction mix was incubated at 30°C for 1-2 h and a post-translational aliquot 
(5pi) was taken for analysis.
4. All samples were adjusted to give equal volumes prior to SDS/PAGE analysis and 
the mature protein was visualised using a Phospholmager.
5. [14C] labelled molecular weight standard markers (Amersham) were used in 
order to assess the molecular weight of the protein produced in tliis system.
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6. 5 pi volumes of this protein were incubated witli 27pg of untransfected COS-7 PI 
or P2 fraction (resuspended in complete KHEM buffer) for 30 minutes on ice at 
4°C.
7. This was to determine whether or not post-translational modifications were 
required in order to facilitate binding of hRDl to components in the PI or P2 
fractions.
8. Samples were subject to centrifugation as described previously and the 
supernatant collected.
9. To investigate the nature of the binding one set of samples were tlien washed once 
with complete KHEM containing 0.1% Triton X-100 before centrifugation and 
the supernatant resulting from this wash step was added to tlie first.
10. Both PI and P2 pellet and supernatant fractions were analysed by SDS/PAGE and 
visualised using a Phospholmager.
11. Similarly hRDl transfected COS-7 cytosolic fraction (S2) was incubated with 
27pg of untransfected COS-7 PI and P2 fractions for 30 minutes at 4°C on ice.
12. These samples were subject centrifugation as above and resulting pellet and 
supernatant fractions were analysed by SDS/PAGE and Western blotting.
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2.15 NaCl Treatm ent o f M em branes
1. Aliquots of PI and P2 fractions were diluted in 150pl complete KHEM buffer so 
that a 50pl volume would give around 14,000 CPM when subject to a PDE assay.
2. The complete KHEM buffer contained increasing concentrations of NaCl (from
0.00IM to 2M) and the PI and P2 fractions were incubated in this buffer on ice at 
4°C for 30 minutes.
3. The PI fraction was then centrifuged at 2000 rev./min (350 gav) for 5 minutes at
4°c and the P2 fraction at 100,000 gav for 30m minutes at 4°C.
4. In both cases the resulting pellet was resuspended in 150pl complete KHEM
containing the appropriate NaCl concentration.
5. Aliquots of 50pl were taken in duplicate from both the PI and P2 supernatant and
pellet fractions and analysed in a PDE assay (at a substrate concentration of 
IpM).
2.16 Phophatase Treatment
Alkaline Phosphatase treatment of cells.
1 OX Alkaline Phosphatase reaction mix (Promega)
0.5M Tris pH 9.3 (HCl) 
lOmM MgCE
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ImM Zn CI2 
lOmM Spermidine
Method. Cells grown in 100mm plates in serum free medium overnight to confluency. 
Scrape cells into 500pl calf intestinal Alkaline Phosphatase buffer.
The Alkaline phosphatase (20 Units) is added after lysis o f the cells which is carried out 
using a 27G needle and centrifuged at 2500rpm at 4 ‘^ C for 5 mins. The Supernatant is 
taken and 20pi Alkaline Phosphatase is added. This is mixed gently and incubated for 1 
hour at 37°C. After incubation the sample is boiled for 5 mins in lOOpl of sample buffer. 
As a control another set of cells grown in exactly the same way should be subject to the 
same treatment but without the Alkaline Phosphatase enzyme added to tlie mix.
2.17 Phosphodiesterase Assay
1. Cyclic nucleotide phosphodiesterase activity was assayed by a modification of 
the two-step procedure of Thompson and Appleman and Rutten et al. as 
described previously by Marchmont and Houslay (1980).
2. All assays were carried out at 30°C and in all expeiiments a freshly prepared 
slurry of Dowex:H20:etlianol (1:1:1) was used for determinations of activities.
3. Initial rates were taken from linear time courses of activity.
4. For the determination of Km values PDE assays were conducted using cAMP 
concentrations over a range from 0.1 pM to 1 OOpM.
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5. The PDE4 inhibitor Rolipram was used in order to determine the IC50 value of 
hRDl, li46 and PDE4A10 for this particular inhibitor.
6. Rolipram was dissolved in 100% DMSO as a lOmM stock and diluted in PDE 
assay buffer (20mM Tris/HCl/lOmM MgCn at a final pH of 7.4) to provide a 
range of concentrations from 0,0001 pmol to lOOpmol.
7.  I C 5 0  values were determined using a substrate concentration (cAMP) equal to tlie 
Km value of each fraction.
8. The PDE activity found in mock transfected ceU fractions was also analysed, 
and although always below background or up to 1% of the activity found in liRDl 
transfected COS-7 cells, was subtracted from those activities found in liRDl 
transfected cells.
2.18 Protein Sequencing
1. Choose a gel system which gives good separation of the desired protein bands; a band 
running in the lower half of the gel will blot better than if it is in tlie top half so adjust 
the acrylamide concentration accordingly.
2. Avoid Urea in the gel if possible - it can cause N-blocks at alkaline pH.
3. Pre-run with separating gel buffer containing O.lmM (6.977pl/L) Thioglycollic acid 
(in the upper electrode buffer), before pouring the stacking gel. The mobile Thiol will 
run aliead of the protein and scavenge for N-blocking fi ee-radicals.
4. Use tliis gels and ensure acrylamide is of high quality and deionise before use.
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5. Where possible, cast gels a day before use to allow die polymerisation to go to 
completion - free acrylamide can N-block proteins.
6. Using 100“200pmol of each protein in one or two tracks of the gel, run the gel and 
tlien soak it, with shaking, in transfer buffer for 10 min. If poor transfer or over­
transfer is experienced, increasing tlie equilibration time to 30 min can be beneficial. 
Transfer buffers commonly used are 25mM Trizma, 190mM glycine, 10% MeOH; 
lOmM CAPS, 5raM D TI, 10%MeOH, pH 11; 50mM N-ethylmorpholine pH8.3, 
10% MeOH, 5mM DTT. The Trizma buffer is suitable for most applications where 
the proteins of interest are below 50-60kDa. The inclusion of SDS is not usually 
necessary, but for difficult proteins (e.g. pl>7) the presence of no more than 0.02% 
SDS can be helpfril. Higher amoimts of SDS can reduce the binding capacity of 
PVDF for protein. The CAPS buffer is generally preferable for high MW proteins 
(e.g. >50 000). For difficult membrane proteins, the inclusion of 0.05% Triton X-100 
or Tween in the equihbration buffer only can help to keep die protein soluble; omit 
the detergent from the transfer buffer.
7. Wliere problems of N-blocking are encoimtered, the use of a lower pH gel system can 
be advantageous and may be worthwhile routinely.
8. NB All washing/equihbration steps must be done with gentle agitation or shaking. 
Wearing gloves at all times when handling PVDF, prepare the PVDF membrane by 
immersion in AR MeOH for 10 sec followed by equilibration in transfer buffer for 5 
min. Prepare a gel/PVDF/blotting paper sandwich as for Western blotting, ensuring 
exclusion of all air bubbles. When blotting onto PVDF for the first time with a given 
protein whose behaviour on electroblotting is unknown, the inclusion of 2 membranes
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on the anionic side of the gel and 1 membrane on tlie cathodic side will monitor 
excessive transfer or the presence of extremely electropositive proteins respectively.
9. Conduct tlie electroblotting using conditions similar to those used for Western 
blotting to nitrocellulose. In wet-blot, 300mA for l-3h is generally sufficient althougli 
transfer time and current must be optimised for each protein studied. Excessive 
transfer time (i.e. overnight) can be detrimental and insufficient transfer leads to poor 
yield. In this respect, it is advisable to optimise the transfer of related proteins before 
submitting the protein under study should tliis be in short supply. In semi-dry blots,
0.8-lmA/cm^ for 30min-1.5h is usually satisfactory.
10. Wlien transfer is thought to be complete, remove the PVDF membrane and wash 
immediately in water for lOmin with shaking. If the membrane is allowed to dry at 
any stage, even partially, it must be re-wet with MeOH before immersion in aqueous 
medium, hnmobilon P - stain the membrane with 0.1% Coomassie Blue R in 50% 
MeOH for 5min and destain with several changes, 2-5min each, of 50% MeOH; 10% 
Acetic acid. Problott - Stain the membrane witli 0.1% Coomassie Blue R in 50% 
MeOH, 1% acetic acid for 5min and destain with several changes, 2-5min each, of 
50% MeOH. The membrane will remain a feint blue colour, do not try to make it 
white! Finally wash the membrane in water (5min) and air-dry thorouglily; damp 
membranes will not be accepted for sequence analysis. Place the membrane in a 
plastic bag and store dry at -20°C.
11. If your protein does not react with Coomassie, Amido Black and Ponceau S stains are 
compatible with sequence analysis.
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2.19 Purification o f DNA from Gels or Solution
In order to purify DNA fragments from Agarose gel slices it is necessary to melt the 
agarose with a suitable buffer so that the DNA is in solution. Various kits are available to 
purify DNA from gel shces and if the DNA is aheady in solution the kits can also be used 
instead of Ethanol precipitation. The most commonly used kit here was from Qiagen and 
employed beads to wliich the DNA bound in order to separate it from the solution. 
Another kit which was frequently used was the Advantage^*^ PCR-Piue Kit from 
Clontech. The protocol is described below:
A Piu’ification of DNA from solution
1. Measure the volume of DNA solution and estimate the DNA concentration.
2. Add SALT solution (3X the volume of the DNA solution). Mix well.
3. Vigorously vortex tlie PCR-Piue BIND, and add the required amount of BIND to tlie 
DNA solution. Always use a minimum of 5pi of BIND per sample. For DNA samples 
less than Ipg use an extra Ipl of tlie BIND per pg of DNA.
4. Incubate at room temperature for 5min to allow DNA to bind to tlie PCR-Piue BIND. 
Keep the BIND in suspension by gently flicking the tube occasionally by hand.
5. Centrifuge the BIND/DNA complex at 14,000rpm for 5sec. Remove SALT 
supernatant and set aside. Although the DNA should remain with tlie pellet (BIND), 
save the supernatant imtil you have assessed the yield.
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6. Add 1ml of WASH solution to the pellet. *For DNA >15Kb Resuspend the pellet in 
the WASH solution by gently pipetting up and down. For DNA smaller than or up to 
15Kb do not Resuspend the pellet. Instead, soak tlie pellet for 5min in the WASH 
solution.
7. Centrifuge the BIND/DNA complex at 14,000rpm (10,000xg) for 5sec. Remove 
WASH supernatant.
8. Centrifuge the BIND/DNA complex at 14,000rpm for 5sec again. Remove any 
residual WASH solution with a narrow pipette tip. Dry tlie pellet.
9. Resuspend the pellet in H2O or a low-salt buffer such as TE. Use 2X the volume of 
the PCR-Pure BIND used in step 3 above. Completely resuspend the pellet by gently 
pipetting up and down. Do not vortex.
10. Incubate at room temperature for 5min to elute the DNA from the BIND. Keep pellet 
in suspension by gently flicking the tube occasionally by hand.
11. Centrifuge the tube at 14,000rpm for Imin at room temperature.
12. As soon as the centrifuge stops, carefully remove tlie supernatant (containing the 
DNA) using a pipette tip. Avoid taking up the white pellet material witli the DNA. 
Transfer the DNA to a fresh tube.
13. Assess the yield of the DNA. It is now ready to use.
B DNA Extraction from Gels
1. Excise the desired band(s) from the EtBr/agarose gel. Weigh the gel slice(s) to 
estimate the volume (Ig = I ml).
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2. For TBE-buffered gels only; add MELT solution (0.5X the volume of the gel slices).
3. Add SALT solution. For TBE-buffered gels: use 4.5X the volume of the gel slices. 
For TAE-buffered gels: use 3X the volume of the gel shces.
4. Incubate at 55°C for 5-lOmin. Gently invert or flick the tube occasionally to mix 
contents and to promote melting. Do not vortex. Make sure that tiie gel is completely 
melted before proceeding to step 5.
5. Vigorously vortex the PCR-Pure BIND and add the required amount of BIND to the 
DNA solution. Always use a minimum of 5pi of BIND per sample. For DNA samples 
>pg use an extra Ipl of BIND per pg of DNA.
6. Incubate at room temperature for 5min to allow DNA to bind to the PCR-Pure BIND. 
Keep the BIND in suspension by gently flicking the tube occasionally by hand.
7. Centrifuge the BIND/DNA complex at 14,000rpm (10,000g) for 5sec. Remove SALT 
supernatant and set it aside. Although the DNA should remain with tlie pellet (BIND), 
save the supernatant until you have assessed the yield.
8. Add I ml of WASH solution to the pellet. For *For DNA >15Kb resuspend the pellet 
in the WASH solution by gently pipetting up and down. For DNA smaller tlian or up 
to 15Kb do not resuspend the pellet. Instead, soak the pellet for 5min in the WASH 
solution.
9. Centrifuge the BIND/DNA complex at 14,000rpm (10,000xg) for 5sec. Remove 
WASH supernatant.
10. Centrifuge the BIND/DNA complex at 14,000rpm for 5sec again. Remove any 
residual WASH solution with a narrow pipette tip. Dry the pellet.
102
11. To recover tlie DNA, resuspend the pellet in H2O or a low-salt buffer such as TE. Use 
2X die volume of the PCR-Pure BIND used in step 5 above. Completely resuspend 
the pellet by gently pipetting up and down. Do not vortex.
12. Incubate at room temperature for 5min to elute the DNA from the BIND. Keep pellet 
in suspension by gently flicking the tube occasionally by hand.
13. Centrifuge the tube at 14,000rpm for Imin at room temperature.
14. As soon as the centrifuge stops, carefully remove the supernatant (containing the 
DNA) using a pipette tip. Avoid taking up the white pellet material witli the DNA. 
Transfer the DNA to a fresh tube.
15. Assess the yield of the DNA. It is now ready to use.
2.20 QuickChange Mutagenesis
Tliis was carried out according to instructions accompanying the Stratagene 
QuickChagne™ Site-Directed Mutagenesis Kit. There are very specific considerations 
regarding the design and synthesis of the QuickChange primers which must be adhered 
to.
1 0 3
2.21 RNA Isolation for RT-PCR
RNA Isolation
1. Remove medium from confluent cells (or spin down suspension cells).
2. Wash witli PBS.
3. Add I ml TRI-REAGENT per I0cm2 cells or 1ml suspension cells, and scrape
cells.
4. Remove cells and place in a 1.5ml eppendorf.
5. Homogenise cells by pipetting up and down lOX witli a 1ml syringe and needle.
6. Centrifuge at 12,000 g for 10 min @ 4°C, keeping tlie clear supernatant.
7. Allow samples to stand for 5 min @ room temp.
8. Cell lysate can be stored in TRI-REAGENT for up to 1 month @ -70°C
9. Add 0.2ml chloroform per ml TRI-REAGENT used. Cover sample and shake
vigorously for 15 sec then stand for 2-15 min@ room temp.
10. Centrifuge the mix @ 12,000 g for 15 min @ 4°C
11. This produces 3 phases; red organic, protein: interphase, DNA: colomless
upper aqueous, RNA. These phases can also be stored.
Preparation for RT-PCR
1. After transfer of aqueous phase to a fresh tube, mix with a tenth vol. isopropanol
and store @ room temp for 5 min.
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2. Centrifuge @ 12,000 g for 10 min @ 4°C.
3. Transfer supernatant to fresh tube and precipitate RNA by adding remaining 
amount of isopropanol.
4. Add 0.5ml isopropanol per ml of TRI-REAGENT used in sample preparation and 
mix. Stand for 5-10 min@ room temp and centrifrige@ 12,000 g for 10 min @ 
4°C.
5. RNA will fonn a peUet on side and bottom of tube.
6. Remove s/n and wash RNA by adding 1ml 75% BtOH per ml TRI-REAGENT 
used.
7. Vortex then centrifuge @ 7,500 g for 5 min @ 4°C. If RNA floats, perform wash 
in 75% EtOH at 12,000 g. Samples can be stored in EtOH @ 4°C for I week or - 
20 for I year.
8. Briefly dry RNA pellet for 5-10 min by air-drying. DO NOT LET PELLET DRY 
COMPLETEY.
9. Add an appropriate vol. of Formamide, H20 or 0.5% SDS solution to the RNA 
pellet. To facilitate dissolution, mix by repeated pipetting witli a micro-pipette @ 
55-60°C for 10-15 min.
10. SPEC. The RNA should have a 260/280 ratio of equal or more than 1.7. Typical 
yields (microgRNA/lXlO 6 cells): epithelial:8-15 pg, fibroblasts: 5-7pg.
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2.22 Sequencing
Nearly all sequencing was carried out on an ABI P rism ^ 377 automated sequencer. The
protocol for preparing the sequencing gel is detailed below.
1. Wash sequencing plates; wann water - Alconox - warm water - dHaO - air dry (wash 
plates, spacers and combs in this way).
2. Prepare the reagents. Mix (for 36cm) : Urea 18g, 40% Acrylamide stock 5ml, dH^O 
25ml, mixed-bed, ion-exchange resin 0.5g. Sth until urea dissolves. While stirring 
mount plates in cassette.
3. To mount plates place cassette on level surface, lift beam stop and open cassette plate 
clamps. Clean inside of plates. Place lower plate - spacers (drops of dHzO to hold) - 
upper plate. Make sure plates go between beam stop and bottom bracket, stops at 
bottom engage lower plate notches. Close plate clamps to hold plates in.
4. To moimt tlie gel in the injection device, place assembly on raised LEVEL platfoim. 
Slide side pegs of clear brace imder clamps, then slide top pegs over top edge of front 
glass plate. Attach bottom support and press down against top edge of rear glass plate. 
Hold bottom fixture at 45° angle against bottom of plates, tlien lay down on plates, 
rubber gasket making flat contact with glass. Turn side tensioning knobs to hold.
5. Inject tlie gel, filter solution - degas 2-5 mhi - transfer to 100ml graduated cylinder. 
Add 5ml lOX TBE buffer and adjust the volume to 50ml with dHaO. Get a clean 
comb, clamps and a 50ml (60 cc) syringe. Gently add to the solution 250pl 10% APS 
and 35pi TEMED. Draw 30-50ml into the syringe. Screw tip of the syringe onto
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bottom fixture. Inject solution slowly and steadily imtil it pools in a notch at the top 
of the plates. Remove the syringe and remove the bottom fixture. Insert gel casting 
comb and clamp down top fixtures with plate clamps. Wait 2 hours.
6. When the gel is set it can be placed in tlie fi-ame inside the sequencer, then the 
running buffer (IX  TBE) added to the top reservoir. After a pre-run (controlled by the 
ABI Prism software run on an Apple Mac) samples suspended in appropriate loading 
dye are then slowly injected into the wells.
7. The sequencer is run using ABI Prism software on Apple Mac.
2.23 Sequencing mixes
Dynamic Universal
Use 2pi of either the A, C, G or T label witli 3pi of DNA template to be sequenced. Use 
the following sequencing cycle: 95°C for 30 seconds, 45°C for 15 seconds, 70°C for 45 
seconds, for a total of 30 cycles.
After the sequencing cycle the products are spim down in a microcentrifuge and the A, C, 
G and T reactions pooled for each clone being sequenced.
Add 8pl of Formamide dye to each tube and load 2pi into a lane on the sequencing gel.
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Mixed deaza ET Reverse Primers
A C G T
Mixes 2 2 4 4
ET Reverse primer 1 1 2 2
Template DNA 5 5 10 10
Total (pi) 8 8 16 16
The PCR cycling conditions are as above and then the reactions (A, C, G and T) for each 
clone are pooled.
The products are Ethanol precipitated using 3.6pi of 7.5M ammonimn acetate and 120pl 
of Ethanol. After being spun in a microcentrifuge the products are washed with 70% 
Ethanol and resuspended in 4pl of Fonnamide dye. 2pi of this is loaded into a well on the 
sequencing gel.
BIG DYE
The sequencing reaction mix is made up as follows:
8 pi T erminator mix
200-500ng Template DNA (ds)
3.2pmol Primer
make up to a total volume of 20pi witli dH2 0 .
Cycling parameters are as follows: 25 cycles of 96°C for 30s, 45°C for 15s, 60°C 4min.
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Samples are then precipitated using Isopropanol as follows;
1. Add 80pl 75% Isopropanol.
2. Vortex then incubate for 15min to precipitate.
3. Centrifuge at maximum speed in a bench-top microcentrifuge for 20min and then 
remove the supernatant.
4. Add 250pl 75% Isopropanol and vortex,
5. Centriflige at maximum speed for 5min.
6. Remove supernatant and air dry for 10-15min or on a block at 90°C for Imin.
2.24 Synthesis of cDNA from Poly A+ RNA
Reverse Transcriptase reaction
l-5pg total RNA (stim)
10.5pl H2O (treated to remove Rnases)
1 pi oligo DT (or a specific primer)
This mixture was placed at 65 °C for 10 minutes and then at room temperature for 2 
minutes. The following was then added in order:
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l.Opl Rnase inhibitor 
4.0pl5X R T buffer 
l.OpllOOmM dNTPs 
1 .Opl Na Pyrophosphate
O.SplAMVRT
Mix by tapping, spin in a microcentrifuge then incubate at 42°C for Ihr. Then raise the 
temperature to 95°C for 2 minutes. Dilute the product with 80pl of sterile H2O and store 
in the -20°C freezer.
2.25 TA cloning
This is a particularly good way to clone small fragments of DNA which need to be 
sequenced. The fragments have generally been created by PCR and then gel-purified so 
they need to be treated with Taq before cloning can proceed in order to re-create the 
correct "A" over-hangs for TA cloning. This eliminates any enzymatic modifications of 
the PCR product. Taq polymerase has a nontemplate-dependent activity which adds a 
single deoxyadenosine (A) to the 3'ends of PCR products. The linearised vector supplied 
witli the Invitrogen kit has a single 3’ deoxythymidine (T) residues allowing PCR inserts 
to ligate efficiently with the vector.
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The Invitrogen kit was used for TA cloning and used the vector PCR2.1 for ligation of 
the PCR inserts. The vector PCR2.1 was supphed with the kit and cloning was carried 
out according to the instructions in the Invitrogen manual supphed with the kit.
2.26 Thermostability assay
1. Ahquots of S2, PI and P2 fractions from liRDl transfected COS-7 cells were
diluted in complete KHEM (in 50ml universals) so that 50pl volume would 
produce 14,000 CPM when subject to a PDE assay.
2. 50pl aliquots of each fraction were taken while the fractions were still on ice and
then the universals containing the fractions were placed in a water bath at 50°C.
3. Once again 50 pi ahquots of each fraction were taken in duplicate every two
minutes and removed to ice-cold micro-ftige tubes every two minutes over a 
period of 40 minutes. This entire procedure was repeated at 55°C.
4. These samples were then assayed for cyclic AMP PDE activity at a substrate 
concentration of I pM.
I l l
2.27 TNT reticulocyte lysate system
This cell-free transcription-translation system is available from Promega and the reaction 
should be carried out according to the instructions in the manual supplied with tlie kit. 
One consideration before ordeiing the kit is the type of promoter contained within the 
vector from which the insert is to be expressed in the TNT system. For example if the 
vector contains a T7 promoter upstream of the initiating ATG for the insert sequence then 
a TNT T7 Coupled Reticulocyte Lysate System kit will be required.
A general protocol for the reaction can be seen below;
1. To reduce the chance of Rnase contamination, gloves should be worn when setting up 
experiments and all microcentrifuge tubes and pipette tips should be Rnase-free. It is 
recommended that Rnasin Ribonuclease inhibitor is added to all TNT Lysate 
reactions to prevent degradation of RNA.
2. It is also recommended tliat a control reaction containing no added DNA is mciuded. 
This reaction will allow measurement of any background incorporation of labelled 
amino acid.
3. Remove the reagents from storage at -70°C. Immediately place the TNT RNA 
polymerase on ice. Rapidly thaw the TNT Reticulocyte Lysate by hand warming and 
place on ice. The other components can be thawed at room temperature and then 
stored on ice.
4. Following the example below assemble the reaction components in a 0.5ml or 1.5ml 
microcentrifuge tube. After addition of all the components, gently mix tlie lysate by
112
pipetting tlie reaction up and down. If necessary, centrifuge briefly to return the 
reaction to the bottom of the tube.
5. Example of a TNT® Lysate reaction using ^^S-methionine:
TNT® Rabbit Reticulocyte Lysate 
TNT® Reaction buffer
TNT® RNA Polymerase (SP6, T3 or T7 if appropriate)
Amino Acid Mixture Minus Methionine; ImM 
^^S-methionine (lOOOCi/ml) at lOmCi/ml 
RNasin® Ribonuclease Inliibitor, 40units/pl 
DNA template(s)
Nuclease-free H2O
25pl
2pl
I pi
Ipl
4pl
Ipl
Ipg
to a final volume of 50pl
NB: Small scale reactions may be performed by reducing die volumes proportionally; 
reactions of 25pl aie common.
Incubate die reaction at 30°C for 60-120min (depending on the promoter - see manual). 
Then analyse the results of the translation reaction using an appropriate gel system.
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2.28 Transfection o f COS cells
1. COS-7 cells were seeded at approx. 50% confluency 24 h prior to transfection on
600cm2 plates and grown in complete DMEM at 37°C.
2. lOpg hRDl DNA was diluted to 250pl (for each 100cm2 of COS-7 cells) in TE 
buffer to which 200pi of DEAE Dextran was added.
3. Tliis was left at room temperature for 15 minutes while the medium was aspirated 
from the cells and replaced with DMEM containing 10% Nu serum and 0.1% 
chloroquine.
4. The DNA/DEAE Dextran was dropped onto the cells and mixed by swirling.
5. These plates were incubated for 3-4 h before being shocked 
withlO% DM SOinPBS.
6. After shocking the cells were incubated in complete DMEM for 48 to 72 h before 
harvesting.
2.29 Transformation of DNA into Bacteria
Tins can be achieved in two ways, either chemically or using electricity. Both are 
described below and depends on the bacteria being used being eitlier electro or 
chemically-competent.
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Electrotransformation o f  E. coli
1. Chill the required number of 0.2cm electroporation cuvettes at -20°C.
2. Add 2 vol of sterile water to ligation mixture. Heat inactivate T4 DNA Ligase at 65°C 
for 10 minutes. NB: Ignore this step if transforming plasmid DNA that was 
resuspended in water.
3. Thaw tlie electrocompetent cells on ice.
4. Add 2pi of the ligation sample per 50 aliquot of cells. Mix gently using a pipette tip.
5. Incubate Imin before pulsing.
6. transfer to the chilled cuvette and electroporate wiüi a single pulse of 6000, 25 pF and 
2kV (use Biorad electroporator at 2.5kV).
7. Immediately add Irai L-Brotli and incubate the cells with shaking at 37°C for half an 
hour before spreading onto plates containing a suitable medium (e.g. LB-agar).
Chemical transformation of E. coli cells
1. Centrifuge the vials containing the ligation reactions briefly and place on ice.
2. Thaw on ice one 50pl vial of E. coli cells for each ligation/transformation.
3. Add 2pi of 0.5M p-Mercaptoethanol to each vial of competent cells and mix by 
tapping gently. Do not mix the cells by pipetting.
4. Pipette 1 to lOpl of each ligation reaction directly into the competent cells and mix by 
tapping gently. The remaining ligation mixes can be stored at -20°C. Ipl of diluted 
supercoiled pUC18 plasmid (hivitrogen) can be used for the transformation control.
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5. Incubate the vials on ice for 30min.
6. Incubate for exactly 30s in the 42°C water bath. Do not mix or shake.
7. Remove vials from the 42°C water bath and quickly place them on ice for 2min.
8. Add 250pl of pre-warmed *SOC medium to each vial. (SOC is a rich medium so 
good sterile technique must be employed to avoid contamination).
9. Place the vials in a microcentrifuge rack on its side and secure vials with tape. Shake 
the vials in the rack for 37°C for exactly Ih at 225rpm in a shaking incubator.
10. Place the vials with the transformed cells on ice.
11. Spread 20pl to 200pl from each transformation vial on sepaiate labelled LB agar 
plates. Note; Plate 50pl from the transformation control. The remaining 
transformation mix may be stored at +4°C and plated out tlie next day if desired.
12. Invert the plates and incubate at 37°C overnight.
13. Select colonies for further analysis by plasmid isolation, PCR or sequencing.
*SOC medium is made in the following way:
1. To 950ml dHiO 20g tryptone, 5g yeast extract and 0.5gNaCl.
2. Prepare 250mM KCl (0.86g KCl in 100ml dHiO) and add 10ml of this to step 1.
3. Adjust the pH to 7 with 5M NaOH and adjust the volume to 980ml with dHzO.
4. Make a IM solution of MgCh (20.33g MgCh.dH20) in 100ml dH20.
5. Autoclave both solutions.
6. Make a 2M solution of glucose (36g glucose in 100ml dH20) and filter sterilise.
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7. Let the autoclaved solutions cool to around 55°C then add lOinl of the 2M glucose 
and 10ml of the IM  MgCh to tlie solution prepared in step 3. Store at room temp or - 
4°C.
2,30 Triton X-100 Treatment of COS cell Membranes
1. Aliquots of PI and P2 fractions were diluted in 150pl complete KHEM buffer
containing a range of Triton X-100 concentrations (from 0.1% to 5%) so tliat a 
50pi volume would give a reading of around 14,000 CPM when subject to a PDE 
assay.
2. The fractions were incubated in the above buffer for 30 minutes on ice at 4°C
before centrifugation.
3. The PI fraction and P2 fraction were centrifriged as described previously.
4. The resulting pellets were re suspended in 150pl complete KHEM containing the
appropriate Triton X-100 concentration and 50pl aliquots were taken in duplicate 
from both the supernatant and the pellet fractions of both PI and P2 for analysis 
by PDE assay (at a substrate concentration of 1 pM).
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2.31 W estern Blotting (after SDS-PAGE)
1. Acrylamide (10%) or low Bis-Acrylamide gels or Novex minigels were used and 
the samples boiled for 2 minutes after being resuspended in Laemmli buffer (or 
reducing sample buffer in the case of Novex minigels and then the manufacturers 
protocol was followed for running of the gels).
2. Gels were run at 8 mA/gel overnight or 50 mA/gel for 4-5 h with cooling.
3. For detection of liRDl, h46 and PDE4A10 in Western blotting, 30-50 pg of 
protein samples were separated by SDS/PAGE and then transferred to nitro­
cellulose before being immimoblotted using antiserum (antibody 97) to tlie 
catalytic core PDE4A region.
4. Labelled bands were identified using anti-rabbit peroxidase-linked IgG (Sigma) 
and the Amersham ECL Western blotting visualisation protocol.
5. Bio-rad prestained molecular weight standard markers were used (myosin, 203 
kDa; 6-galactosidase, 116 kDa; bovine sermn albumin, 83 kDa; ovalbumin, 48.7 
kDa; carbonic anhydrase, 33.4; soybean trypsin inliibitor, 28.2 kDa; lysozyme, 
20.7 kDa; aprotinin, 7.6 kDa) in order to detennine the molecular weight of liRDI 
and the results indicated a size of approx. 82.4 kDa on SDS/PAGE (predicted size 
72 kDa).
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General Protocol for Western blotting;
1. After running the gel, wet (witli transfer buffer: 72g glycine plus 15g Tris made up in 
4L then add IL MeOH) 4 pieces of blotting paper and 1 piece of nitrocellulose, all cut 
slightly larger than the gel.
2. Make sandwich, with nitro-cellulose covering the gel, in between two layers of 
blotting paper (and then sponge), above and below the gel. Make sure tliere are no air 
bubbles between the nitro-cellulose and the gel.
3. Place in a transfer tank for Hi at lAmp (with cooling) or 2h at 0.5Amps. Use tlie 
transfer buffer made earher in the tank during transfer.
4. Take the nitro-cellulose blot out of the sandwich.
5. Wash the blot with, then stain with Ponceau red stain (optional). Then wash with 
TBS/PBS buffer (TBS: 0.5M NaCl, 20mM Tris HCl at pH 7.5 or PBS made using 1 
PBS tablet per 100ml CIH2O which disolve upon sterilisation).
6. Block for Ih or overnight with 5% Marvel (or 2% BSA).
7. Add Antibody (dilution usually 1 in 1000 to 1 in 10,000) in TBS/PBS with 2% 
Marvel for Ih or ovemiglit.
8. Wash 3 times for 5min in 1% Tween 20 in TBS/PBS.
9. Add 2"^  ^ Antibody-HRP conjugated (1 in 1000) in TBS/PBS with 2% Marvel and 
incubate for 0.5-1 h.
10. Wash 3 times for 5min in TBS/PBS.
11. Put on ECL (5ml of each solution A and B using a different pipette for each) for 1 
minute.
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12. Quickly drip-dry the blot and put in film cassette between 2 pieces of sparkle film
13. Expose from Imin to 30min depending on the intensity of the bands.
120
CHAPTER 3
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3.1 Cloning of hRDl
3.1.1 Introduction to cloning of hRDl
RDI is a rodent short-form PDE (Shakur et al. 1993). Short-form PDEs differ to long- 
forms in tliat they only contain UCR2 whereas the long-forms contain both UCRl and 
UCR2. RDI is unique in that the protein is found to be associated witli the membrane. 
Detection using immunological methods revealed that RDI was exclusively associated 
with the membrane fraction (McPhee et al. 1995). Further studies showed that ability to 
target this isoform to the membrane was contained within tlie first 23 residues of the 
unique N-tenninal (Scotland and Houslay 1995).
Sequencing of tlie HSPDE4A gene revealed the existence of a human homologue to the 
rodent RDI with an identical N-terminal sequence. It was decided to clone and express 
the sequence encoding this isoform and investigate whether or not the same targeting 
properties would be exhibited by the protein.
Fine mapping of the HSPDE4A gene on to cliromosome 19 (Sullivan et al. 1998) 
authenticated the existence of tlie hiunan RDI by locating the exons encoding the imique 
N-terminal sequence. This work also demonstrated that the point of alternative mRNA 
sphcing in short-form PDE4A is distinct from that used in the generation of PDEB and 
PDED short-forms. PDE4B and PDE4D sequences both encode a complete UCR2 
whereas the active PDE4A short-form cDNA only possesses 2 of the 3 exons that encode 
UCR2.
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In this chapter I have identified, cloned and characterised the short human homologue of 
rat RDI. I found tiiat it is a catalytically active species and has the abihty to associate 
with membranes.
3.1.2 PDE4A1 (hRDl) sequence
The schematic diagram in figure 13 shows the location of the hRDl splice junction 
relative to tlie otlier structural components of this PDE enzyme. The diagram in figure 14 
shows tlie entire coding sequence for the long-fonn PDE isoform PDE4A4B (h46) 
highlighting tlie sequence encoding the particular domains (N-terminal domain, UCRl, 
UCR2, position of the hRDl sphce junction site, die catalytic domain and die C-tenninal 
region) of this isoform. The position of all primers used for sequencing liRDl clones are 
also shown as die majority are located in die PDE4A common region which is sequence 
shared with PDE4A4B (h46).
Forwards primers used included: FBI5a, FB2, FB3, FB4, 4AS1, 4AS3, 4AS5, 4AS7, 
4AS8 and Universal primer to read in from the 5' vector sequence. The reverse primers 
wliich were used were as follows: FB7, FB6, FB5, FB9, 4AS2, 4AS4, 4AS6, 4AS9, 
4AS 10, 4A3' and Reverse primer to read in from the 3' vector sequence (see schematic in 
figure 15 and also figure 14 for specific location).
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3.1.3 Primers designed to target regions of unique sequence encoding hRDl
In an attempt to clone the sequence encoding the human form of RDI the first strategy 
was to PCR amplify the sequence from an endogenous source. Various human cDNAs 
were used as the template and it was hoped to amplify the region encoding both the 
unique N-terminal region as well as some common PDE4A sequence downstream of the 
splice junction. The sequence encoding tlie entire open reading frame for the gene could 
then be obtained either through direct PCR from human cDNA or else the unique N- 
terminal region could be spliced onto the common region already placed within an 
expression vector.
The following primer pairs were designed to attempt to amplify unique human RDI 
sequence (including some common region in tlie fragment) from various cDNA sources 
(detailed below). The primer pair used for liRDl used the 5' primer FB-RDl (CCA TGT 
AAC CAG GGC T) and the 3' primer FB6 (CTG GAG AAC CTG AAC AAG) and the 
expected band size 407. The cycling conditions used were 94°C for 10 seconds, 55°C for 
30 seconds and 72^C for 1 second.
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3.1.4 Screening Clontech cDNAs for hRDl plus RTPCR Using Poly A+ RNA (also 
from Clontech)
The cDNAs used as template for the target gene hRDl were purchased from Clontech 
and Stratagene and the range included cDNA from die following tissues: Frontal Cortex, 
Liver A, Liver B, Lung (normal). Heart as well as a haematopoetic cell line (HL60) and 
T-cell DNA. The PCR conditions were optimised and changed several times but these 
investigations did not yield any positive results.
The major problem involved in attempting to amplify native liRDl sequence was now 
becoming apparent. The sequence encoding the unique hRDl N-tennmal region is very 
GC-rich (this would include any sequence with more than 60% GC content) as is tlie 
sequence directly upstream of it. Any sequence with a majority of GC content is likely to 
be difficult to PCR due to the formation of secondary structure which prevents primers 
annealing to it. It was also possible tliat die cDNA may have not been of high enough 
quality so die first strategy was to order RNA from wliich to produce cDNA instead of 
using ready-made cDNA.
RNA was ordered from Clontech fr om which to make cDNA. Tliis included human brain 
whole cerebellum Poly A+ RNA, human whole cerebral brain Poly A+ RNA and human 
skeletal muscle Poly A+ RNA. New primers were also designed to amplify liRDl and 
figure 16 hsts all of the primers used in this particular investigation.
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3.1.5 Clontech A dvantage-G C -M eit cDNA PC R Kit
None of the previous PCR reactions to amplify native hRDl sequence from human 
cDNA had been working. A Clontech Advantage-GC-Melt cDNA PCR kit was used to 
overcome the problems involved in amplifying very GC-rich sequences. Such sequences 
possess strong secondary structure that resists dénaturation and prevents primer annealing 
so the PCR fails to yield a product.
The GC-Melt kit included a buffer containing DMSO which disrupts base-pairing in GC- 
rich sequences and a GC-Melt reagent which further weakens tlie base-pairing. These 
PCR reactions were carried out with two different types of enzymes. TaqStart and 
TthStart are both designed to improve efficiency and specificity of PCR amplification 
and both have neutralising monoclonal antibodies directed against Taq and Tth 
polymerases respectively. The polymerase activity is restored at the onset of thermal 
cycling because the antibodies are rendered non-functional by temperatures greater than 
70°C and the polymerase regains complete enzymatic activity for the PCR.
Despite the use of these reagents none of the PCR reactions designed to amplify unique 
human RDI sequence from human cDNA templates produced any positive results.
3.1.6 hRDl cloning strategy
None of the previously detailed methods designed to amplify the unique human RDI N- 
terminal sequence from an endogenous source had yielded positive results. A new
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approach was required and this was based on the fact that the sequence encoding the 
unique N-terminal region of human RDI (the rodent short-fonn PDE4A) was already 
known (from sequencing of the HSPDE4A gene) and so too was the position of the splice 
junction, from the rodent RDI sequence. This was particularly useful as we could now 
engineer a frill length hRDl sequence by synthesising the N-terminal sequence and 
splicing it onto the PDE4A common region at the same position as in the rodent form. 
This would remove any problems caused by the GC-rich nature of the N-tenninal 
sequence.
The strategy to clone tlie full length hRDl sequence included synthesising the unique 87 
base pair-long N-terminal region which was 100% homologous to the rodent form. This 
was achieved by synthesising two long oligonucleotides containing the unique N-terminal 
sequence, one reverse and complimentary to tlie other, which could then by annealed 
together to form double stranded DNA. The sequence chosen would also include 
restriction enzyme sites suitable for cloning this DNA into an expression vector. This 
would create a stable situation for the newly created DNA as it would be more prone to 
dissociate if it were not contained within a larger piece of DNA. Sequencing of the 87 
base pair N-terminal sequence is also easier when it is contained within an expression 
vector as sequencing primers anneahng outside of the sequence can be used to give good 
quality sequencing data to verify the bases at the N- and C-tenninal ends of tlie cloned 
fragment. Sequencing is necessary to check that the two long oligonucleotides have 
annealed as expected where tliey are reverse and complimentary to each other and not in 
any other way.
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The core or common PDE4A region (the region downstream from the RDI splice 
junction) containing the conserved catalytic domain, a region of 1,8Kb, was PCR 
amplified separately. The sequence of this region in human RDI is based on die rodent 
sequence in that it does not contain UCRl and an incomplete UCR2 as tlie splice junction 
occurs downstream of the first exon encoding UCR2.
Based on tliis strategy the entire hRDl open reading frame is contained within two 
fragments. One 87 base pairs long, encoding the unique N-terminal and another 1.8Kb 
long encoding the human common PDE4A region downstream of the splice junction for 
hRDl. Both fragments were cloned into separate expression vectors so that they could be 
sequenced. They were also engineered so tiiat they could be ligated together at the splice 
junction and then the entire new gene sub-cloned into a different vector for expression.
The unique N-tenninus was generated by annealing two long 87-mer oligonucleotides 
(synthesised by Cruachem). The resulting double stranded DNA was then cloned into the 
vector PK19 using the BamHI and Sail restriction sites. The common region (a region 
1.8Kb long encoding the common HSPDE4A region downstream of the RDI splice 
junction in UCR2) was amplified from DNA encoding the HSPDE46 sequence using 
primers 5', FBI5a (AAG TTT AAA AGG ATG TTG AAC C) and 3', FB3'Sall (GTC 
GAG GAG GTC TGG GGA TCA GGT A). Cycling parameters were 25 cycles of 95'^C 
for 30 seconds, 60°C for 30 seconds then 12°C for 2 minutes. The polymerase PWO was 
used to amplify this fragment due to its high proofreading fidehty and increased half-life 
at higlier temperatures.
The 5' and 3' primers used to amplify this fiagment were designed to introduce 
recognition sites for restriction endonucleases Dral and Sail respectively. This allowed
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the fragment to be cloned into the vector pZERO Blimt (Invitrogen). Both of the 
fragments (the unique 87 base pair human RDI N-terminal sequence and the 1.8Kb 
human PDE4A common region) were sequenced after cloning using the ABI prism 377 
automated sequencer.
The full length construct was created by digesting the 1.8Kb common PDE4A sequence 
out of tlie pZERO Blunt vector using the Dral and Sail restriction endonuclease sites. 
This fragment was then sub-cloned into the vector pK19 already containing the unique N- 
tenninus. This was achieved by digesting the pK19 vector using the unique internal Dral 
site in the N-terminal sequence and then the Sail site which had been placed next to it. 
This sub-cloning event produced a full length hRDl construct in the vector pK19. The 
orientation of the sequence was confirmed using diagnostic restriction enzyme digestion.
3.1.7 Generation of a COS-7 cell expression Vector for hRDl
The next step was to investigate the properties of the protein encoded for by the human 
RDI (liRDl) gene. In order to do this the sequence had to be expressed using an 
expression vector suitable for expressing proteins in a mammalian cell line. Once the 
protein was expressed in this type of system the location of the protein and the kinetic 
properties can be investigated.
The full length liRDl construct was sub-cloned into the mammalian expression vector 
pcDNA3 for expression in COS-7 cells under the control of the CMV promoter wliich 
gives particularly good expression of proteins when transfected into mammalian cells.
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This was achieved by cutting the hRDl sequence out of tlie vector pK19 using the unique 
restriction enzyme sites BamHI and Sail. The vector pcDNA3 was digested with BamHI 
and then Xliol. The hRDl sequence fragment was then ligated into the vector pcDNA3. 
This was consequently digested with Notl (a site between BamHI and Xhol in pcDNA3) 
in order to cut away empty vector. Diagnostic restriction enzyme digests were made to 
check the orientation of the construct in the vector and revealed that the BamHI site had 
been recreated but the Sall/Xhol sticky ends (which had been hgated at the 3' end) had 
been destroyed. This was ftirther confirmed by sequence analysis (using the ABI 377 
automated sequencer).
3.1.8 Cloning of the fragment encoding the unique N-terminal region of hRDl
As described previously direct amplification of the region encoding the imique N- 
terminal region of human RDI using human cDNA as template proved unsuccessful due 
to the liigh GC content of the sequence. The C-terminal region of liRDl is composed of 
sequence identical to HSPDE46, except that it lacks UCRl and part of UCR2. liRDl can 
therefore be created by placing sequence encoding its unique N-tenninus directly 
upstream of the shared C-terminal sequence (PCR amplified fiom HSPDE46 DNA) at the 
point at which the splice junction occurs.
The following section describes how tlie unique N-tenninal sequence was therefore 
synthesised from two 87 base pair oligonucleotides (one reverse and complimentary to 
the other) which were annealed together to form double stranded DNA. The unique N-
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terminai sequence of human RDI encodes for 22 amino acids (66 nucleotides). 
Additional nucleotides were required at either side of the coding region (8 at the C- 
terminal and 13 at the N-terminal) to provide restriction enzyme sites to be used for 
subsequent subcloning of the sequence.
The two long oligonucleotides encoding the N-terminus of hRDl (syntliesised by 
Cruachem) consisted of the following sequences: 5' primer encoding the upper (sense) 
sequence, hRD15’UP (GAT CCA CCA TGC CTT TGG TGG ATT TCT TCT GCG
AGA CCT GCT CTA AGC CTT GGC TGG TGG GCT GGT GGG ACC AGT TTA
AAC TTA AGG) and the 3' primer encoding tlie complimentary antisense sequence, 
hRD15'L0W (TCG ACC TTA AGT TTA AAC TGG TCC CAC CAG CCC ACC AGC
CAA GGC TTA GAG CAG GTC TCG CAG AAG AAA TCC ACC AAA GGC ATG
GTG).
This sequence was designed with a Dral restriction endonuclease site (TTT AAA from 
bases 75 to 80) at the N-terminal as this is the sequence encoding the region at which the 
splice jimction for hRDl occurs in the PDE4A sequence, which is specifically the first T 
in this sequence (or nucleotide number 899 in the HSPDE46 sequence L20965).
The preparation of this sequence for ligation onto the N-tenninus of the common PDE4A 
sequence (which is tlie sequence shared by botli the human RDI and the long-fonn 
PDE4A HSPDE46) started with the digestion of the plasmid pkl9 to create BamHI and 
Sail ends. Phenol chloroform extraction was used between each separate digest. Once the 
digestion was complete the linearised vector was purified by ethanol precipitation and 
resuspended for later use.
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The two long oligonucleotides were now annealed to make double stranded DNA. This 
was done using lOOmM stocks and mixing Ipl of each primer along with 93 pi of water 
and 5pi of buffer H (total volmne of lOOpl). This mixture was incubated at 95°C for 2 
minutes, 80°C for 5 minutes, 65°C for 5 minutes, 50'^C for 5 minutes and tlien room 
temp for 5 minutes.
The resulting DNA was then ligated (overnight at 16“C) into the linearised pkl9 
(Kanamycin resistant) and the product was then transformed into TOPIO E.coli. A 
maxiprep was then made from the resultant colonies.
A diagnostic restriction enzyme digest was carried out to check tliat the long 
oligonucleotides (the insert) had been successfully hgated into tlie pkl9 DNA. The insert 
contained the unique restriction enzyme site Dral and the vector contained the unique 
Bglll site. If the insert is present this will produce two bands, one of 5-600bp and another 
of around 2.2-2.4Kb. The diagnostic restriction enzyme digest showed tliat colony 
number 7 contained the insert and this was selected to be prepared for sequencing (three 
other positive clones were also found).
Sequencing of the insert was necessary to verify that it had not mutated in any way and 
the two oligonucleotides had annealed correctly. This was carried out using tlie Vistra 
robot and Thermo Sequenase dye Primer sequencing kit with ET (energy transfer) dye 
primers. Universal and Reverse primers (which annealed to sequences in the vector) were 
used. Sequencing was carried out on the ABI prism 377 automated sequencer (see 
methods). This sequencing showed that the insert had been cloned into pkl9 correctly 
and contained no errors on either the upper or the lower strand. The general cloning 
strategy can be seen in figure 17.
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3.1.9 PC R am plification o f common 4A region for hR D l
The following primer pairs were designed in order to amplify a region of sequence 
encoding the C-terminal sequence wliich is common to both hRDl and HSPDE46 and 
contains the conserved catalytic domain. The primer pairs used were FBRD2, forwards 
witli FB9, reverse and FBRD2 witli 4A3'. The PCR conditions were optimised and 
different cycling parameters used but without success. Next the primer pair Smetl, FB9 
and FBI, FB9 were used to produce fragments of 1054 and 853 respectively, which could 
be used m a second PCR reaction. These reactions were successffil and the products of 
1054 base pairs (Smetl, FB9) and 853 base pairs (FBI, FB9) were purified and 
resuspended in sterile water. 1 and lOpl of each of these fragments were used with the 
primer pair FBI5, FB9 designed to amplify a region from the start of hRDl. Neither of 
these reactions worked so it was decided to use the primer FB I5 but replace FB9 with 
4A3' which is designed to anneal at tlie extreme C-terminal of the HSPDE46 coding 
region.
Two overlapping fragments containing the sequence of interest were to be amplified and 
then annealed togetlier so tliat they could be used as template in a further PCR reaction. 
Tliis reaction could work more efficiently as there would be less "unnecessary" or 
contaminating sequence in the reaction. The primer pairs used for this were Smetl, FB9 
and FB4, 4A3'. The primers were added after the first round of amplification in the PCR 
machine to allow the fragments to ligate togetlier. The diagram in figure 18 shows the 
general scheme.
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AU of these PCR reactions were carried out using the polymerase Pwo which has 
particularly good proofreading activity. DMSO (at a final concentration of 10%) was also 
added to the reaction mix to help disrupt secondary structure caused by GC-rich 
sequence. In this case a band of around the correct size of 1.2Kb was obtained. This was 
actuaUy smaller than predicted wliich indicated an artefact (predicted size was around 
1.8Kb) nevertheless tliis fragment was excised from the gel, purified and ligated into the 
vector pZero Blimt. This was done in order to analyse the sequence which had been 
amplified by this PCR reaction and to establish whetlier it was an artefact or not.
The pZero Blimt containing the PCR fragment was transfoiined into TOPIC E.coli and 
the colonies obtained (38 in total) were PCR screened using the primers MSU2 (a 
forwards Universal primer made by Mike Sullivan) and Zrev (a reverse primer for use 
with the pZero Blimt vector). Five positive clones were obtained and mini-prepped for 
sequencing. The Dynamic Universal and Mixed deaza ET Reverse primers were used for 
sequencing (see methods).
3.1.10 Sequencing the FB15, 4A3' fragment PCR amplified from two smaller 
fragments covering the hRDl C-terminal (common PDE4A) domain
Sequencing of the clones containing the FB I5, 4A3' fragment showed that the primer 
4A3' was annealing to a region approximately 1.2Kb away from the 4A3' priming site. 
FBI5 is not a particularly good primer as it is a GC-rich primer (over 60% GC content) 
so I believe that the primer 4A3' is out-competing any reaction involving FB15.
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Therefore I determined to redesign tlie primer FBI5 and also (later on) to redesign the 
primer 4A3’ to make it more specific. Tlie polymerase Pwo used in the reaction is 
actually helping the primer 4A3' to bind to a site which only contains the first three base 
pairs in common witli its sequence. The primer FBI5 was changed from: AAG TTT 
AAA AGG ATG TTG AAC C, to FBI5a: TTT AAA AGG ATG TTG AAC CG. The last 
CG in the sequence would help it to bind to the first base in the target sequence (GC 
clamp). It was also decided to use DMSO (final concentration 10%) in the reaction and 
increase the annealing temperature which would hopeftilly increase tlie specificity of the 
reaction.
3.1.11 PCR reaction with new primer FB15 (FBlSa) and redesigned 3' primers 
4A3' Sall/Sal2
At first the same piece of DNA composed of fragments A and B (from the PCR reactions 
Smetl, FB9 and FB I5, 4A3' in the previous section) was used as template for the PCR 
reaction witli primers FBI5a (redesigned) and 4A3'. The same 1.2Kb band appeared so 
tlie primer 4A3' was redesigned. Two new primers were designed to replace 4A3' which 
would anchor at the extreme 3’ end of the PDE4A coding region at a unique restriction 
enzyme site Sail. The new primers were FB3’Sall (GTC GAC GAG GTC TGG GGA 
TCA GGT TA) and FB3’Sal2 (GTC GAC GGA ACA GGG ACA GAG GGT). Both of 
these primers were now used in reactions with both primers FB I5 and FBI5a. The
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reactions were carried out with and without DMSO (final concentration 10%) and all of 
them with the DNA polymerase Pwo.
In the first instance the template used was IDA DNA, but then we discovered that the 
new primers FBS'Sall and FB3'Sal2 anchored to sequence just outside the region wliich 
lOA encodes. The same reactions were then carried out using PDE46 DNA instead.
3.1.12 PCR amplification of the sequence encoding the common region of PDE4A
The PCR reactions using the newly designed primers FB15/FB15a and 
FB3'Sall/FB3'Sal2 and PDE46 DNA as template were all successfiil. Each reaction (with 
or witliout 10% final concentration DMSO) produced a fragment of the predicted size of 
1.8Kb. The photograph in figure 19 shows the 1.8Kb bands produced by each PCR 
reaction in each lane of the gel. Further reactions were carried out witli an increased 
annealing temperature to increase specificity of the primer binding. Once again every 
reaction produced a fragment of the correct size. One of these bands was chosen to be 
excised from tlie gel and purified for ligation into a vector so that the sequence which had 
been PCR amplified could be checked to determine if it was conect or not.
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3.1.13 Ligation of the PDE4A common region 1.8Kb fragment into pZero Blunt for 
sequencing.
One of the bands from the above reactions was chosen (reaction primers FBI5a with 
FB3'Sall) and excised from the agarose gel. The DNA was purified from the gel shce 
and used in a ligation reaction with pZero Blunt vector. This was ligated at 16°C for one 
hour. Half of the ligation mix was used to transform into TOPIO E.coli cells and plated 
out on LB/Kanamycin plates (see methods).
Ninety-six of the resultant colonies were screened for presence of the insert. The PCR 
screen was carried out using two primers whose sequence lies inside the PDE4A common 
region sequence. These were FB2 (forwards) and FB9 (reverse). The expected size of the 
fragment which these primers should produce is 657bp.
Most of the 96 colonies screened with tlie above primers showed a positive band of 
657bp, indicating that they contained the 1.8Kb insert (see figure 20). The first five 
clones were picked for sequencing. Five clones were chosen because it was possible with 
the amplification of a large piece of DNA (1.8Kb) that mistakes or mutations could have 
been introduced, even though the higli proofreading enzyme Pwo polymerase had been 
used.
All of the primers designed to internal sequence in the PDE4A common region 
downstream of the hRDl sphce junction were used in order to sequence the 1.8Kb 
fragment. Foiivards primers used included: FBI5a, FB2, FB3, FB4, 4AS1, 4AS3, 4AS5, 
4AS7, 4AS8 and Universal primer to read in from the 5' vector sequence. The reverse 
primers which were used were as follows: FB7, FB6, FB5, FB9, 4AS2, 4AS4, 4AS6,
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4AS9, 4AS10, 4A3' and Reverse primer to read in from the 3' vector sequence (see 
schematic in figure 15 and also figure 14 for specific location).
It was very important to read the sequence immediately adjacent to the vector sequence 
as it was crucial tliat the imique restriction enzyme sites designed into the primers had 
been reproduced exactly during the original PCR reaction. A clone with perfect sequence 
and with Dral and Sail restriction sites intact was required.
At the same time as the 1.8Kb common region was being sequenced, the annealed 87-mer 
oligonucleotides encoding tlie unique N-terminus of liRDl which had been cloned into 
the pZero Blunt vector was sequenced again. This was to double check tliat the DNA had 
remained stable while in storage and it was found to have exactly the same sequence 
(namely 5'-GAT CCA CCA TGC CTT TGG TGG ATT TCT TCT GCG AGA CCT GCT 
CTA AGC CTT GGC TGG TGG GCT GGT GGG ACC AGT TTA AAC TTA AGG-3'). 
One clone encoding the PDE4A common region was also found to contain sequence 
which was 100% homologous to the C-terminal region common to both hRDl and 
HSPDE46 (no mistakes had been introduced during the PCR reaction), and both the 3' 
and 5' imique restriction enzyme sites were intact. The plasmid DNA from both of these 
clones was maxi-prepped in order to be prepared for ligation.
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3.1.14 Cloning of the 1.8Kb fragment encoding the PDE4A common region into 
pK19 containing the unique N-terminus of hRDl
Botli the vectors containing either the 1.8Kb common region or the short imique liRDl 
N-terminus were digested with tlie restriction enzymes Dral and then Sail (both unique 
restriction endonuclease sites in these constructs). Digesting tlie pZero Blimt vector 
containing the 1.8Kb PDE4A C-terminal region fragment with these restriction enzymes 
released tlie entire 1.8Kb insert. Digesting tlie vector (pK19) containing the unique hRDl 
N-terminal domain linearised the vector at tlie point where the splice junction between 
the liRDl N-terminal domain sequence and the catalytic C-terminal region sequence 
occurs. The linearised vector pK19 liRDl 5' has a size of 2.7Kb.
The products resulting from these restriction enzyme digestions were then subject to 
electrophoresis on an agarose gel and the bands of the correct sizes (tlie PDE4A common 
region of 1.8Kb and the linearised pK19 vector containing the imique hRDl N-terminal 
region of 2.7Kb) were excised and the DNA was purified from the gel. The 1.8Kb 
fragment was hgated into tlie pK19 vector so as to place it downstream of the imique N- 
terminus.
Plasmid DNA was prepared from at least 10 of the resultant clones positive for the insert. 
Several diagnostic restriction enzyme cuts were carried out. These included Sall/Xho (to 
verify tliat the 1.8Kb fragment had been inserted), Dral/Bgl2 (to verify tlie orientation of 
the insert), and Bgl2 alone (to give an indication that the of the size of the final construct 
was as expected).
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These restriction endonuclease digestions revealed that the 1,8Kb fragment encoding the 
C-terminal PDE4A domain common to both hRDl and HSPDE46 had been successfrilly 
ligated downstream of the unique hRDl N-terminal at the hRDl splice junction. This had 
been achieved by cloning the 1.8Kb C-terminal domain into the vector (pK19) which 
aheady contained the imique hRDl N-terminal sequence. The entire liRDl coding region 
sequence was now contained within one vector. The general cloning strategy can be seen 
in figure 21.
3.1.15 Cloning of full length hRDl into pcDNA3 (CMV promoter)
The full length hRDl construct was cloned into die vector pcDNA3 which has a CMV 
promoter in order to increase expression of the gene in mammahan cells. Tliis was 
chosen as it was intended to express liRDl in COS-7 cells for biochemical analyses. 
hRDl was cloned into pcDNA3 using the following strategy. The frill length liRDl 
construct in the vector pK19 was cut out using restriction enzyme digestion with BamHlI 
and Sail. The vector pcDNA3 was prepared by digestion with BamHI and Xhol. These 
were separate digests radier than double digests and the products were cleaned up in 
between using a DNA Bind kit (see mediods). The insert was ligated into the vector 
overnight at 16°C. The product was then digested with Notl wliich would cut any 
remaining empty vector therefore reducing the number of possible false positive colonies 
after transformation into E.coli.
140
Potential positive clones were PCR screened using the primers CMV5' (commercially 
available) and tlie internal 3' PDE4A primer FB7. Sequencing was carried out on tlie 
clones testing positive in the PCR screen and all of these had the correct sequence at the 
5’ and 3' ends directly adjacent to the vector. It was not necessaiy to sequence the entire 
insert as the cloning had been carried out using a simple "cut and paste" strategy and the 
risk of mistakes was thus eliminated except for the regions in wliich the digests had 
occurred and these were recreated.
3.1.16 Conclusion
The cloning of liRDl represents the first identification of a human shoit-foim PDE4A 
and confirmation of tlie existence of a major splice junction in the PDE4A. The splice 
jimction occurs inside the UCR2 region towaids the N-tenninus so only includes two of 
the three exons encoding UCR2. The position of this splice junction is conserved between 
PDE4 family members.
The intronic region of rat fonns of PDE4B and PDE4D between tlie first exon of UCR2 
and tlie upstream exon is several thousand base pairs long, This indicates that there is 
plenty of scope in these two genes for the existence of alternative promoters and unique 
5' exons to create other short-forms. The corresponding region of the PDE4A gene 
contains an intron which is only 138bp long which is obviously not large enough to 
accommodate either of these.
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It would be interesting to know if the lack of one exon encoding UCR2 as well as the lack 
of UCRl and LRl in die short-fonn has an effect on the catalytic activity of the 
conserved domain. This would be very difficult to establish as the shorter UCR2 may be 
capable of interacting vrith the catalytic domain in the absence of the other regions and 
exerting an effect that way.
The cloning procedure employed to create hRDl and die exploratory PCR reactions to try 
and identify TM3 highhghted just how difficult it is to amplify certain regions of PDE4A 
sequence due to the highly GC-rich sequence creating tertiary structure. However, several 
methods were employed and future difficulties could possibly be overcome using a 
combination of 5-10% DMSO in the reaction mix plus a polymerase witii extended 
thermostability to resolve these difficulties.
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3.1.17 Figures
PDË4A19xrtfam 
^ iœ jm cticn
UricfcN-taninal reÿcn
LRl
i UCRl
PDBlALcngfdîTi 
^ iœ jm c b c n
Œtalyticregon C-teminai 
-  regcn
UCR2
LR2
Figure 13. The domain organisation o f PDE4A isoforms. Also shown are the 
location o f the long isoform splice junction and the short isoform splice junction within 
UCR2.
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Unique N-terminal Domain
ATG GAA CCC CCG ACC GTC CCC TCG GAA AGG AGC CTG TCT CTG 
TCA CTG CCC GGG CCC CGG GAG GGC CAG GCC ACC CTG AAG CCT 
CCC CCG CAG CAC CTG TGG CGG CAG CCT CGG ACC CCC ATC CGT 
ATC CAG CAG CGC GGC TAC TCC GAC AGC GCG GAG CGC GCC GAG 
CGG GAG CGG CAG CCG CAC CGG CCC ATA GAG CGC GCC GAT GCC 
ATG GAC ACC AGC GAC CGG CCC GGC CTG CGC ACG ACC CGC ATG
TCC TGG CCC TCG TCC TTC CAT GGC ACT GGC ACC GGC AGC GGC
GGC GCG GGC GGA GGC AGC AGC AGG CGC TTC GAG GCA GAG AAT
GGG CCG ACA CCA TCT CCT GGC CGC AGC CCC CTG GAC TCG CAG GCG
UCRl
AGC CCA GGA CTC GTG CTG CAC GCC GGG GCG GCC ACC AGC CAG CGC
CGG GAG TCC TTC CTG TAC CGC TCA GAC AGC GAC TAT GAC ATG
^FBIO
TCA CCC AAG ACC ATG TCC CGG AAC TCA TCG GTC ACC AGC GAG 
GCG CAC GCT GAA GAC CTC ATC GTA ACA CCA TTT GCT CAG GTG 
CTG GCC AGC CTC CGG AGC GTC CGT AGC AAC TTC TCA CTC CTG
ACC AAT GTG CCC GTT CCC AGT AAC AAG CGG TCC CCG CTG GGC GGC 
CCC ACC CCT GTC TGC AAG GCC ACG CTG TCA GAA GAA ACG TGT CAG
FB8
CAG TTG GCC CGG GAG ACT CTG GAG GAG CTG GAC TGG T c f  CTG 
GAG CAG CTG GAG ACC ATG CAG ACC TAT CGC TCT GTC AGC GAG
F B 15_^
ATG GCC TCG CAC AAG TTC AAA AGG ATG TTG AAC CGT GAG CTC 
ACA CAC CTG TCA GAA ATG AGC AGG TCC GGA AAC CAG GTC TCA
FB2
GAG TAC ATT TCC ACA ACA TTC CTG GAC AAA CAG AAT GAA GTG
^  FB7
GAG ATC CCA TCA CCC ACG ATG AAG GAA CGA GAA AAA CAG CAA GCG
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Catalytic Domain
CCG CGA CCA AGA CCC TCC CAG CCG CCC CCG CCC CCT GTA CCA CAC 
TTA CAG CCC ATG TCC CAA ATC ACA GGG TTG AAA AAG TTG ATG CAT
FB3
AGT AAC AGC CTG AAC AAC TCT AAC ATT CCC CGA TTT GGG GTG 
AAG ACC GAT CAA GAA GAG CTC CTG GCC CAA GAA CTG GAG AAC
^  FB6
CTG AAC AAG TGG GGC CTG AAC ATC TTT TGC GTG TCG GAT TAG 
GCT GGA GGC CGC TCA CTC ACC TGC ATC ATG TAG ATG ATA TTC CAG 
GAG CGG GAC CTG CTG AAG AAA TTC CGC ATC CCG GTG GAC ACG
FB4 ^
ATG GTG ACA TAG ATG CTG ACG CTG GAG GAT CAC TAG CAC GCT 
GAC GTG GCC TAG CAT AAC AGC CTG CAC GCA GCT GAC GTG CTG 
CAG TCC ACC CAC GTA CTG CTG GCC ACG CCT GCA CTA GAT GCA
FB5
GTG TTC ACG GAC CTG GAG ATT CTC GCC GCC CTC TTC GCG GCT 
GCC ATC CAC GAT GTG GAT CAC CCT GGG GTC TCC AAC CAG TTC 
CTC ATC AAC ACC AAT TCG GAG CTG GCG CTC ATG TAC AAC GAT
^  FR9
GAG TCG GTG CTC GAG AAT CAC CAC CTG GCC GTG GGC TTC AAG 
CTG CTG CAG GAG GAC AAC TGC GAC ATC TTC CAG AAC CTC AGC 
AAG CGC CAG CGG CAG AGC CTA CGC AAG ATG GTC ATC GAC ATG
4AS1
GTG CTG GCC ACG GAC ATG TCC AAG CAC ATG ACC CTC CTG
GAC CTG AAG ACC ATG GTG GAG ACC AAG AAA GTG ACC AGC TCA 
GGG GTC CTC CTG CTA GAT AAC TAC TCC GAC CGC ATC CAG GTC 
CTC CGG AAC ATG GTG CAC TGT GCC GAC CTC AGC AAC CCC ACC
4AS2
AAG CCG CTG GAG CTG TAC CGC CAG TGG ACA GAC CGC ATC ATG
4AS3
-►
GCC GAG TTC TTC CAG CAG GGT GAC CGA GAG CGC GAG CGT GGC 
ATG GAA ATC AGC CCC ATG TGT GAC AAG CAC ACT GCC TCC GTG
14 5
GAG AAG T C T  CA G  G T G  G G T  T T T  A TT G AC TAC A TT G TG  CA C CCA TTG  
TG G  GAG A C C  T G G  G C G  G AC C T T  G T C  CAC CCA  G A T G C C  CA G GAG
4AS4
A TC  T T G  G A C A C T T T G  GAG G A C  AAC C G G  G A C T G G  TA C  TA C AGC
G C C  A TC C G G  CA G  A G C CC A  T C T  C C G  CCA  C C C  G A G  GAG  G AG TCA  
 ----------------------------------------------------
AGG G G G  C C A  G G C  CA C CCA  C C C  C TG  C C T  G A C AAG T T C  CAG T T T
C-terminal Region
G AG  C T G  A CG  C T G  G A G  G AG  GAA G AG GAG GAA GAA ATA TCA ATG
GCC CAG ATA CCG TGC ACA GCC CAA GAG GCA TTG ACT GCG CAG GGA
4 A S 7 ^
TTG TCA GGA GTC GAG GAA GCT CTG GAT GCA ACC ATA GCC TGG GAG
4AS6 
<----------
GCA TCC CCG GCC CAG GAG TCG TTG GAA GTT ATG GCA CAG GAA GCA 
TCC CTG GAG GCC GAG CTG GAG GCA GTG TAT TTG ACA CAG CAG GCA 
CAG TCC ACA GGC AGT GCA CCT GTG GCT CCG GAT GAG TTC TCG TCC
4AS9 4A S8^
CGG GAG GAA TTC GTG GTT GCT GTA AGC CAC AGC AGC CCC TCT GCC 
CTG GCT CTT CAA AGC CCC CTT CTC CCT GCT TGG AGG ACC CTG TCT GTT 
TCA GAG CAT GCC CCG GGC CTC CCG GGC CTC CCC TCC ACG GCG GCC 
GAG GTG GAG GCC CAA CGA GAG CAC CAG GCT GCC AAG AGG GCT TGC
4AS10 
<--------
AGT GCC TGC GCA GGG ACA TTT GGG GAG GAC ACA TCC GCA CTC CCA
4A3'
< --------
GCT CCT GGT GGC GGG GGG TCA GGT GGA GAC CCT ACC TGA TCC C
Figure 14. This diagram shows where primers anneal to the HSPDE4A1A (h46) 
sequence L20965 showing sequence starting at nucleotide numbers 116 (the initiating 
ATG o f PDE4A1AB, h46) to 2779 (end o f the PDE4A1A open reading frame). These 
primers were designed to sequence within PDE4A1 (hRDl) that is common to both hRDl
1 4 6
and PDE4A4B (h46). Forward (sense) primers are highlighted red and the reverse 
(antisense) primers are highlighted blue. The highlighted and underlined bold text in 
black shows the sequence encoding the various domains o f PDE4A4B (unique N-terminal 
domain, UCRl, UCR2, the catalytic domain and the C-terminal region).
147
4A3
Reverse PDE4A sequencing primers
4AS10
4AS9
  4AS6
4AS4
4AS2
FB5
FB9
FB7
FB6
N -tm rinal nc0un UCRl UCR2
FB15a --------
Catdvtic dumain
FB2
FB3
FB4
4AS1
4AS3
4AS5
Forward PDE4A sequencing primers
4AS7
4ASN
Figure 15. Schematic diagram showing the approximate location of primers designed 
to anneal to sequence in the PDE4A common region downstream o f the hRDl splice 
junction for use in sequencing.
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FBRDl CCA TGT AAC CAG GGC T
FBRD2 TCC ACT ACC CAC CTG C
FB8 CAG ACA CCA GTC CAG CTC
FB9 AGG TGG TGA TTC TCG AG
FB12 AGA CGC CTT CGG CTT C
4A3’ GTC GAC GAT CAG GTA GGG TCT CCA C
SMETl AGG ATC CAC CAT GTC ACC CAA GAC CAT G
SMET2 AGG ATC CAC CAT GTC CCG GAA CTC ATC G
Figure 16. Sequence o f primers used to screen for the presence o f  the PDE4A gene, 
hRDl in human cDNAs.
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hRDlS’ UP
Oligonucleotide cassette  ^5 ’LGW  ^' overhang T
AGCT
BainHI
BamHI Sail
pK19 2816bp
Dral Sail
GATCCACCATG................ GACCAGTTTAAACTTAAGCAGC
GTGGTAC CTGGTCAAATTT
Figure 17. General cloning strategy fo r  cloning the two annealed long 
oligonucleotides encoding the unique N-terminal sequence o f hRDl into the vector pkI9. 
The long primers have been designed so that the insert has the appropriate overhangs for  
the BamHI/Sall digested vector.
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Fragment A 
Sm etl FB9
FB4 4 A 3’
Fragment B
FBI 5 4 A 3’
Second PCR reaction using A and B annealed as tem plate
Figure 18. Method used to create one single fragment from two overlapping smaller 
fragments o f PCR amplified DNA (A and B). Fragments A and B overlap and cover the 
entire sequence encoding the C-terminal region common to both hRJ)l and HSPDF46 
downstream o f the hRDl splice site. The PCR reaction using the primer pair FBI 5 and 
4A3' was carried out to amplify one continuous piece o f DNA from the two smaller 
fragments A and B.
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1 kb DNA marker
1.8Kb fragment
3 4 5 6 7 8
Figure 19. The photograph above shows that every reaction with the primers FBI5 or 
FBI 5a and FBS'Sall or FB3'Sal2 (with or without DMSO) produced a fragment o f I.HKb 
which can be seen in every lane on this ethidium bromide stained agarose gel (l.H%). 
Lanes 1-4 show products obtained from primer pairs FBI 5a Sal 2, FBI 5a Sal I, 
FBI5Sal2, FBI5SalI respectively all without DMSO present, flânes 5-8 show the 
products obtained form primer pairs FBI5a Sal2, FBI5a Sail, FBI5 Sal2 and 
FBI 5 Sail all with 10% final concentration o f  DMSO in the reaction mix.
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1Kb DNA ladder
657bp
657bp
657bp
Figure 20. This photograph shows the result o f a 96 well PCR screen for the l.HKh 
insert encoding the PDE4A common region in the vector pZero Blunt. The internal 657hp 
fragment in the insert was amplified using primers FB2 (forwards) and FB9 (reverse).
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In fact most PDE4 isoforms appear to exhibit a similar aberrant behaviour on SDS/PAGE 
in migrating more slowly than would be predicted. One possibility is that the conserved 
poly (acidic) regions found towards the C-terminus of the catalytic region in these 
proteins lower the SDS binding and hence affect migration.
3.2.3 Km values of hRDl
The phosphodiesterase assay described in the methods section was used to ascertain the 
level of PDE activity in each transfection using hRDl DNA in COS-7 cells. Different 
amounts of protein from COS-7 cell fractions were assayed to establish the linear range 
of PDE activity in each separate transfection. Once this was known then the amount of 
hRDl transfected COS-7 cell fraction which gave a reading of around 14,000 CPM in a 
PDE assay was used for further assays. The specific activity of the liRDl expressed in 
each fraction was calculated from data in the linear range and tliese can be seen in figure 
23.
Furtlier assays included those investigating the kinetics of the enzyme encoded by the 
hRDl sequence. First, the specific activity of the enzyme was established and then the 
Kni. This is a measui e of the substrate concentration at half the maximum velocity of the 
enzyme. The Km values for each fraction of hRDl transfected COS-7 cells separately 
were obtained using the basic PDE assay but varying the amoimts of substrate added to 
the assay (see figure 24) and in all instances were done over linear time courses. The 
amounts of cAMP added to the assay varied from 0.25 to 25 pM final concentration in
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the assay. This range was used as saturation of the active site occurred at around 16 pM 
cAMP. The Km values for hRDl are shown in figure 25.
3.2,4 ICso values of hRDl
The phosphodiesterase assay was also used to investigate the inhibition of hRDl activity 
using tlie PDE4 selective inhibitor, rolipram. Final concentrations of rolipram used in the 
assay varied from 0.0001 to 100 pM and included samples containing no rolipram. 
Assays were again carried out at least three times on at least four separate transfections. 
The assays were also carried out at the cAMP concentration which corresponded to the 
Km value for each particular j&action (see figui*e 27). Under such conditions and assuming 
rohpram acts as a simple competitive inliibitor then tlie IC50 values obtained are 
equivalent to the K{ values i.e. the affinity of the enzyme for the inliibitor (or ligand). The 
results obtained can be seen in figure 26.
3.2.5 Distribution of hRDl phosphodiesterase activity in COS-7 cell fractions
liRDl was successftilly over-expressed in COS-7 cells and routinely accounted for >99% 
of the PDE cAMP hydrolysing activity detected in COS-7 cell tractions. As the graph in 
figure 28 shows, most of the PDE activity was found to be located in the P2 fraction
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(44% +/-11). The remainder was shared between the PI fraction (33% +/-10) and the S2 
fraction (23% +/-8).
3.2.6 PCR screening of cDNA panel (Origene/Clontech) using primers for hRDl 
plus RT-PCR and p-Actin controls
I decided to screen for the presence of hRDl transcripts in human tissue in order to assess 
the distribution of this PDE4A gene product. The better tlie quality of cDNA, the higher 
the chance of detecting lower levels of message for the gene. Human brain cDNA library 
(Clontech) was prepared and screened using PCR to detect the presence of hRDl.
The primers used were specific to an N-tenninal region found only in liRDl and were as 
follows: 5* (AHR19) - TCG AAT TCT GAT GCC CTT GGT G and 3' (AHR20) - TGG 
ATC CCG GGG CTG TAA GTG. Cycling conditions were: 95°C for 1 minute, 55°C for 
1 minute and then 72°C for one minute. Botli negative and positive controls were carried 
out. The positive control was earned out on plasmid DNA containing the sequence for 
hRDl. Negative controls included the use of the above primers with plasmid DNA which 
contained sequences for two other PDE4As (PDE46 and 2EL). The p-Actin control 
primers were used to verify that the cDNA had been syntliesised correctly and could be 
used to successfully amplify a region of DNA in a PCR reaction. None of tlie reactions 
using the PDE isofonn specific primer pairs were successful in tliis instance.
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3.2.7 Detection of a 276bp band - correct size for hRDl in human brain cDNA 
(Y2H library)
Human brain cDNA was used as template to search for expression of the hRDl gene. The 
two primers which were used in this PCR reaction were as follows: 5' primer, AHR19 
(TCG AAT TCT GAT GCC CTT GGT G) the last 12 bases of which are specific to the 
hRDl sequence, and tlie 3' primer, AHR20 (TGG ATC CCG GGG CTG TAA GTG) 
again, the last 12 base pairs of which are specific to the hRDl sequence. This primer pair 
produced a band of 276 base pairs in size (see figure 29). The details of the PCR cycling 
conditions were as follows: 94°C for 30 seconds, 37°C for 30 seconds then 72°C for one 
minute, for a total of two cycles and then 25 cycles of 94®C for 30 seconds, 55°C for 30 
seconds and then 12°C for one minute.
3.2.8 Screening Origene multiple choice cDNAs for the presence of hRDl 
transcripts
Twelve different types of tissue cDNA were screened for tlie presence of hRDl. These 
included testis, ovary, small intestine, lung, muscle, prostate, leukocytes, brain, heart, 
kidney, spleen and liver. The primers used were AHR19 and AHR20 as described 
previously for detecting hRDl. The cycling conditions used were as follows 94°C for 30 
seconds, 37‘^ C for 30 seconds, 72°C for 1 minute for two cycles and tiien 94°C for 45 
seconds, 55°C for 1 minute and then 72°C for 1 minute for a total of thirty five cycles.
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Beta Actin primers were also used to check that the cDNA was good quality template and 
the PCR reaction should be working. The conditions for the p-Actin primers were as 
follows: 94°C for 45 seconds, 55°C for 1 minute, 72°C for 1 minute for 34 cycles and 
then one cycle of 94°C for 45 seconds, 55°C for 1 minute and then 12°C for 5 minutes. 
The p-Actin primers produced a band of 614 base pairs in size. The results of this screen 
were unclear and inconclusive.
3.2.9 Thermal dénaturation
Proteins are normally thermolabile. Upon heating they are denatured and generally lose 
activity as a first order process (active to inactive) described as a single exponential. Thus 
a plot of log percentage activity remaining against time should be linear and can be used 
to calculate a half life fi"om the time at which 50% of the original activity is remaining. 
Different proteins decay at different rates due to conformational differences. Indeed, 
conformational changes can alter the thermostability and thus calculation of half lives can 
be used to infer differences in conformation. I set out to: 1) evaluate if the half lives were 
different for hRDl in the PI, P2 and supernatant fiactions implying different 
confoimational states and 2) to compare with half life values for rRDl to see if 
differences in the common region between rat and human forms altered the conformation. 
Ahquots of each hRDl transfected COS-7 cell ifraction were immersed in a water bath at 
50°C. The samples were placed in the water bath in a container witli a stirrer to ensure 
even distribution of heat tliroughout the sample, giving a homogenous sample for
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assaying. Samples were taken in duplicate every two minutes and removed to ice cold 
eppendorf tubes over a period of 40 minutes. The PDE activity assay was then carried out 
on tliese samples in the usual way at a substrate concentration of 1 pM. The volume of the 
COS-7 cell fractions had been adjusted before the assay so that a 50pl aliquot would give 
a reading of around 14,000 CPM (i.e. witliin the linear range for tlie assay) before any 
heat was applied to the samples. The entire procedure was repeated at 55°C.
This experiment showed hRDl to be remarkably thermostable. Even after 40 minutes at 
50°C, or indeed 55^C, inactivation of the catalytic activity was still incomplete. Tlie S2 
fraction proved to be considerably more thennolabile tlian either tlie PI or the P2 
fractions (see figure 30).
The thermostability data is interesting as it shows distinct differences between the rat 
(RDI) and human (hRDl) forms of tlie enzyme (see figures 31 and 32). The human form 
has much higher tliennostability at 55°C (approximately eight times higher). These two 
enzymes have a high degree of homology so the basis for this difference in 
thermostability might be associated with the hypervariable LR2 region encoded by exon 
8 and the C-terminal region encoded by exon 15. The LR2 regions are all hydrophobic 
and consist of positively charged amino acids. The LR2 region of PDE4A has 
considerable predicted coil regions and it has been suggested that, along with LRl, this 
region may be able to confer conformational controls on UCR1/UCR2 interactions. There 
is also a higher percentage of pro line residues in the human RDI isofonn and tliis residue 
is associated with confonnational status. The Mnker regions may influence the orientation 
of the UCRl and UCR2 domains witli respect to each other and the catalytic core and 
also the orientation of the unique N-terminal regions.
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It is also interesting to note the difference in tliennostability between the two fractions of 
liRDl. The membrane bound fraction P2, displays a higlier tliennostability than tlie 
cytosohc fraction S2, (approximately five times higlier). Tliis difference miglit be 
accounted for by some membrane components or binding partners having a protective 
effect or else the binding itself has caused a conformational change in the hRDl enzyme 
which makes it less heat labile.
3.2.10 High Salt/Triton X-100 treatment
Proteins can associate witli the membrane in two ways. They can be peripheral, binding 
to other proteins at the membrane or the lipid headgroup in tlie lipid bilayer tlirough 
electrostatic interactions. Alternatively they can be integrated into the lipid bilayer and 
interact with the lipids or other integral proteins in the bilayer. Detergent (Triton X-100) 
is required to extract integral proteins as this disrupts the interactions between lipids in 
the bilayer. Peripheral proteins, however, can be extracted by changes in ionic strength or 
the pH at the membrane which disrupts electrostatic interactions.
The first treatment involved changing the salt concentration. Increasing tlie salt up to a 
high level (from 0.00IM to 2M) can be expected to cause disruption of ionic bonds. 
Adding Triton X-100 (0.5-5%) to membrane boimd hRDl would disrupt hydrophobic 
bonds.
Treatment of the particulate liRDl with Triton X-100 led to the release of nearly all of the 
enzyme (>96%; n ==3). The results can be seen in figure 33. Treatment with NaCl did not
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release the enzyme and above a concentration of 0.00IM interfered with the PDE assay 
so as to render the data unrepresentative. The effects of these treatments were assessed by 
PDE assay. These results indicate that the association of the hRDl enzyme with the 
membrane is not due to charge but that hydrophobic interactions are required.
3.2.11 TNT cell-free expression of mature hRDland COS-7 cell membrane binding
From the previous experiments it can be concluded that the liRDl enzyme is integrated 
into biological membranes. To test this an in vitro assay was used. The mature liRDl 
protein was produced using a cell-free transcription-translation system (Promega, see 
methods) and then mixed with membranes from COS cells to determine association. Tliis 
may occur either as a result of insertion concomitant witli translation or by post- 
translational insertion. As it appears tliat a small region is involved in membrane 
association of rat RDI (Scotland and Houslay 1995) I decided to determine if mature 
hRDl could bind to membranes. It has previously been shown that cliimaeras of normally 
soluble enzymes engineered to posses the RDI N-terminal region are able to bind to 
membranes in die same way as RDI. This is also the case when such chimaeras aie 
produced as mature proteins in the cell-free transcription-translation system.
When hRDl was produced in this way it was able to bind to COS-7 cell membranes. 
These experiments show that the ability to bind to membranes must be an inherent 
property of the N-terminal region of hRDl as it has been shown previously that the core
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or common region of the PDE4A protein does not bind to membranes (Scotland and 
Houslay 1995).
However, efficiency of insertion is seemingly not as good with liRDl as with rat RDI. 
This may be due to the very different LR2 regions that, in human 4A4 have been shown 
to bind to SH3 domains containing proteins like LYN. Indeed 4A4 binds to LYN in COS 
cells. If such an association occurs for RDI tlirough the LR2 region then this might 
impair insertion efficiency. Alternatively in die case of liRDl the reason may be technical 
as a low concentration detergent wash was used to clean up fractions after incubation 
with hRDl. In retrospect this might not have been a good idea as this could disrupt bonds 
formed during incubation. There is also current evidence from our laboratory suggesting 
that Ca^^ is required to promote insertion. The absence of added calcium may have 
decreased efficiency.
These blots (see figure 34) demonstrate the ability of liRDl produced in the cell-free 
transcription-translation system to bind to COS-7 cell membranes. Blot A also shows that 
after treatment with a low concentration of Triton X-100 die protein loses the ability to 
bind to the membranes. This confirms the results observed using the Triton X-100 
treatment detected using the PDE assay metiiod.
3.2.12 Conclusion
The human fonn of RDI and the rat form share 100% homology at their N-terminus. This 
provides a possibility to investigate the effects of the N-terminus of the rest of die
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enzyme. These two enzymes do appear to have very similar kinetic properties. They have 
similar Km values for the substrate cAMP, hRDl at around 1.5 +/-0.5 pM compared to 
RDI for which the Km is around 4 +/- 2.3 pM (Shakur et al. 1993). The ICso value of 
hRDl for the inhibitor rolipram is sliglitly lower at 0.29 +/-0.09 pM than that of RDI 
which is around 0.7 pM. This indicates Üiat the N-terminal is interacting with the 
catalytic regions of hRDl and RDI in a very similar way.
The major difference is seen when the thermostabihty of hRDl is compared to that of 
RDI which is approximately eight times less thermostable. This difference must be due 
to confonnational differences between the two isoforms with extra tertiary structure 
being formed in the human fonn conferring added stabihty on the catalytic domain 
through different types of bonds.
Both the human and rat forms have an intrinsic ability to bind to membranes. This must 
be a property contained within the N-terminus and not an element which is die product of 
post-translational modification. The cell-free transcription-translation experiments 
showed that no such modifications are required for liRDl to form interactions with the 
membrane. Interestingly these interactions between hRDl produced in the cell-free 
system and P2 membranes are disturbed by low concentrations of Triton X-100 in the 
same way as they are between liRDl produced in COS-7 cells and the ceU membranes.
It would be interesting to investigate the effects of the lack of UCRl, LRl and part of 
UCR2 as these domains are thought to have regulatory effects on the catalytic domain. 
This could be investigated by producing a chimera which consists of the unique hRDl N- 
terminus and a catalytic domain wliich includes the UCRl, LRl and the missing exon 
encoding part of UCR2. Tliis would in effect make it into a long-form PDE. The kinetic
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properties of tliis enzyme could be compared to tliat of the short-fonn liRDl and any 
differences attributed to the presence of tliese domains. Differences in the catalytic 
activity and inhibitor affinity of this chimera and h46 would then point to effects of the 
unique N-tenninus on die catalytic domain.
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3.2.13 Figures
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Figure 22. Western Blot o f hRDl expressed in COS-7 cell fractions. Lane I contained 
20pg o f PI fraction, lane 2: 5pg o f P2 fraction, lane 3: 20pg o f S2 fraction and lane 4 
was loaded with 20pg o f homogenate from the mock transfected COS-7 cells. Fractions 
were subject to SDS-PAGE with immunoblotting using a human PDE4A specific 
antiserum.
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P I P2 S2
nmol/min/mg prot. 0.9+/-0.2 12.1+/-0.8 0.8+/-0.1
Figure 23. Table showing the specific PDE activity o f  hRDl in each fraction (PI, P2 
and S2) o f  COS-7 cells. This is expressed as nmol o f  cAMP hydrolysed per minute per mg 
o f protein. Fractions from mock transfected (vector only) COS-7 cells were also tested 
and they had specific activities as follows: PI: 0.027+/-0.005, P2: 0.019+/-0.004, S2: 
0.05+/-0.009 nmol cAMP/min/mgprotein.
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Figure 24. Graph showing a Michaelis Menten plot describing the substrate 
dependence o f hRDl activity. These data were obtained using a transfected COS-7 cell 
P2 fraction. The curve shown is a least squares fit  assuming simple Michaelis Menten 
kinetics, V^VrnaxS/fKm +S), yielding a Km o f 1.2 juM.
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PI P2 S2
Kjn cAMP (^M) 3.3 +/-2.0 1.5 +/-0.5 3.0 +/-1.5
Figure 25. This table shows the Km values fo r  hRDl expressed in various COS-7 cell 
fractions PI, P2 and S2. The values were obtained from PDE assays carried out at least 
three times on samples from at least four separate transfections o f COS-7 cells and the 
standard errors (means +/-S.E.M. ; n= 3) fo r  each value are shown beside each one.
PI F2 S2
ICso Roiipram (pM ) Q .3 6  + /-0.07 0.29 +/-0.09 0.52 +/-0.28
Figure 26. Table o f ICso values fo r  rolipram inhibition o f hRDl activity found in each 
fraction o f hRDl transfected COS-7 cells. Assays were carried out three times on at least 
four separate transfections. The graph below shows a typical inhibition plot o f hRDl 
found in COS-7 cell fractions in response to the inhibitor rolipram. These experiments 
were carried out using a cAMP concentration equal to that o f  the Km fo r  cAMP fo r  each 
fraction.
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Figure 27. Graph showing a typical inhibition curve (IC50)  fo r  the response o f hRDl 
expressed in COS-7 cell fractions (P f P2 and S2) in response to the inhibitor rolipram. 
Activity remaining at different inhibitor concentrations is expressed as a percentage o f  
the maximum activity when no inhibitor is present in the assay. The cAMP concentration 
was at [Km
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Distribution o f PDE activity (hR D l) 
between COS7 cell fractions
•S 40
10
PI P2 
COS7 cell fraction
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Figure 28. This graph shows the amount o f hRDl phosphodiesterase activity 
distributed in each COS-7 ceils fraction by volume alone. The PI fraction contained 
33%+ -10 o f the total activity per volume, the P2 fraction 44%> +/-I1 and the S2 fraction
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Figure 29.
cDNA.
Photograph o f 276hp fragment o f hRDl PCR amplified from human brain
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T o s(m in )  50^C To sCm in) 55 °C
P I >120 93 +A8.7
P2 >120 95 +A5.5
S2 22 +M.5 7.3 +/-0.6
Figure 30. This table shows the half lives fo r  the hRDl expressed in each COS-7 
fraction when incubated at 50 T7 and then 55 T7 before being subject to PDE assay to 
assess the activity remaining. Each experiment was carried out three times on samples 
from three separate transfections.
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Figure 31. Residual activity o f P2 fraction from hRDI transfected COS-7 cells 
incubated at 55X1. The dots indicate data obtained from COS-7 cells transfected with 
hRDI DNA and the dashed line indicates data obtained from COS-7 cells transfected 
with RDI DNA (from other data fo r rat enzyme). The logarithm o f the percentage 
residual activity is plotted as a function o f time. Thermal dénaturation o f proteins occurs 
as a first-order process which is defined as a single exponential. Thus fo r  enzymes, semi­
log plots o f the residual activity against time will be linear and can be used to derive half 
lives (Shakur et al. 1993). Such analyses offers a simple way o f ascertaining whether the 
human and rat RDI forms are conformationally distinct.
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Temp °C Fraction Half life (min) hRDI RDI
55 P2 31+/-2 4
Figure 32. Thermostability (shown as half life in minutes) o f  P2 hRDI compared to 
thatofP2RD l at 55 V .
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Figure 33. Typical results o f incubating hRDI transfected COS-7 cell P2 fraction 
with increasing amounts o f Triton X-IOO fo r  30 minutes before centrifugation to produce 
a supernatant.
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Figure 34. Western blot o f TNT hRDI. Blot A shows the results o f incubating I ’NT 
hRDI with P2 membranes and then subjecting them to a 0.001% Triton X-IOO wash. 
After centrifugation the blot shows that the hRDI is now present in the P2 supernatant 
fraction as opposed to binding to the P2 membranes. In blot B TNT hRDI had been 
incubated with P2 membranes (with no subsequent Triton X-IOO wash) and appears in 
the pellet fraction after centrifugation (lane I).
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CHAPTER 4
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4.1 Cloning and expression of PDE4A10
4.1.1 Introduction
Human PDE4A10, a long-forai PDE isoform, was initially cloned in this laboratory by 
Graham Rena who based liis cloning strategy on a rat cDNA that contained novel N- 
terminal sequence indicating a novel N-tenninus. Using primers based on tlie rat 
sequence he was able to detect PDE4A10 in human cell lines using RT-PCR. He then 
used human cosmid clones containing sequence from the human PDE4A exons to reveal 
the sequence of a unique region plus sequence lying upstream of the unique 5' end of this 
splice variant. The upstream region lying between the 5' exon of PDE4A10 and the 5' 
exon of TM3 was thought to contain the promoter sequence for the gene (see figure 36). 
This investigation showed that the novel human N-tenninal sequence represented the 
discovery of a novel PDE4A as the sequencing revealed the point at which the splice 
junction occurred (see figures 35, 36 and 37) and the common PDE4A region began 
(downstream of the unique N-terminus, see figure 37).
The sequence discovered by Graham Rena (wliich included 434 base pairs encoding the 
promoter region upstream of the unique N-terminus plus the unique N-tenninus) was 
cloned into PCR2.1. This vector already contained the common (core) PDE4A region 
sequence starting from the PDE4A10 splice jimction onwards. The novel sequence was 
cloned into the vector upstream of the PDE4A10 splice junction. The sequence was tlien 
expressed in COS cells.
At first it was thought that the open reading frame for PDE4A10 contained three (or four, 
including one situated too far upstream of the N-terminus to be a potential initiating AT G
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for PDE4A10 but named ATGl by Graham Rena nonetheless) potential in-frame ATG, 
methionine, transcriptional "start" sites (see figures 37 and 38). Fuitlier sequencing 
througli this extremely GC-rich region revealed that only one of these "start" sites was a 
true ATG and this was ATG2. The others, ATG3 and ATG4 (at base pair numbers 46 to 
48 and 52 to 54 respectively in the PDE4A10 sequence, see figures 38 and 42) were 
shown to in fact to be CTG. PDE4A10 was re-engineered so that the construct only 
contained the PDE4A10 ORF starting from the true ATG; ATG2 (see figure 42). This 
construct also contained an improved flanking Kozak sequence to enhance expression of 
the protein in mammalian cell lines. Studies carried out on the sequence flanking 
transcriptional start sites (ATG) showed that the presence of either a G or an A at tlie 
position 3 base pairs upstream of die ATG and die presence of G directly downstream of 
the ATG were crucial to maximizing translational efficiency of die ribosome (Kozak 
1987a; Kozak 1987b). The presence of the G or A 3 base pairs upstream of the ATG was, 
however, not critical for efficient translation whereas the G downstream of the ATG was. 
This means diat the sequence G(or A)CCATGG would form an optimal Kozak sequence 
flanking the ATG (see figure 38). ATG2 did not have an optimal Kozak sequence so it 
was changed from CCCATGC to CCCATGG, a single silent base pair change not 
changing the amino acid it encoded.
ATGl in PDE4A10GR was too far away from the N-terminal sequence (840 base pairs 
upstream of ATG2) to be the true ATG, so was discounted but was still considered as 
ATGl for die purposes of the study. ATGl was discounted on the basis that it was found 
to be located in the promoter sequence, was not flanked by a Kozak sequence, and would 
have produced a protein of a predicted weight of 144 kDa taking into account the
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abeixant migration of PDE4A10 on SDS-PAGE analysis. A major immunoreactive 
species of this molecular weight was not observed.
4.1.2 QuickChange primers designed to mutate PDE4A10 ATGs
Prior to the PDE4A10GR construct being sequenced, a strategy which could rapidly 
reveal tlie true initiating ATG of PDE4A10 was designed. Tliis involved QuickChange 
mutational analysis (see methods) to silence ATGs 2, 3 and 4 in turn. The primers 
designed for this investigation are shown in figure 39. It was presumed that ATG3 was 
the most likely start site and had been chosen as such by Graham Rena as the sequence 
flanking it on either side was that which most resembled an optimal Kozac sequence. If 
ATG3 was the true initiating codon as presumed then mutating it should mean that no 
protein would be produced. Mutating either ATG2 or ATG4 would result in protein being 
made as ATG3 would be imaffected. This method presumed that translational was only 
occurring as the result of one ATG and was supported by the lack of a double band on 
SDS-PAGE and Western Blotting.
It was hoped that the QuickChange metliod would provide a rapid answer as to which 
ATG was tlie true initiating ATG. At this time sequencing had not progressed far enougli 
to reveal that only one ATG actually existed. The QuickChange PCR reactions were not 
successful but tlie fact that tliis region was so GC-ricli was interfering with all 
experiments involving PCR based strategies. Tlie high fidelity DNA polymerase Pwo was
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also used in conjunction with QuickChange to enhance tlie possibility of the reactions 
working but it did not produce any positives.
4.1.3 Sequencing Construct PDE4A10GR
The construct designated PDE4A10GR was the original construct made by Graliam Rena 
in the vector pSV-SPORT. It was unclear what the precise sequence of this construct was. 
Thus I set out to sequence it in frill, in order to reveal the sequence of the unique 
PDE4A10 5' N-terminal region which had been included in the construct therefore 
identifying the 5' exon of PDE4A10.
Sequencing of PDE4A10 was initially done using the SP6 primer which anneals upstream 
of tlie multiple cloning site in pSV-SPORT. The primers GR84, GRIO and GRl 1 were 
also used along with primer GRl 14 (see figure 40a). The exact sequences and positions 
of these primers can be seen in figure 37). GRIO was a primer which had been designed 
to rat sequence but matched the human sequence at certain points crucially at the start at 
finish of the primer sequence which are important for prhner annealing (see figure 40b 
and c).
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4.1.4 A ttem pt to sequence the N-term inal region of PDE4A10 protein
Wliile awaiting sequencing data for the original PDE4A10GR construct to confirm the 
existence of the proposed ATGs an alternative approach to estabhsh the true initiating 
ATG was also used. Tliis involved expressing tlie protein PDE4A10 encoded by the 
sequence in the construct PDE4A10GR. By sequencing the protein this should tell us 
where initiation of transcription and translation starts.
In order to obtain sufficient protein for sequencing immimo-precipitation was used to 
maximise the amount of the PDE4A10 protein present. Immuno-precipitation was carried 
out using the antibody 97 which recognises a peptide sequence in the common region of 
PDE4A. The antibody was of a small enough moleculai weight so tliat it would not 
interfere with the sequencing of the target protein PDE4A10. The protocols for the 
immuno-precipitation and the preparation of samples for protein sequencing can be found 
in the methods section.
Staining of the protein for sequencing was crucial in order to identify the pai ticular band 
to be sequenced. The only stain available which was compatible with the type of 
membrane used to transfer the protein onto and the sequencing process was Coomassie 
Blue R. This unfortunately did not identify tlie band very strongly indicating that there 
was a low amount of immunoreactive protein present. It was decided that neitlier of the 
six or so attempts to isolate a PDE4A10 band had yielded enough protein for the 
sequencing to be successful.
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4,1.5 First re-cloning strategy for PDE4A10 to start from ATG3
This cloning strategy was devised to dispense with the need to use Quick Change to 
mutate the ATGs as this strategy had been unsuccessful. It was decided to use ATG3 as 
tlie initiating methionine its flanking sequence best fitted the Kozac rule. Graham Rena 
had also decided that this must be the initiating ATG for the same reason. This re-cloning 
strategy would do two things at once. It would create a construct which started at ATG3 
but also the new construct would not contain the sequence upstream of ATG3 making the 
new construct approximately 434bp smaller than PDE4A10GR. This additional 5' 
sequence could potentially interfere witli expression of tlie protein. The general cloning 
strategy can be seen in figure 41.
Once the 1.3Kb fragment (with a Kpnl site at tlie 5' end and a PaeR7I at the 3' end) had 
been amplified using primers PDE4A10FB21F and PDE4A10FB22R this was gel 
piurfied for ligation back into the vector. Before the 1.3Kb fragment was ligated into the 
vector pSV-SPORT it was digested with the restriction enzymes Kpnl and PaeR7I thus 
removing a 1.7Kb fragment. This was replaced by the 1.3Kb fragment which staited at 
ATG3.
Once this construct had been created further sequencing data became available which 
showed that ATGs 3 and 4 were in fact CTG and ATG2 was in fact the authentic 
initiating ATG. A further new cloning strategy had to be developed and tlie construct 
PDE4A10ATG3 was not used for biochemical analyses.
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4.1.6 Second re-cloning strategy for PDE4A10 to start from  ATG2
Sequencing of the original PDE4A10GR construct had been hampered by the Ihgh GC- 
rich regions it contained but new primers were used and revealed that two ATGs (3 and 
4) were actually CTG instead. This is shown in figure 42. This meant that the construct 
PDE4A10ATG3 was in fact incorrect and would have to be re-engineered to start at 
ATG2,45 base pairs further upstream of ATG3.
Engineering the construct so that it now started at ATG2 was straightforwaid and used 
the same strategy as the first re-cloning which produced PDE4A10ATG3. A new primer 
was designed to anneal in the region of ATG2 and contained a Kpnl restriction site by 
changing the region GGC TCC to GGT ACC. The new foiwards piimer was called 
FBPDE4A10ATG2 (CGA CGG TAC CTG GCT ACC ATG CGC TCC GGT GCA GC) 
and was used with the existing reverse primer PDE4A10FB22R. The flanking sequence 
around ATG2 was also changed from CCC ATG GGC to ACC ATG CGC so that this 
better fit the Kozac rule and expression of this gene sequence would be enhanced. These 
primers produced a fragment of 1.335Kb (see figure 43). This fragment was gel purified 
and tlien Taq treated before ligation into the vector PCR2.1.
4.1.7 Sequencing of the 1.335kb fragment for PDE4A10ATG2 construct
Although the PCR reaction used to amplify the 1.335Kb fragment for PDE4A10ATG2 
had been carried out using the high fidelity DNA polymerase Pwo it was vital to check
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tliat the sequence had been amplified exactly and that no mistakes or mutations had 
occurred in the sequence. The sequencing was carried out using internal PDE4A primers 
including FB5, FB6, FB3, FB7, FB2, FB8 and FBI. The sequence and position of these 
primers can be seen in figure 14. One clone (29) was found to contain sequence 
homologous to the common PDE4A long-fonn region with no mistakes introduced by the 
PCR reaction.
4.1.8 Screening multiple choice cDNAs for presence of PDE4A10
The first round of screening for the presence of PDE4A10 in human tissues was carried 
out using Origene Multiple Choice cDNAs. These included cDNA from the following 
tissues: testis, ovary, small intestine, lung, muscle, prostate, leukocytes, brain, heart, 
kidney, spleen, hver. Plasmid DNA from 4A1GR pSV-SPORT, h46pSV-SPORT and 
cDNA from human brain library were also used as template with the PDE4A10 primers. 
The forwards primer (GRIO) anneals to sequence in the unique N-tenninus of PDE4A10 
and tlie reverse primer (GR84) anneals in the common PDE4A region. These primers 
should produce a band of 224bp. (3-Actin primers were also used to verify tliat the cDNA 
had been made correctly in the reverse transcriptase reaction. Many different PCR 
cycling parameters plus the addition of 5-10% final concentration DMSO were used in 
this reaction but no positive bands of the correct size were seen. The primers were able to 
amplify a band of the correct size from PDE4A10GR plasmid DNA and the negative 
controls produced no bands.
187
4.1.9 Screening cell lines for expression o f PDE4A10
Previous experiments had shown PDE4A10 to be present in a niunber of different cells 
lines including Hek293, SK-N-SH, FTC 133, U118 and HeLa cells. Using RT-PCR for 
PDE4A10 in cell hnes it was hoped to discover the true N-terminal sequence of native 
PDE4A10 so these cells were grown again along with other cell hnes iucluding U87, 
Jurkat, U937's, B cells, F442A, Molt 3 and HLA-60. When tlie cells reached confluency 
or a density of around 1X10^ cells per ml they were harvested and prepared for RNA 
extraction (see methods). cDNA was made using the RNA from the cell lines and any 
cDNA remaining was stored in the -80°C freezer. PCR was carried out the cDNA using 
tlie primer pairs GRIO and GR84 (224bp) or GRl 14 with GR84 which produced a larger 
fragment of 497bp. p-Actin primers were also used in each roimd of PCR to check that 
cDNA had been made successfully. The p-Actin controls were always positive but the 
primers were probably unable to amplify any sequence due to its high GC-rich nature.
4.1.10 Primer pairs for detecting presence of PDE46 and hRDI
The following primer pairs (see figure 44 for sequences) were designed and made to 
screen for the presence of either PDE4A4B (PDE46) or PDE4A1 (hRDI). The PDE4A4B 
primers were designed in order that if screening for PDE4A10 was successful then it 
would be possible to verify that PDE4A10 rather Üian PDE4A4B had been PCR 
amplified. The PDE4A1 primer pair was designed so that a complimentary screening
study could be carried out at the same time. However, as the screens for PDE4A10 were 
unsuccessful there was always some doubt as to the quality of the cDNA and the focus 
remained on screening for PDE4A10 rather than any other PDE4A isoforms. The N- 
terminal (forwards) primer in each case is designed to anneal to a region in the unique N- 
terminal sequence of each isoform and the C-teiminal (reverse) primer is designed to 
anneal to common PDE4A sequence. In tliis way a fragment spanning across the splice 
jimction is created. The primer pairs for each isoform can be seen in figure 44. These 
primer pairs may be of use for future screening.
4.1.11 RT-PCR using GR29, a PDE4A10 specific primer to make cDNA
Due to the lack of signal after RT PCR using cDNA from cell lines with PDE4A10 
specific primers many different PCR conditions and cycling parameters were used to see 
if this would effect the outcome. The primer used in tlie reverse transcriptase element of 
the procedure (to produce the cDNA) was also changed. A "random" Notl d-(T) primer 
which produces fragments of cDNA of varying lengths wherever it anneals to a Notl site 
had been used with the first strand cDNA syntliesis kit (see methods). This was replaced 
with tlie primer GR29 (sequence CCACGATGTGGACCACCCTG synthesised reverse 
and complimentary for the reverse transcriptase reaction) which is designed to anneal 
downstream from the unique PDE4A10 sequence and produce cDNA covering this 
region (see figure 40a for position). This should increase the percentage of target DNA in 
tlie resulting cDNA, however, the outcome did not change in tliis case.
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4.1.12 R T-PCR using IM  prim er to produce longer fragm ent
Another strategy which was used to amplify a PDE4A10 specific band from cell line 
cDNA was to use primers which were further away from tlie unique region. This would 
result in the primers annealing to sequence which was less GC-rich and therefore have a 
better chance to read through the more GC-rich areas. The primers used in this case were 
5'PDE4A10at3’ (forwards) GCA CCC TCC GGG CAG ATC TGT C which was designed 
to anneal at the 3' end of the unique N-terminus and out witii tlie most GC-rich region in 
that area. The reverse primer was rtCATPDE4A10at5’ AGT GTG TCA GGC TGT TAC 
TA which together with the forwards primer would produce a band of 750bp. The 
forward primer 5PDE4A10at3' could also be used with common 4A primers FBIO 
(406bp) or FB8 (190bp). Once again none of the reactions using these primer pairs 
produced positive bands witli the cell hne cDNA.
4.1.13 RT-PCR detects PDE4A10 transcripts in RNA from human tissue
The sense primer IMl (TCC GGG CAG ATC TGT CAG CTT; position 120 to 140 in 
HSPDE4A10) was used with the antisense primer ESH4 (ACT GGG AAC GGG CAC 
ATT GGT; HSPDE4A common region, position 412 to 432 of HSPDE4A10) in order to 
amplify a 313bp region in HSPDE4A10 (see figure 40a for relative positions). This 
primer pair was to probe a panel of human tissue RNA samples ("Panel 1 " RNA from 
Clontech; cat. K4000-1). Both positive (using HSPDE4A10 plasmid DNA) and negative
190
(using water) PCR reaction were also carried out at the same time. HSPDE4A10 
transcripts were detected in aU of tlie various tissue types analysed (see figure 45). The 
strongest signal was detected in heart although it must be noted that this analysis is 
quahtative only and not quantitative.
4.1.14 Expression of the sequence encoding PDE4A10GR
Wlien DNA encoding the PDE4A10GR sequence was transfected into COS-7 cells it was 
found to have a very low level of expression. This had not previously been a problem 
when Graham Rena has expressed PDE4A10 from the vector PCR2.1. The decrease in 
expression levels could have been due to changes in the COS-7 cells. New COS-7 cells 
were used but the expression levels did not increase. The low levels of PDE4A10 
expression also meant that the overall specific activity of the enzyme was 
unrepresentative as the endogenous PDE activity can become significant, making kinetic 
studies invalid. This could have been overcome by immimoprecipitating PDE4A10 prior 
to kinetic analyses. In order to avoid this expression levels could be increased by re- 
engineeiing the construct to contain a Kozak sequence which would give optimmn 
expression of the gene. The strategy of optimising tlie Kozak sequence is often employed 
dur ing the cloning of genes and in this case proved very successful leading to high levels 
of the expression of the PDE4A10 gene.
Western blotting of the PDE4A10GR protein after SDS-PAGE showed, as for all known 
PDE4 enzymes, that the expressed protein migrated at a higher molecular weight than
191
predicted from the amino acid sequence. PDE4A10 appeared to migrate in a similar 
fashion to HSPDE4A4B (PDE46). However, its predicted molecular weight is 9kDa less 
than that of HSPDE4A4B (see figure 46). Tliis is a small difference and higher resolving 
gels are needed to discriminate between the two proteins.
As discussed above, PDE enzymes characteristically migrate more slowly on SDS-PAGE 
tlian predicted by their amino acid sequence. Tliis can be a result of the conserved poly 
(acidic) regions found towards the C-terminus of tlie catalytic region. Another possible 
reason for aberrant migration on SDS-PAGE is that the enzyme might be phosphorylated. 
The degree to which phosphorylation could be a contributing factor could be investigated 
using a simple de-phosphorylation experiment.
4.1.15 De-phosphorylation of PDE4A10
As described in the previous section phosphorylation due to motifs present in the unique 
N-terminus of PDE4A10GR could be a cause of aberrant migration of PDE4A10 on 
SDS-PAGE. These included the motifs PESL (p-adrenergic receptor kinase), TGPE and 
SDED (casein kinase 2) none of which are present in PDE4A4B. There was also an 
additional TRR motif (protein kinase C) in the PDE4A10 N-termmal sequence although 
PDE4A4B (PDE46) also contains several protein kinase C motifs in the common region 
shared witli PDE4A10.
A simple experiment to demonstrate wheüier this was the case involved using a 
phosphatase treatment to de-phosphorylate the protein. COS-1 cells which had been
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transfected with PDE4A10GR DNA were semm starved overnight prior to ü’eatment. 
Alkahne phosphatase was used either alone or after pre-treatment of cells witli Protein 
Kinase C inhibitor (see methods). The results can be seen in figure 47, It is possible that 
the MW of PDE4A10GR was reduced sliglitly by tlie de-phosphorylation but further 
experiments were unable to clarify this. Thus a more intensive investigation needed to be 
carried out as a separate project to evaluate tliis.
4.1.16 Expression of PDE4A10ATG2 in COS-1 cells
Once the final construct ATG2 was made three clones were used for expression in COS-7 
cells. COS-1 cells were chosen as the expression system for characterisation of the 
protein as PDE4A10 appeared to be expressed more efficiently in these than in C0S7 
cells. Indeed >98% of total PDE activity was due to recombinant enzyme. Thus any 
endogenous PDE activity would not interfere with the characterisation of PDE4A10. 
These data were tlien compared to die other PDE4A long-fbnn PDE4A4B (PDE46).
Figure 48 shows how the predicted molecular weights of the three proteins PDE4A4B 
(PDE46), PDE4A10ATG3 and PDE4A10ATG2 compared. This was done on the basis of 
the amino acid sequence obtained firom the sequence making up the open reading frame 
of gene. From the number and type of amino acids in the sequence it is possible to 
calculate the approximate molecular weight of the protein and how they should compare 
when resolved by SDS-PAGE.
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Using die traditional 8% cross-linked SDS-polyacrylamide gels to resolve PDE4A10 
meant that its size could not be distinguished from tliat of PDE4A4B by eye as the 
separation was not particularly good. To obtain higher resolution in order to resolve these 
proteins a new range of pre-cast Tris-Acetate 3-8% polyacrylamide gels (Novex) was 
used. These were designed to separate proteins in the size region of aroimd 125kDa i.e. 
exactly in the region required (see figure 49).
Not only was it now possible to show a difference in size between PDE4A4B and 
PDE4A10 (see figure 50) but also this confirmed tliat ATG2 was die initiating 
mediioniiie in that bodi constructs PDE4A10GR (wild type) and PDE4A10ATG2 
encoded similarly migrating species. The construct PDE4A10ATG3 contained 15 fewer 
amino acids and also produced a smaller protein which was visible only with this 
particular system.
While the predicted ATG2 was the correct one it was only a prediction. Thus to elucidate 
it I generated constructs that would encode either only an ATG2 start or only an ATG3 
start. These gave single bands on SDS PAGE that migrated differently from each other. 
Secondly I used a "native" construct diat had cloned the entire "presumed" 5' exon of 
PDE4A10 plus the presmned 5' intron (this was later considered to contain part of the 
putative PDE4A10 promoter sequence). It follows therefore that all possible ATG starts 
were made available in this construct. However, only one band appeared and this 
migrated with the protein encoded for in the ATG2 construct rather than the ATG3 
construct. This is excellent evidence for my contention that ATG2 provides the 
PDE4A10 initiating "start" codon.
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4.1.17 Conclusion
The original construct encoding PDE4A10 produced a protein which when over 
expressed in COS-1 cells appeared to have a much higlier molecular weight than 
expected. Most PDE4s migrate aberrantly slowly on SDS-PAGE which could be as a 
result of structural motifs, post-translational modifications or phosphorylation. In the 
original PDE4A10 construct there was additional sequence upstream of the presumed 
initiating codon. This was thought to also perhaps be having an effect on the production 
of the protein.
The first step in clarifying the situation was to make a construct which started 
immediately at the initiating codon. De-phosphorylation of tlie protein produced was also 
used to see if these reduced the size of the protein tlierefore accoimting for its higher 
molecular weight. This did result in a shght reduction.
Additional sequencing showed that the presumed initiating codon was in fact not an 
ATG. The difficulty in sequencing tliis region once again reflected the GC-rich nature of 
some of the N-terminal regions of PDE4s. The protein produced from the sequence 
starting from the true initiating ATG interestingly produced a protein of identical 
molecular weight to tlie original construct which contained additional 5' sequence. This 
showed that none of the upstream sequence had been influencing the production of the 
PDE4A10 protein. Any increase in molecular weight above tliat expected was therefore 
likely to be intrinsic due to the nature of the residues, in particular the conserved poly- 
acidic regions present in the C-terminal region, or some kind of post-translational 
modification.
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The cloning of hie gene encoding PDE4A10 represents the discovery of a new long-form 
PDE wliich shares the same splice junction as PDE46 as well as a homologous catalytic 
C-terminal domain although the N-tenninal region of h46 is some 61 amino acids longer.
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4.1.18 Figures
PDE4A10and 
PDE4A4B Lcngfcrm 
^lœ jiiictiG n
i
PDE4A1 Shcrt form 
^iœ jLficüG n
LR1
UCR1 catalytic regcn
UCR2 
LR2
C-terrrinal 
® -------  regcn
Figure 35. Schematic diagram of location of the PDE4AK) long-form N-terminal 
splice Junction. This position is shared with the other human PDE4 long isoform 
PDE4A4B (h46). Also shown are the positions of the internal regions UCRI, IJCR2, 
linker regions I and 2 (LRI and LR2) and the catalytic region which are all common to 
both PDE4AI0 andPDE4A4B.
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Figure 36. Schematic diagram of position of the PDE4AI0 5' exon encoding the 
unique N-terminal region in the HSPDE4A gene. Also shown are the relative positions in 
the HSPDE4A gene of the 5' exons encoding the unique N-terminal regions of PDE4A4 
(h46) and 4Al (hRJ)I).
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G R l l^
G GGG GGG AAA TTG GTG CGA TTC CGC AGG ACC CCT GCA GGG GGA GGC
AGA CAG AGC GCC CGT GCG CTC CCT TCC CCC GTG CAG ACC CGG GAA
CGT TCG ACC GCC CGG GGC TGT CCC TGG GGG GGT CAC CAG AGG CGT
GGA GGC GGT GCC GGC AGT GGA GGC CGC AGA CAC CTT GGG CCT GGC
CAG CAG CGC GCC CAC ACC GCC CTG CCG CCG TCC CCA TGC GCG CCC
2 Novel 5’ region
CGA CGA CGG CGC TTG GCT CCC ATG C G C  T C C  G G T  G C A  G C G  C C C  C G G
3 G R H ^  4
G C C  C G G  C C C  C G G  C C C  C C T  G C C  ATG GCA ATG C C C  C C C  ACG G G C
C C C  GAG T C C  C T G  A C C  CA C T T C  C C C  T T C  A G C G A T G AG  G AC A CC
^ G R ll
C G T  C G G  CA C C C T  C C G  G G C  AGA T C T  G TC  AGC TTC GAG GCA GAG AAT
GGG CCG ACA CCA TCT CCT GGC CGC AGC CCC CTG GAC TCG CAG GCG
U C R I
AGC CCA GGA CTC GTG CTG CAC GCC GGG GCG GCC ACC AGC CAG C G C
^ R 8
C G G  G AG  T C C  T T C  C TG  TA C  C G C  TCA  GAC A G C G A C TA T G A C A TG
TC A  C C C  AAG A CC A TG T C C  C G G  AAC TCA  T C G  G T C  A C C  A G C GAG
G C G  CA C G C T  GAA G AC C T C  A TC GTA  ACA CCA T T T  G C T  CAG G TG
C T G  G C C  A G C C T C  C G G  A G C G T C  C G T  AGC AAC T T C  TC A  C T C  CTG
A CC AAT GTG CCC GTT CCC AGT AAC AAG CGG TCC CCG CTG GGC GGC
UCR2
CCC ACC CCT GTC TGC AAG GCC ACG CTG TCA  GAA GAA A CG  T G T  CAG 
CAG T T G  G C C  C G G  G A G  A CT C TG  GAG GAG C TG  G A C TG G  T G T  C TG  
G AG  CAG C TG  GAG  A CC A TG  CAG A CC TA T C G C  T C T  G T C  A G C GAG 
A TG  G C C  T C G  CA C AAG T T C  AAA A GG ATG T T G  AAC C G T  GAG C T C  
ACA CA C C T G  TC A  GAA A TG  A G C A GG  T C C  G G A  AAC CA G  G TC  TCA  
GAG TA C A TT T C C  A CA A CA T T C  C T G  G A C AAA CA G  AAT GAA G TG  
GAG A TC C C A  TC A  CCC ACG ATG AAG GAA CGA GAA AAA CAG CAA GCG
199
CCG CGA CCA AGA CCC TCC CAG CCG CCC CCG CCC CCT GTA CCA CAC
TTA CAG CCC A TG  TC C  CAA ATC ACA GGG TT G  AAA AAG TT G  ATG  CAT 
C atalytic region
AGT AAC AGC C TG  AAC AAC T C T  AAC A TT CCC CGA T T T  G GG G TG  
AAG ACC GAT CAA GAA GAG C TC  C TG  GCC CAA GAA C TG  GAG AAC 
C TG  AAC AAG TG G  G GC C TG  AAC ATC TTT TG C G TG  TC G  GAT TAC 
G CT GGA G GC CGC TCA CTC ACC TG C  ATC A TG TAC A TG ATA TTC CAG 
GAG CGG GAC C TG  C TG  AAG AAA TTC CGC A TC CCG  G TG  GAC ACG 
ATG G TG  ACA TAC A TG C TG  ACG CTG  GAG GAT CAC TAC CAC G CT 
GAC G TG  G CC TAC CAT AAC AGC CTG  CAC GCA G C T GAC G TG  CTG 
CAG TCC ACC CAC GTA CTG  C TG  GCC ACG CCT GCA CTA GAT GCA 
G TG  TTC A CG GAC CTG  GAG A TT CTC G CC G CC C TC  TT C  G CG G CT 
G CC ATC CAC GAT G TG  GAT CAC CCT GGG G TC TC C  AAC CAG TTC 
CTC ATC AAC ACC AAT TC G  GAG C TG  GCG CTC A TG  TAC AAC GAT 
GAG TCG G TG  CTC GAG AAT CAC CAC CTG  G CC G TG  GGC TTC AAG 
CTG  CTG  CAG GAG GAC AAC TG C GAC ATC TTC CA G  AAC CTC AGC 
AAG CGC CAG CGG  CAG AGC CTA CGC AAG A TG G TC ATC GAC ATG 
G TG CTG GCC ACG GAC A TG  TCC AAG CAC ATG A CC CTC CTG  GCT 
GAC CTG  AAG ACC ATG GTG  GAG ACC AAG AAA G TG  ACC AGC TCA 
GGG GTC CTC CTG  CTA GAT AAC TAC TCC GAC CGC ATC CAG GTC 
CTC CGG AAC A TG  G TG CAC TG T GCC GAC CTC AGC AAC CCC ACC 
AAG CCG CTG  GAG CTG  TAC CGC CAG TGG ACA GAC CG C ATC ATG 
GCC GAG TTC TT C  CAG CAG G G T GAC CGA GAG CGC GAG CGT GGC 
ATG GAA ATC AGC CCC A TG TG T  GAC AAG CAC ACT G CC TCC GTG
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GAG AAG TCT CAG GTG GGT TTT ATT GAC TAC ATT GTG CAC CCA TTG
TGG GAG ACC TGG GCG GAC CTT GTC CAC CCA GAT GCC CAG GAG
ATC TTG GAC ACT TTG GAG GAC AAC CGG GAC TGG TAC TAC AGC
GCC ATC CGG CAG AGC CCA TCT CCG CCA CCC GAG GAG GAG TCA
AGG GGG CCA GGC CAC CCA CCC CTG CCT GAC AAG TTC CAG TTT
C-terminal region
GAG CTG ACG CTG GAG GAG GAA GAG GAG GAA GAA ATA TCA ATG
GCC CAG ATA CCG TGC ACA GCC CAA GAG GCA TTG ACT GCG CAG GGA 
TTG TCA GGA GTC GAG GAA GCT CTG GAT GCA ACC ATA GCC TGG GAG 
GCA TCC CCG GCC CAG GAG TCG TTG GAA GTT ATG GCA CAG GAA GCA 
TCC CTG GAG GCC GAG CTG GAG GCA GTG TAT TTG ACA CAG CAG GCA 
CAG TCC ACA GGC AGT GCA CCT GTG GCT CCG GAT GAG TTC TCG TCC 
CGG GAG GAA TTC GTG GTT GCT GTA AGC CAC AGC AGC CCC TCT GCC 
CTG GCT CTT CAA AGC CCC CTT CTC CCT GCT TGG AGG ACC CTG TCT GTT 
TCA GAG CAT GCC CCG GGC CTC CCG GGC CTC CCC TCC ACG GCG GCC 
GAG GTG GAG GCC CAA CGA GAG CAC CAG GCT GCC AAG AGG GCT TGC 
AGT GCC TGC GCA GGG ACA TTT GGG GAG GAC ACA TCC GCA CTC CCA 
GCT CCT GGT GGC GGG GGG TCA GGT GGA GAC CCT ACC TGA TCC C
Figure 37. Complete coding sequence for PDE4A10. The regions highlighted and 
underlined indicate sequence encoding distinct domains within this PDE. These regions 
include 1) the novel N-termina! domain, 2) UCRI, 3) UCR2, 4} the catalytic domain and 
5) the C-terminal region. The position o f ATGs 2, 3 and 4 are also highlighted in red.
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Also indicated are the positions and sequences o f the primers used to sequence the 
construct PDE4A10GR.
Residue numbers and flanking sequence of ATGs 2,3 and 4 in 4A10 N terminus
Residue 
Numbers 1-3 46-48 S2-S4 Calculated MWkDa
ATGŒCTODGGTXXACOjCOOCXXjGCCXXKXXXDCXXXXXXXnXXrATGœAATGCCXXXC........
?
OXATCXXÎT
^ Œ A T c g c A
gcAATGCXX
^ O C A T ( §
Q  essential
A P M R S
R A M A M
M A M P P
Kozac rule
91.4
89.8
89.6
Figure 38. The relative positions o f PDE4A10 ATGs 2, 3 and 4 and their flanking 
sequence in comparison to the Kozak rule sequence.
2 0 2
Prim ers pairs designed to m utate A T G s 2, 3 and 4 from  A T G  to
TTGGCTCCCGCGCGTTCCGGTGCAGCGCCCCGG
CCGGGGCGCTGCACCGGAACGCGCGGGAGCCAA
FBQC3 ^
CCGGCCCCGTGCCGCGGCAATGCCCCCCACCGG
FBQC4
CCGTGGGGGGCATTGCCGCCGCACGGGGCCGG
FBQC5 ^
CCCGTGCCATGGCAGCGCCCCCCACGGGCCCCG
FBQC6
CGGGGCCCGTGGGGGGCGCTGCCATGGCACGGG
Figure 39. List o f  QuickChange primers used to mutate PDE4A10ATGs 2 
(FBQC1/FBQC2), 3 (FBQC3/FBQC4) and 4 (FBQC5/FBQC6) and the position o f  the 
desired change from  ATG to GCG.
2 0 3
(a) PDE4A10and PDE4A4B Long form 
spüœjuxticn
PDE4A1 Short fd*m 
spliœj motion
LR1
I j  UCR1 I catalytic regpon C-terrrinal 
regon
IM1
GR114 GR10
UCR2
GRB4
ESH4
LR2
GR11
GR29
(b) Imnun PDE4AI0 rat PDB4A10
Inonui PDE4A10 
rat PEC4A10
lurmn PDE4A10 
rat POE4A10
Immui PŒ4A10 
rat PDE4A10
A T G C G C T C C G G T G C A G C G C C C C G G G C C C G G C C C  C 14
T G C C C C C C A C G G G C C C
T G C c  c | G g B  c  c 17
C C C C T T C A G C G A T G A G 102
c B  C C T T C A G C G a H  g A G 51
C C G G G C A G A T C T G T C A 1.36
C C G G G C A G A t B T G T C A 85
ttumon PDE4A10 
rat PDE4A10
liuiinn FÜE4AI0 
rat PEÆ4A10
M R S G A A P R A R P R P P A L A L  P P T G P
A L p H I g  P
23
6
E S L T H F P F S D E D T R R H P P G R S V S  46 
E S L T H f H  F s B  E D t | |  R H P P G r Q  V S 29
Figure 40. Position o f PDE4A10 sequencing primers. Diagram (a) shows the 
approximate positions o f the primers (including the PDE4 specific primer IMÏ) used to 
sequence the N-terminal portion o f the construct PDE4A10GR. Primer GRIO was
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designed to rat PDE4A10 sequence and diagrams (b) and (c) show the regions o f  
similarity that the human and rat nucleotide and amino acid sequences share.
5’ seq upstream of ATG3
I  0  1.297Kb PCR fragment #
Kptil T RaeKTI
ti-------- 1[=:-------- i^L_
MCSinpSV-SPORT I
Kpnl ▼
4A10GR
P!acR7I
4A10ATG3
Q Forward primer 4AL0FB21F desisted to include a new restiicticaiemynie site
IQhiI in addition to the unique kP)nl site present in the pSV-SPCMT multi{4e clonh% site
CC
# #
GODCX^GGTACXpitXTATCGCAAT
Kpiil
@ Reverse primer 4A10FB22R designed to anneal at another unique
restriction enzyme site PaeRTI
|CTOG^CACr!GACI€ATCmTCT^
PaeRTI
Figure 41. This diagram shows how the construct PDE4A10GR pSV-SPORT was re­
engineered to start at ATG3, This involved designing a primer 434bp downstream o f  the 
start o f  the insert sequence which included a Kpnl restriction site (as does the multiple 
cloning site in the vector) and another 1.3Kb downstream o f  it to PCR amplify this 
region.
2 0 5
® @ 0
ATGGCAATGCCCCCCAC
ATGCGCTCCGGTGCAGCGCCCCGGGCCCGGCCCCGGCCCCCTGCCCTGGCACTGCCCCCCAC
10 20 30 40 50 60
B.
MRSGAAPRARPRPPALALPPTGPESL
j # ] # # $ # # # # #
MAMPPTGPESL
Figure 42. Diagram A shows the position o f  ATGs 2, 3 and 4 and the sequence 
change from  ATG to CTG in ATGs 3 and 4. Diagram B also shows how the nucleotide 
differences change the amino acid sequence in this region.
2 0 6
XIV 1 2 3 4 5 6 7 N XIV
M  1 . 3 3 5 K b
X I V  9  1 0  11 1 2  1 3  1 4  1 5  1 6  X I V
1 . 3 3 5 K b
Figure 43. The 1.335Kh bands obtained using the primers FBPDH4AI0A r(j2 and 
PDE4AI0FB22R. Lanes 1 to 4, 5 to 8 , 9 to 12 and 13 to 16 show hands obtained with 
varying MgCl2  concentrations (0.5, 1 .0 , 1.5 and 2 pi stock per 25 pi reaction volume from 
left to right in each set). Reactions I to 8  were carried out using i'aq DNA polymerase: I 
to 4 contained no DMSO and 5 to 8  contained 2% DMSO. Reactions 9 to 16 were 
carried out using Pwo DNA polymerase with or without DMSO as before.
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Band Size
h463’ -------► AGCCTGTCTCTGTCACTGC
h465’ 
<-------
TGAGCGGTACAGGAAGGACT 419
hRD15' 
-------►
GAGACCTGCTCTAAGCCTTG
hRD13’ TGGTAGTGATCCTCCAG 538
Figure 44. Primer pairs used to amplify fragments o f the PDE4A isoforms PDE4A4B 
(h46) or PDE4AJ (hRDl). In each case the N-terminal (forwards) primer is specific to 
the isoform and the N-terminal (reverse) primer is a generic 4A primer.
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313bp I
Figure 45. Bands o f predicted size (313hp) amplified by RT-PCR using PDE4AI0 
primers IMI and ESH4 from human tissue RNA. Lanes I to 9 show the hands obtained 
from this RT-PCR reaction carried out in the following samples: I) +vc control, 2) liver, 
3) trachea, 4) brain, 5) heart, 6 ) lung, 7) kidney, 8 ) DNA size markers, 9) -ve control. 
Data kindly supplied by Ian McPhee.
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Gene Amino acids Predicted MW kDa
PDE4A4B 886 98.5
PDE4A10 810 89.79
Figure 46. Number o f  amino acids which make up PDE4A4B (PDE46) and
PDE4A10ATG2 compared to their predicted molecular weight.
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203
125-
83-
48.7-
Kda , . ' '
1 2 3 4 5 6 7 8
m m-fpp 4A10 4A10 4A10 4A10 h46 hRDl
+ PKi +PP +PKi-3pp
Figure 47. The above blot shows the effect o f incubating PDE4AI0 expressed in 
COS-7 cells with phosphatase on the subsequent mobility o f  the protein on SDS-PAGPT 
The key under the lane numbers denotes the following treatments/samples: m=^mock 
COS-1 cells, pp^phosphatase treated, Pki=pre-treatment with protein kinase C inhibitor. 
PDE4AI (hRDl) andPDE4A4B (PDE46) are used as standards.
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Construct Size bp (ORF) Total aa Predicted MW kDa
PDE4A10ATG3 2433 811 89.79
PDE4A10ATG2 2478 826 91.4
HSPDE4A4B 2661 887 98.15
Figure 48. Predicted sizes (JcDa) o f  constructs HSPDE4A4B, PDE4A10ATG2 and 
PDE4AI0ATG3 from the sequence in their open reading frames.
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h46 4A10 4A10GR 4A10
ATG2 ATG3
170------►
116 ►
55.5 ►
Combithek protein 
MW size markers kDa
Figure 49. Western Blot showing the differences in MW between the proteins 
PDE4A10GR (there is no assumption as to the correct A TG in this protein therefore it 
should be considered "native"), PDE4A10ATG2 and PDE4A10ATG3 compares to 
PDE4A4B using the pre-cast Tris-Acetate 3-8% polyacrylamide minigel system from 
Novex. All o f the above were expressed in COS-I cells. The amounts o f protein (from left 
to right 2, 2, 30 and 2pg) loaded in each well varied in the attempt to achieve bands o f  
similar immunoreactivity.
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Protein Size kDa Standard e rro r
PDE4A4B 124.9 0.59
PDE4A10GR 120.9 0.52
PDE4A10ATG3 119.4 1.18
PDE4A10ATG2 120.7 0.36
Figure 50. Molecular weights o f  HSPDE46, PDE4A10GR, PDE4AI0TAG3 and 
PDE4A10TAG2 observed when resolved on Novex Tris-Acetate 3-8% polyacrylamide 
minigels (n^4). The figures presented here show no significant difference but this is 
evidently clear on the gels.
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4.2 Biochemical Analysis o f PDE4A10ATG2
4.2.1 Separation of two distinct PDE4A10 immunoreactive bands
After subjecting all PDE4A10 constructs to SDS-PAGE and Western blotting there 
appeared to be two distinct iinmunoreactive bands present. These appeared when 
PDE4A10 DNA was over-expressed in both COS-1 and COS-7 cells. The major band 
was tlie full length protein with a molecular weight of around 120kDa and the smaller 
band was around 83kDa. It was important to establish whether the smaller band was the 
result o f protease cleavage and whether it displayed any PDE activity which may 
interfere with or mask tlie true enzymatic nature of PDE4A10 during characterisation 
experiments. The smaller band did, however, appear when mock-transfected cells were 
included in the same SDS-PAGE Western blot but this band was intensified in the cells 
over-expressing the PDE4A10 protein.
It was luilikely that the smaller band was a truncation product of the larger protein as 
none of the other PDEs produce truncation products.
In order to separate tliese two bands an ion exchange column was used. Approximately 
2mg of COS-1 cell cytosolic fraction (where most of the PDE4A10ATG2 was expressed) 
was applied to a Superose 6 column. Fraction volumes of 0.5ml were collected and 
assayed for PDE activity in order to detect the level of activity in each fraction. The 
results can be seen in figure 51 which shows a peak of activity in fraction 29.
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This fraction corresponded to a molecular weight of around 250kDa (see cui*ve for the 
markers in this column in figure 52) which is approximately twice the size of PDE4A10 
when resolved by SDS-PAGE and Western blotting.
The procedure was repeated using PDE assay buffer as before but with an increased NaCl 
concentration (to 125mM) to decrease the possibility of the enzyme stickmg to the 
column. The same result was seen again with a peak of activity appearing in the fraction 
corresponding to a molecular weight of 250kDa. On interpretation of these results the 
indication is that PDE4A10ATG2 may form a dimer. The localisation of PDE activity to 
one fraction also indicated that the smaller protein did not display any PDE activity so 
would not be interfering witli PDE assays to establish the enzymatic characteristics of 
PDE4A10ATG2. Tliis meant that I could tlierefore go ahead with biochemical analyses.
4.2.2 ELISA of PDE4A10ATG2 and h46 to establish relative immuno-reactivity
Calculating the percentage of PDE activity on tlie basis of volume in each fraction may 
give an indication of where the majority of the PDE activity is located in the cell but does 
take into consideration the relative levels of expression the two isofonns PDE4A4B and 
PDE4A10ATG2 which can vary from one transfection to anotlier. In order to compare 
the expression levels of these two proteins in COS-I cells an ELISA assay was used. 
ELISA plates were prepared by incubating increasing amounts of COS-1 cell fractions 
(PI, P2 and S2) from either PDE4A10ATG2 or PDE4A4B transfected cells (see 
methods). The ELISA used a common PDE4A antibody to target the two isoforms which
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recognises a peptide sequence of tlie common region present in both enzymes. The 
antibody (in tliis case Ab 97) should bind in proportion to the amoimt of PDE present in 
each well and a range of concentrations are tested in order to ensure that readings are 
taken from witliin the hnear range for binding.
After detection of the antibody the colour development is read in the plate reader. 
Expression levels can be compared by converting absorbance units to immunosorbant- 
enzyme units and then calculating the enzyme units per jug of protein in the well. The 
table in figure 53 shows the percentage of isoforms PDE4A10ATG2 and PDE4A4B 
expressed in each fraction of COS-1 cells. Using the ELISA method the majority (82.8% 
+/-7.8) of tlie immimoreactive PDE PDE4A10ATG2 was foimd to be located in the S2 
fraction, 12.8% +Z-5.5 associated with the PI fraction and 4.3% +Z-2.3 with the P2. In the 
case of PDE4A4B the majority (66.45% +Z-6.5) of the iinmunoreactive protein was also 
found in the S2 fraction, 20.1% +Z-2.23 was associated with the PI fraction and 13.6% 
+Z- 7.4 was found to be associated with tlie P2 fraction.
4.2.3 Relative distribution of PDE4A10ATG2ZPDE4A4B activity by volume
The distribution of activity was also calculated on the basis of volmne i.e. in a volume of 
1ml what percentage of die total PDE activity present was within each fraction. This 
gives an approximate view of die location of die majority of the PDE activity on the cell. 
The data for this calculation was taken when the PDE assay was in the hnear range. PDE 
activity due to over expression of PDE4A10ATG2 DNA in COS-1 cells was foimd to be
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mainly located in the S2 fraction (82.8% +7-7.8) and the remainder was shared between 
the PI fraction (12,8% +7-5.5) and the P2 fraction (4.2% +7-2.3). Roughly the same 
distribution of activity was seen with PDE4A4B DNA expressed in COS-1 cells with the 
majority being located in the S2 fraction (66.15% +7-6.5) and the remainder being shared 
between the PI fraction (20.18% +7-2,23) and the P2 fraction (13.6% +7-7.4). The results 
can be seen in figure 54.
The pre-cast Tris-Acetate 3-8% polyacrylamide minigels from Novex were also used to 
show tlie approximate distribution of PDE4A10ATG2 expressed in COS-1 cells on the 
basis of volume (2pi of each fraction were loaded in each well). This can only be an 
approximation as the S2 fraction contains far more iinmunoreactive PDE4A10ATG2 
protein tlian the other two lanes which in comparison are barely visible using this system 
(see figure 55).
4.2.4 Western Blot showing native PDE4A10 immnnoreactive bands in cell lines
Protein samples fiom a range of different cells lines (Hek, COS-1, U118, FTC and SK) 
were subject to SDS-PAGE (using the pre-cast Tris-Acetate 3-8% polyacrylamide 
minigel system from Novex) and subsequent Western Blotting using a common PDE4A 
antibody (Ab 97). Protein standards run alternately alongside each cell sample were 
HSPDE4A1 (li46) protein or E1SPDE4A10 protein obtained from over-expressed 
HSPDE4A1 or HSPDE4A10 DNA in COS-1 cells. Up to 50 pg of cell-line sample 
protein was nm in each lane and around 0.1 pg of die PDE4A1 and PDE4A10 protein
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standards. This was due to the detectable level of native protein being anticipated to be 
very low. It was necessary to over-expose the Western blot in order to detect any native 
PDE4A10 in this way. The amount of PDE410 and PDE4A1 standard protein tlierefore 
had to be very low in order not to obscure tlie detection of any native protein on over­
exposure of the blot.
A faint band of aiound 125kDa was observed in the lane containing SK cell protein (see 
figure 56). This corresponds to the band seen in the lane containing the PDE4A10 
standard. Tliis result could be confirmed if an antibody specific for the unique N-terminal 
region of PDE4A10 were to become available.
4.2.5 Km value of PDE4A10
Once it had been established that the kinetic characteristics of PDE4A10ATG2 would not 
be confused by the existence of a smaller active PDE the kinetic analyses could proceed 
starting with establishing the Km for its substrate cAMP. All of the chaiacterisation 
assays were carried out at least tliree times on fractions from at least tliree separate 
transfections to ehminate differences due to expression levels and to present a more 
accurate pictiue of the kinetic properties of PDE4A10ATG2 expressed in. this system 
compared to PDE4A4B.
To determine the Km value of PDE4A10ATG2 PDE assays were conducted using cAMP 
concentrations over a range from 0.01 pM to 50pM. The graph in figure 57 shows a 
typical Michaelis-Menten plot. This data was fitted by regression analysis to the
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Michaelis-Menten equation (v^VmS/(Knx+s)) in order to calculate the Km value for tlie 
PDE4A10ATG2 found in the S2 fraction of COS-1 cells. Km values were also calculated 
for PDE4A4B in order to compare the two enzymes.
During analyses to establish the kinetic characteristics of PDE4A10ATG2 the PDE 
activity foimd in mock transfected COS-1 cells was also measured. The level of activity 
from this source was always below background or < 1% of the activity found in 
PDE4A10ATG2 transfected COS-1 cells which was then subtracted from the activity 
data for PDE4A10ATG2. Figure 58 gives the Km values calculated for the 
PDE4A10ATG2 enzyme found in COS-1 cell fractions PI, P2 and S2 compared to those 
calculated for the enzyme PDE4A4B. These Km values are very similar to those observed 
for other PDE isoforms. The two other long PDE4A isoforms, HSPDE4A4B and the rat 
isoforms RNPDE4A5 (RPDE6) and RNPDE4A8 (RPDE39) each have Km values of 2, 2 
and 3 pM cAMP respectively. Km values for PDE4As short and long-forms vary from 2 
to 6 pM cAMP. The PDE subtypes B, C and D all display Km values of 3 pM cAMP or 
below, all Km values for group D are around 1.3-1 pM cAMP.
4.2.6 Vmax of PDE4A10ATG2 relative to PDE4A4B
Using the ELISA data to work out tlie relative expression levels of each type of PDE in 
tlie various COS-1 cell fractions it was tlien possible to calculate the relative Vmax values 
of the two enzymes PDE4A10ATG2 and PDE4A4B. Figure 59 shows how these values 
compare on the basis of activity per immimoreactive enzyme unit.
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4.2.7 Specific activities o f  PDE4A4B and PDE4A10ATG2
The specific activities of the two enzymes PDE4A4B and PDE4A10ATG2 were 
calculated fi'om data obtained fi-om PDE assays during the lineai- phase of the 
experiments. These values do not take into account the level of expression of the enzyme 
but is interesting to note that the higher level of activity is found in the fraction where the 
majority of the enzyme is expressed. Figure 60 displays the specific activities of the two 
enzymes PDE4A4B and PDE4A10ATG2 and figiue 61 shows the ratios for this activity 
relative to each other and the ratio of activity in different fi'actions relative to that found 
in tlie cytosolic traction. In other studies which have compared distribution of activity in 
cell fi-actions the two long rat form PDE4As (RNEPDE4A5 and RNPDE4A8) had 
particulate/cytosolic activity ratios of 0.7 and 2 respectively. Studies carried out on 
PDE4B isofonns also foimd values of aroimd the same level in that the isoforms 
HSPDE4B1, HSPDE4B2 and HSPDE4B3 each had particulate/cytosolic activity ratios of 
0.3, 0.4 and 1 respectively. This shows that the ratio of activity obtained for PDE4AÎ0 
while being fairly low compared to otlier isoforms is at a similar level.
4.2.8 Inhibition of PDE4A10ATG2 by rolipram (ICso)
The PDE4 inliibitor rolipram was used in order to determine the IC50 value of 
PDE4AI0ATG2 for this particular inhibitor. Rolipram is a cAMP analogue and therefore 
binds at the active site on the enzyme and is a competitive inhibitor in all studies done to
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date (Bolger et a l, 1996; Houston et al., 1996; McPhee et a l, 1995; MiiUer et a l, 1996; 
Owens et a l, 1997).
Rolipram was dissolved in 100% DMSO as a lOmM stock and diluted in die PDE assay 
buffer (20mM Tris/HCl/lOmM MgCE at a final pH of 7.4) to provide a range of 
concentrations from 0.001 pmol to 50pmol. IC50 values were determined using a substrate 
concentration (cAMP) equal to the Km value of each fraction. Under such conditions the 
IC50 equals the Ki assuming simple competitive inhibition. Once again any activity found 
in mock transfected COS-1 cells was eitiier below background levels or it was subtracted 
from the PDE4A10ATG2 activities. Figure 62 shows how the IC50 values for the 
enzymes PDE4A4B and PDE4A10ATG2 compare and figure 63 shows a typical 
rolipram inhibition curve.
4.2.9 Conclusion
The cloning of PDE4A10 by engineering a construct starting from ATG2 showed that the 
protein produced by the construct GR was initiated fr om the same ATG. This was made 
possible using the Novex mini-gel system which gave particularly good resolution of 
proteins at a particular molecular weight depending on the gel used.
It was also possible to show that PDE4A10 is most probably produced as a dimer using 
the column fractionation method. This was not initially investigated from this point of 
view but because of fears that a smaller iinmunoreactive band seen on tlie Western blots
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would be contributing activity during kinetic assays on PDE4A10. It would be interesting 
to run the same experiment using PDE4A4B to see if this is also a dimer.
PDE4A10 differs from PDE4A4B solely in the N-terminal region where as well as being 
61 amino acids shorter is also quite different in sequence. It also contains several 
potential phosphorylation motifs not present in the PDE4A4B amino acid sequence.
The kinetic properties displayed by PDE4A10 are sliglitly different to that of PDE4A4B. 
For example although tlieir Km values are more or less equivalent tlie IC50 value of 
PDE4A10 found in the cytosolic fraction is approximately 66 times lower than tliat of 
PDE4A4B. Tliis difference may be a reflection of the imique N-terrainus of PDE4A10 
having some kind of influence over the rolipram binding site within the catalytic region 
perhaps by changing the conformation of this region slightly. The IC50 value of the 
PDE4A10 found in the cytosolic fraction is a lot lower tlian that of any other PDE4A 
(values range from 0.2 to 1 pM cAMP) isoform expressed in the cytosohc fraction, 
however, it is a similar range to isoforms of PDE type B, C and D which are expressed in 
the cytosol (which vary from 0.02 to 0.14 pM cAMP). The IC50 value of tlie PDE4A10 in 
the particulate fraction is comparable to the values found for the other PDE4A isoforms 
which range from 0.2-1.2 pM cAMP).
PDE4A10 like PDE4A4B is found mainly in the cytosol (82.8% +/- 7.8 of PDE4A10 
compared to 66.45 +/- 6.5% of PDE4A4B) and although some is foimd associated with 
the P2 membranes tliis is probably an effect of overexpression of tlie protein in the cell. It 
is interesting to note that the specific activity of both PDEs is also higher in the cytosolic 
fraction, perhaps a reflection of their endogenous expression pattern.
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The RT-PCR analyses of cell lines and tissue and the Western blot showing native 
PDE4A10 both confiim the existence of tliis PDE isofonn and the native blot shows that 
the molecular weight of the endogenous protein is very similar to that seen in the COS-1 
expression system. This could reinforce tlie theory that additional weight is caused by 
features intrinsic to tlie protein and not because of post-translational modifications. This 
could be confirmed using an in-vitro cell-free transcription-translation system where 
post-translational modification due to the surrounding cellular macliinery is excluded.
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4.2.10 Figures
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Figure 51. PDE activity found in 0.5ml fractions separated on the basis o f molecular 
weight through a Sepharose 6 ion exchange column. A peak o f PDE activity is observed 
in the fraction corresponding to 250kDa. The sample applied to the column was COS-1 
cell S2 fraction containing over-expressedPDE4AÎ0ATG2 protein.
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Figure 52. Elution curve for the Superose 6 HRlO/30 ion exchange column and 
displaying the elution volume (which corresponds to fraction number) against the 
molecular weight o f the standard molecular weights (375kDa, 325kDa, 282kDa, 244kDa 
and 230kDa) which are also run with the column.
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COS-1 cell fraction Percentage of activity Percentage of activity
PDE4A10ATG2 PDE4A4B
P I 13 +/-6 20 +1-2
P2 4.3 +A2.3 13.6 +A7.4
S2 83 +/-S 66 +1-1
Figure 53. Percentage expression o f isoforms PDE4A10ATG2 and PDE4A4B in each 
fraction (PI, P2 and S2) o f  COS-1 cells calculated from ELISA data. Experiments were 
carried out three times on fractions from three separate transfections.
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Figure 54. Percentage o f PDE activity in each fraction o f COS-1 cells due to over- 
expression o f PDE4AI0ATG2 DMA compared to that o f PDE4A4B DNA on the basis o f  
volume.
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Figure 55. Western Blot showing the distribution o f PDH4A I0ATCj2 expressed in 
COS-l cell fractions (2f.mil per lane) resolved using the Novex Iris-Acetate minigel 
system.
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Figure 56. A. Photograph o f  Western blot used to detect the presence o f HSPDE4A10 
protein in cell lines. Lanes I, 5, and 9 contain 0.1 pg o f HSPDE4A1 protein and lanes 3, 
7 and 11 contain 0.1 pg o f HSPDE4A10 protein run as standards. These proteins were 
obtained from PDE4A1 and PDE4A10 DNA over-expressed in COS-l cells. Samples 
from cell lines in the other lanes were as follows: 2) Hek, 4) COS-l, 6) U118, 8) FTC and 
9) SK. B. Portion o f same Western blot at a higher exposure. The samples in the lanes 
are as follows: 1) HSPDE4A1 standard, 2) SK cells and 3) HSPDE4A10 standard. Up to 
50pg o f protein was run in each lane containing cell samples. This analysis was carried 
out using the pre-cast Tris-Acetate 3-8% polyacrylamide minigel system from Novex.
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Figure 57. Hyperbolic Regression used to calculate the value o f the enzyme 
PDE4A10ATG2. The data for this calculation was obtained from PDE4AJ0ATG2 over­
expressed in the S2 fraction o f COS-1 cells and is typical o f the curves obtained in these 
experiments. In this particular case the calculated for PDE4AI0ATG2 present in the 
S2 fraction was 3.4 pm cAMP.
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PDE4A10 Km (fiM cAMP) PDE4A4B Km (jiM cAMP)
PI 4.1+/-0.5 P2 1.9+/-0.3
P2 3.8+/-1.1 S2 2.6+A0.6
S2 2.9+/-0.6
Figure 58. Km values fo r  PDE4AJ0ATG2 in COS-l cell fractions PI, P2 and S2
compared to those calculatedfor PDE4A4B.
Fraction PDE4A4B PDE4A10ATG2 Ratio (unity)
PI 1 1.7 1.7
P2 1 1.25 1.25
S2 1 1.7 1.7
Figure 59. F^ax ratios fo r  the two enzymes PDE4A4B and PDE4A10ATG2 based on 
PDE activity (pmol substrate/min) per immunoreactive PDE unit.
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P I P2 S2
(pmol/min/jj,g) (pmol/min/pg) (pmol/min/pg)
PDE4A10ATG2 0.9+/-0.1 0.4+/-0.01 1.9+/-0.4
PDE4A4B 2+/-0.1 1.6+/-0.6 3.9+/-0.1
Ratio 1:2 1:4 1:2
PDE4A10:PDE4A4B
Figure 60. Specific activity o f  PDE4A4B and PDE4A10ATG2 (pmol cAMP 
hydrolysed per minute per pg o f  protein assayed). The table also shows the ratio o f  
specific activity (PDE4AI0:PDE4A4B) found in each COS-l cell fraction.
P1/S2 P2/S2
PDE4A10ATG2 0.47 0.22
PDE4A4B 0.52 0.42
Figure 61. Ratio o f PDE activity in the PI and P2 COS-l cell fractions relative to 
that found in the S2 (cytosolic) fraction.
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PDE4A10ATG2 IC 50 PDE4A4B IC 50
P I 0.93+/-0.20 P2 0.19+A0.03
P2 0.31+/-0.08 S2 1.6+/-0.3
S2 0.02+/-0.01
Figure 62. IC 5 0  values o f  enzymes PDE4A4B and PDE4A10ATG2 fo r  the inhibitor 
rolipram in the various COS-l cell fractions.
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Figure 63. Typical inhibition curve (IC5 0) fo r the response o f PDE4AJ0 expressed in 
the S2 fraction o f COS-l cells in response to the inhibitor rolipram. Activity remaining at 
different inhibitor concentrations is expressed as a percentage o f the maximum activity
when no inhibitor is present in the assay. The cAMP concentration was at [Km
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CHAPTER 5
2 3 6
5 Discussion
The research presented here has shown the existence and characterisation of two novel 
PDE4As. One a short-form, the otlier a long-form. This also confirms and demonstrates 
the complex nature of tlie organisation of the PDE4A gene. Not only does the gene 
encode many isoforms but it is capable of producing significantly shorter and different 
isoforms due to alternative sphcing sites within it.
The variation produced by this alternative sphcing which creates both short and long- 
forms each with novel N-termini, has also been demonstrated through biochemical 
means. Different exons making up each PDE area also able to confer different properties 
upon it. This is particularly distinct when the two N-termini of hRDl and PDE4A10 are 
compared. The sequences encoding these regions are not homologous although the two 
isoforms have identical catalytic regions. liRDl is targeted to Hie cell membrane due to 
its N-terminus which has been the subject of much investigation. It has been shown that 
using the N-terminal sequence alone this is able to confer membrane association on tiie 
normally soluble bacterial protein chloramphenicol acetyl transferase (CAT) when the 
two are produced as a chimera (Scotland and Houslay 1995).
These experiments were carried out using the rat RDI but the human form is identical in 
the N-terminal region. Studies on the rat form defined the residues in the N-terminal 
which are responsible for targeting to the first 23. This was confirmed using chimeras as 
before with CAT. Cliimeras consisting of 1-25 RDI-CAT and another of 1-100 RDl- 
CAT were both expressed in COS-l cells and foimd to associate with the membrane. 
However when the first 25 residues were excluded (26-100 RDI-CAT) the resulting
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protein was found to be expressed exclusively in the cytosol. Due to the rat and hiunan 
N-tenninal sequences of RDI and hRDl being identical it can be presumed that the same 
residues are responsible for the targeting of tlie human fonn. There would therefore be 
very little basis on which to produce an hRDl-CAT chimera and carrying out the same 
mutational studies.
The abihty of hRDl to bind to COS-7 cell membranes was confirmed by incubating 
hRDl expressed in a cell-free transcription-translation system with COS-7 cell 
membranes (from the liigh speed P2 fraction). This demonstrated tliat the abihty of the 
protein to bind COS-7 cell membranes must be an intrinsic feature of the protein itself 
rather than due to post-translational modifications. The expression of hRDl in tiie cell- 
free transcription-translation system produced a protein of comparable molecular weight 
to tliat expressed in COS-7 cells (81 +/- 3 kDa compared to 83 +/- 1 kDa respectively). 
These proteins both display significantly lower mobility on SDS-PAGE analysis than the 
predicted from their amino acid sequence (72 kDa). This lower mobility must therefore 
be a featiue of the enzyme itself (probably due to tlie conserved poly-acidic regions found 
towards the C-terminus of tlie catalytic region) and supports the theory tliat little or no 
post-translational modification of the enzyme occurs when expressed in COS-7 cells. 
However, this may not reflect the true state of the enzyme in~vivo and any post- 
translational modification may be dependent on cell type.
It would be interesting to investigate how and if indeed the mass of endogenous hRDl 
varies depending on cell type. This would, however, be dependent on the ability to detect 
native hRDl in human tissue which would in turn depend on the level of expression of
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hRDl in a particular cell type. This particular investigation would also reveal whether 
liRDl is targeted to tlie membrane in different cell types.
Investigations into the nature of hRDl binding to membranes revealed that the enzyme 
was almost completely released (> 96%) by low concentration of the detergent Triton X- 
100 (0.01-1%) whereas treatment witli IM NaCl did not cause release of the enzyme. 
This indicates that the nature of hRDl association with its membrane anchor is due to 
hydrophobic interactions which is supported by structural and mutational studies on RDI. 
These revealed that the region of the N-terminal region that interacts with membranes is 
highly hydrophobic (Smith et al. 1996).
Thermal dénaturation experiments carried out on hRDl produced some interesting 
results. The human isoform (hRDl) has a much higher half life than the rodent isoform. 
The activity of tlie rodent form is halved after 4 minutes at 55°C whereas the activity of 
tlie human isoform is halved after aroimd 30 minutes. The N-terminal sequences of these 
two isofonns are identical therefore the sequences of their C-tenninal domains must 
encode proteins with different structures.
However, investigations into the catalytic properties of hRDl revealed that they were 
comparable to that of RDI. hRDl enzyme found in the P2 fraction of transfected COS-7 
cells had a Km for cAMP of 1.5 +/- 0.5 pM and RDI had a Km for cAMP (also COS-7 P2 
fraction) of +/- 2.3 pM. Their IC50 values for inhibition by rolipram are also comparable, 
hRDl having a slightly lower IC50 value of 0.29 +/- 0.09 pM compared to 0.7 pM for 
RDI (both values obtained for enzyme expressed in the P2 fraction of COS-7 cells). This 
indicates tliat the differences in thermostabihty of the two enzymes are due to structural 
differences found in regions outside of the catalytic domain. It is possible that the
239
structural interactions in or around the catalytic domain of the human isoform are less 
easily de-stabilised by heat so the active site of this enzyme is intact for longer at 55°C. 
Stiuctural studies have so far been limited to the N-terminal region of RDI. Further 
structiRal investigation into the C-terminal regions of PDE4A isoforms may reveal the 
nature of the proposed interactions between the linker regions LRl, LR2, the Upstream 
Conserved regions UCRl and UCR2 and the catalytic domain.
PDE4A10 is the second human long PDE4A isoform to be cloned and characterised. It 
shares the same splice junction as PDE4A4B but its unique N-terminal region is 46 
amino acids in length compared to the 107 which make up tlie imique N-terminal region 
of PDE4A4B. Expression of PDE4A10 cloned by Graham Rena in COS-7 cells revealed 
a protein that co-migrated with PDE4A4B. This protein seemed to have a much lower 
mobility on SDS-PAGE than predicted from its amino acid sequence. However, the 
construct used for expression in this case also contained sequence upstream of tlie 
PDE4A10 initiating codon. In fact the location of tlie initiating codon and therefore the 
exact sequence encoding PDE4A10 were imclear.
It was postulated that phosphorylation of residues in the PDE4A10 unique N-terminal 
region may be contributing to tlie aberrant migration of PDE4A10 on SDS-PAGE. De- 
phophorylation experiments showed a very slight reduction in observed molecular weight 
but not enougli to account for the aberrant migration of PDE4A10.
Many attempts were made to sequence the N-tenninal protein expressed by the construct 
PDE4A10GR and this would have quickly revealed the initiating ATG. However, these 
attempts were unsuccessful. Only when furtlier DNA sequencing was carried out using
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sequencing primers designed to read througti the very GC-rich regions of sequence in the 
N-terminal region of PDE4A10 that the location of the initiating ATG was revealed.
The hypothesis that this ATG represented tlie location of the endogenous initiating ATG 
(ATG2 in Graham Rena's original sequence) for PDE4A10 was supported by the 
identification of a band in SK cells co-migrating with PDE4A10 on SDS-PAGE.
The abeiTant migration of PDE4A10 on SDS-PAGE may be due to residues located in the 
unique N-terminal region as its C-terminal region sequence shows 100% homology with 
PDE4A4B. It has been proposed previously that aberrant migration of PDE4A isoforms 
on SDS-PAGE is due to conserved poly-acidic regions found towards tlie C-terminus of 
the PDE4A catalytic region. This would not account for the difference in mobility on 
SDS-PAGE in this case. It is possible that post-translational modifications within the cell 
are responsible for tliis. The expression of PDE4A10 in a cell-free transcription- 
translation system and subsequent SDS-PAGE analysis of the protein produced would 
reveal whether or not this could be the case.
RT-PCR analysis to detect the presence of PDE4A10 transcripts in human tissue RNA 
proved rather difficult due to the high GC-rich nature of PDE4A10. Many different 
primer pairs were used along with an internal RT primer to increase tlie level of possible 
target in samples. Eventually tlie primer pair IMl and ESH4 (data provided by Ian 
McPhee) were able to detect tlie presence of PDE4A10 tmnscripts in a range of human 
tissue RNA samples including liver, trachea, brain, heart, lung and kidney. This showed 
that PDE4A10 has a relatively wide distribution in human tissues. Future work could use 
RT-PCR analysis to identify PDE4A10 transcripts in cell lines. The identification of an
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endogenous PDE4A10 in a cell line and subsequent biochemical and distribution analysis 
may be more representative of the characteristics of the enzyme in an in-vivo situation. 
PDE4A4B and PDE4A10 display very similar distribution in COS-l cells with the 
majority (detected either using phosphodiesterase assays or immunoreactivity in ELISA 
assays) found in the cytosolic fraction. Around 83% of PDE4A10 expressed in COS-l 
cells is foimd in the cytosol compared to 66% of PDE4A4B. Previous studies have shown 
tliat PDE4A4B association with cytoskeletal components of the cell could be due to the 
SH3 binding domains found in the unique N-terminal region of this isoform. The 
interaction of SH3 domains with binding proteins occurs thiough proline-rich motifs in 
the form of PxxPxxR which are present in the N-terminal region of PDE4A4B. PDE4A10 
does not contain proline-rich motifs in this particular context, although it does contain a 
prohne rich LR2 region in the context PRxRPRPP. Tliis witliin tlie extreme N-terminal 
region could account for the lower level of this isofonn detected in the membrane 
fractions of COS-l cells.
A simple way to investigate the nature of PDE4A10 membrane association would involve 
treatment of membranes witli the detergent Triton X-100 and high ionic strengtli 
solutions. If PDE4A10 enzyme activity is not released by either treatment this would 
indicate strong interactions with cytoskeletal components in a similar fashion to 
PDE4A4B. Subsequent investigations into the ability of PDE4A10 to bind SH3 domains 
would reveal whether the proline rich region of this particular isoform contributes to 
membrane association.
PDE4A10 and PDE4A4B have comparable Km values for cAMP (both around 2 pM for 
enzyme found in the cytosolic fraction) but exliibit markedly different I C 5 0  values for the
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iniîibitor rolipram (0.02 pM and 1.6 pM respectively). This must be due to differences in 
their unique N-terminal regions as the sequence encoding their C-terminal and catalytic 
domains are 100% homologous. The N-terminal region of PDE4A10 must be exerting 
some kind of regulatory effect on the catalytic activity of this enzyme. The structure of 
the unique N-terminal region may be influencing the orientation of the UCR domains 
(UCRl and UCR2) which are also thought to have a regulatory influence on catalytic 
activity. The structure and position of the PDE4A10 N-terminal domain may also be able 
to interact in some way with the rolipram binding site.
Further investigations into the inhibition of PDE4A10 activity could be investigated 
through mutational analysis to identify particular residues interacting with the C-terminal 
regions.
The discovery of new PDE inhibitors with general clinical use is dependent on the 
identification and characterisation of the many PDE isoforms. It is crucial to identify their 
distiibution within tissues and their intracellular locations and binding partners. One 
novel approach to inhibiting PDE frinction involves the use of small molecules to dismpt 
tlieir interactions of specific isoforms with tlieir binding proteins. The effects of this 
tailored approach would be two fold. The PDE ftinction would presumably be lost if it is 
no longer correctly positioned with regard to other signalling molecules and the 
specificity of tliis action would hopefully reduce many of the adverse side-effects seen 
with current PDE inhibitors.
The data presented in this tliesis makes a significant contribution to our understanding of 
the range, location and function of PDE4A isoforms. This will aid the design of novel 
PDE4A inhibitors and our understanding of the influence of PDEs in cell signalling.
243
References
244
References
1. Aceves-Pina, E. O., Booker, R., Duerr, J. S., Livingstone, M. S., Quinn, W. G., 
Smith, R. F., Sziber, P. P., Tempel, B. L. and Tully, T. P. (1984). Cold Spring 
Harbour Symposium in Quantitative Biology 48, 831-840.
2. Adams, S. R., Harootunian, A. T., Buechler, Y. L, Taylor, S. S. and Tsien, R. Y. 
(1991). Nature 349, 694-697.
3. Altenbach, C., Yang, K., Farrens, D., Faralibaklish, Z., Kliorana, H. and Hubbell, 
W. (1996). Biochemistry 35, 12470-12478.
4. Alvarez, R., Sette, C., Yang, D., Eglen, R. M., Wilhelm, R., Shelton, E. R. and 
Conti, M. (1995). Molecidar Pharmacology 48, 616-622.
5. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. and Lipman, D. J. (1990). 
Journal o f  Molecidar Biology 215, 403-410.
6. Bacskai, B. J., Hochner, B., Mahaut-Smith, M., Adams, S. S., Kaang, B. K., 
Kandel, E. R. and Tsien, R. Y. (1993). Science 260, 222-226.
7. Baelir, W., Champagne, M. S., Lee, A. K. and Pittler, S. J. (1991). FEBS Letters
245
278, 107- 114.
8. Baldwin, J., Scheitler, G. and Unger, V. (1997). Journal o f  Molecular Biology 
272, 144-164.
9. Banner, K. H. and Page, C. P. (1995). European Respiratory Journal 8, 996-1000.
10. Barnette, M. S., Grous S., Cieslinski L. B., Biirman M., Cliristensen, S. B. and
Torphy, T. J. (1995). The Journal o f  Pharmacology and Experimental
Therapeutics 273,1396-1402.
11. Barsony, J. and Marks, S. J. (1990). Proceedings o f  the National Academy o f  
Science USA 87, 1188-1192.
12. Beavo, J. A. (1995). Physiology Review 75, 725-748.
13. Beavo, J. A. (1988). Advances in Second Messenger and Phosphoprotein Research
22, 1-38.
14. Beavo, J. A., Conti, M. and Heaslip, R. J. (1994). Molecular Pharmacology 46, 
399-405.
15. Beavo, J. A., Hansen, R. S., Harrison, S. A., Hiirwitz, R. L., Martins, T. J. and
2 4 6
Miiraby, M. C. (1982). Molecular and Cellular Endocrinology 28, 387-410.
16. Beavo, J. A., Hardman, J. G. and Sutherland, E. W. (1971). Journal o f Biological 
Chemistry 246, 3841-3846.
17. Beavo, J. A. and Reifsnyder, D. H. (1990). Trends in Pharmacological Science 11, 
150-155.
18. Beebe, S. J. and Corbin, J. D. (1986) in The Enzymes (Boyer P.O., ed.), Academic 
Press, Orlando, E L M ,  44-100.
19. Beltman, J., Becker, D. E., Butt, E., Jensen, G. S., Rybalkin, S. D., Jastorff, B. and 
Beavo, J. A. (\995). Molecular Pharmacology 41, 330-339.
20. Bentley, J. K. and Beavo, J. A. (1992). Regulation and fiinction of cyclic 
nucleotides. Current Opinion in Cell Biology 4, 233 240.
21. Bentley, J. K., Kadlecek, A., Sherbert, C. H., Seger, D., Sonnenburg, W. K., 
Charbonneau, H., Novack, J. P. and Beavo, J. A. (1992). Journal d f Biological 
Chemistry 261, 18676-18682.
22. Bloom, T. J. and Beavo, J. A. (1996). Proceedings o f the National Academy o f  
Science USA 93, 14188-14192.
247
23. Bluml, K., Schnepp, W., Schroder, S., Beyermaim, M., Macais, M., Oschkinat., H. 
and Lohse, M, (1997). EMBO Journal 16, 4908-4915.
24. Bol, G. F., Gros, C., Hulster, A., Bosel, A. and PfeufFer, T. (1997). Biochemical 
and Biophysical Research Communications 237,251-256.
25. Bolger, G. B. (1994). Cellular Signalling 6 (8), 851-859.
26. Bolger, G. B., Erdogan, S., Jones, R. E., Lougliney, K., Scotland, G., Hoffinan, R., 
Wilkinson. I., Farrell, I. C. and Houslay, M. D. (1997). Biochemical Journal 328, 
539-548.
27. Bolger, G. B., McPhee, I. and Houslay, M. D. (1996). Journal o f  Biological 
Chemistry 21 1065-1071.
28. Bolger, G., Michaeli, T., Martins, T., St Jolm, T., Steiner, B., Rodgers, L., Riggs, 
M., Wigler, M. and Ferguson, K. (1993). Molecular and Cellular Biology 13, 
6558-6571.
29. Borisy, F. F., Ronnett, G. V., Cunningham, A. M., Juilfs, D., Beavo, J. and Snyder,
S. H. (\992). Journal o f Neuroscience 12, 915-923.
248
30. Bregmaii, D. B., Bhattacharayya, N. and Rubin, C. S. (1989). Journal o f 
Biological Chemistry 264, 4648-4656.
31. Bregman, D. B., Hirsch, A. H, and Rubin, C. S. (1991). Journal o f Biological 
Chemistry 266, 7207-7213.
32. Bums, F. and Pyne, N. J. (1992). Bichemical and Biophysical Research 
Communications, 189, 1389-1396.
33. Burns, F, Rodger, I. W. and Pyne, N. J. (1992). Biochemical Journal 283, 487- 
491.
34. Butt, E., Beltman, J,, Becker, D. E., Jensen, G. S., Rybalkin, S. D., Jastorff, B. and 
Beavo, J. (1994). Molecular Pharmacology 47, 340-347.
35. Byers, D., Davis, R. L. and Kigler, J. A. (1981). Nature 289, 79-81.
36. Cannizzaro, G., Gagliano, M., La Rocca, S., Novara, V. Flugy, A. (1989). 
Pharmacological Research 21, Suppl 1:53-54.
37. Charbonneau, H. (1990). Cyclic Nucleotide Phosphodiesterases, ed. Beavo, J. and 
Houslay, M. D. 2, 267-298. Chichester, John Wiley.
2 4 9
38. Charbomieau, H., Beier, N., Walsh, K. A. and Beavo, J. A. (1986). Proceedings o f  
the National Academy o f Science USA 83, 9308-9312.
39. Charbonneau, H., Kumar, S., Novack, J. P., Blumenthal, D. K., Griffin, P. R., 
Shabanowitz, J., Hunt, D. F., Beavo, J. A. and Walsh, K. A. (1991). Biochemistry 
30, 7931-7940.
40. Chen, C., Denome, S. and Davis, R. L. (1986). Proc. Natl, Acad. Sci. USA 83, 
9313-9317.
41. Chen, J., DeVivo, M., Dingus, J., Harry, A., Li, J., Siu, J., Carty, D., Blank. J., 
Exton, J., Stoffel, R., Inglese, J., Lefkowitz, R., Logothetis, D., Hildebrandt, J. and 
Iyengar, R. (1995). Science 268, 1166-1169.
42. Chen, Y., Harry, A., Li, J., Smit, M. J., Bai, X., Magnusson, R., Pieroni, J. P., 
Weng, G. and Iyengar, R. (1997). Proceedings o f the National Academy o f Science 
LX4 94, 14100-14104.
43. Chen, Y., Weng, G., Li, J., Harry, A., Pieroni, J., Dingus, J., Hildebrandt, J., 
Guamieri, P., Weinstein, H. and Iyengar, R. (1997). Proceedings o f  the Nationsl 
Academy o f  Science USA 94, 2711-2714.
44. Cheung, P. P., Xu, H., McLaughlin, M. M., Ghazaleh, F. A., Livi, G. P. and
250
Colman, R. W. (1996). Blood 88, 1321-1329.
45. Chidiac, P., Herbert, T. E, Valiquette, M., Dennis, M. and Bouvier, M. (1994). 
Molecular Pharmacology 45, 490-499.
46. Clapham, D. and Neer, E. (1997). Annual Review o f  Pharmacological Toxicology 
37, 167-203.
47. Colicelli, J., Nicolette, C., Birclnneier, C., Rodgers, L., Riggs, M. and Wigler, M. 
(1991). Proceedings o f  the National Academy o f Sciences USA 88, 2913-2917.
48. Conti, M. and Jin, S. L. (1999). Progress in Nucleic Acid Research *  Molecular 
Biology 63, 1-38.
49. Conti, M., Jin, S. L. C., Monaco, L., Repaske, D. R. and Swinnen, J. V. (1991). 
Endocrinology Review 12, 218-234.
50. Conti, M., Nemoz, G., Sette C. and Vicini E. (1995). Endocrinology Review 16, 
370-389.
51. Cooper, D. M. F. (1998). Advances in Second Messenger Phosphoprotein 
Research 32.
251
52. Cooper, D. M. F., Mons, N. and Karpen, J. M. (1995). Nature 374, 421-424.
53. Corbin, J. D. and Keely, S. L. (1977). Journal o f Biological Chemistry 252, 910- 
918.
54. Corbin, J. D., Keely, S. L. and Park, C. R. (1975). Journal o f  Biological Chemistry 
250,218-225.
55. Corbin, J. D., Soderling, T. R. and Park, C. R. (1973). Journal o f  Biological 
Chemistry 24H, 1813-1821.
56. Cvejic, S. and Devi, L. A. (1997). Journal o f Biological Chemistry 272, 26959- 
26964.
57. Davis, R. L. and Kauvar, L. M. (1984). Advances in Cyclic Nucleotide Research 
and Protein Phosphorylation 16, 393-402.
58. Davis, R. L., Takayasu, H., Eberwine, M. and Myers, J. (1989). Proceedings o f the 
National Academy o f Science USA 86, 3604-3608.
59. Degerman, E., Manganiello, V. C., Newman, A. H., Rice, K. C. and Belfrage, P. 
(1988). Second Messenger Phosphoproteins 12,171-182.
252
60. DeU'Acqua, M. L. and Scott, J. D. (1997). Journal o f Biological Chemistry 272, 
20, 12881-12884.
61. Deterre, P., Bigay, J., Forquet, F., Robert, M. and Chabre, M. (1988). Proceedings
o f the National Academy o f Sciences USA 85, 2424-2428.
62. Dias, J. A , Lindau-Shepard, B., Hauer, C. and Auger, ï. (1998). Biological 
Reproduction 58, 1331-1336.
63. Dixon, R. A., Kobilka, B. K., Strader, D. J., Benovic, J. L., Dohlman, H. G,
Frielle, T., Bolanowski, M. A., Bennett, C, D., Rands, E., Diehl, R. E., et al.
(1986). mrwrg 321, 75-79.
64. Doublie, S., Tabor, S., Long, A. M., Richardson, C. C. and Ellenberger, T. (1998). 
Nature 392, 251-258.
65. Dudai, Y., Jan, Y. N., Byers, D., Quinn, W. G. and Benzer, S. (1976). Proceedings 
o f the National Academy o f Science USA 73, 1684-1688.
66. Edehnan, A. M., Blumenthal, D. K. and Krebs, E. G. (1987). Annual Review o f  
Biochemistry 56, 567-613.
67. Engels, P., Fitchel, K. andLubbert, H. (1994). FEBSLetters 350, 291-295.
253
68. Engels, P., Sullivan, M., Muller, T. and Lubert (1995). FEBS Letters 358, 305- 
310.
69. Fantozzi, D. A., Taylor, S. S. , Howard, P. W., Maurer, R. A., Feramisco, J. R. and 
Meintkotli, J. L. {1992). Journal o f  Biological Chemistry 267, 16824-16828.
70. Farrens, D., Altenbach, C., Yang, K., Hubbell, W. and Khorana, H. (1996). 
Science 274, 768-770.
71. Fawcett, L., Baxendale, R., Stacey, P., McGroutiier, G., Harrow, I., Soderling, S., 
Hetman, J., Beavo, J. A. and Phillips, S. C. (2000). Proceedings o f  the National 
Academy o f Science USA 97, 3702-3707.
72. Fisher, D. A., Smitli, J. F., Pillar, J. S., St. Denis, S. H. and Cheng, J. B, (1998a). 
Journal o f  Biological Chemistry 273, 15559-15564.
73. Fisher, D. A., Smitli, J. F., Pillar, J. S., St. Denis, S. H. and Cheng, J. B. (1998b). 
Biochemical and Biophysical Research Communications 246, 570-577.
74. Francis, S. H. and Corbin, J. D. (1994). Annual Review o f Physiology 56, 237-272.
75. Gaimn, D. M., Baude, E. J. and Uhler, M. D. (1996). Journal o f Biological
254
Chemistry 211, 15736-15742.
76. Gaüey, D. A., Jackson, F. R. and SiegI, R. W. (1982). Genetics 102, 771-782.
77. Genain, C. P., Roberts, T., Davis, R. L., Nguyen, M., Uccelli, A., Faulds, D., Li, 
Y., Hedgpeth, J. and Hauser, S. L. (1995). Proceedings o f  the National Academy o f  
Sciences USA, 92, 3601-3605.
78. Gether, U. and Kobilka, B. K. (1998). The Journal o f  Biological Chemistry 273, 
29, 17979-17982.
79. Gibbs, C. S., Knighton, D. R., Sowadski, J. M., Taylor, S. S. and Zoller, M. J.
(1992). Journal o f Biological Chemistry 267, 4806-4814.
80. Gillespie, P. G. and Beavo, J. A. (1988). Journal o f Biological Chemistry 263, 
8133-8141.
81. Giembycz, M. A. (1996). Trends in Pharmacological Sciences 17, 331-336.
82. Glantz, S. B., Amat, J. A. and Rubin, C. S. (1992). Molecular Biology o f the Cell 
3, 1215-1228.
83. Glantz, S. B., Li, Y. and Rubin, C. S. (1993). Journal o f Biological Chemistry 268,
255
12796-12804.
84. Gonzalez, G. A. and Montminy, M. R. (1989). Cell 59, 675-680.
85. Gordon, L. A., Bergman, A., Christensen, M., Danganan, L., Lee, D. A., 
Ashwortli, L. K., Nelson, D. O., Olsen, A. S., Molirenweiser, H. W., Carrano, A. 
V. and Brandriff, B. F. (1995). Genetics 30, 187-194.
86. Grossmann, M., Weintraub, B. and Szkudlinski, M. (1997). Endocrinology 
Reviews 18, 476-501.
87. Gutkind, J. S. (1998). The Journal o f  Biological Chemistry 273, 4, 1839-1842.
88. Hagiwara, M., Brindle, P., Harootunian, A., Armstrong, R., Rivier, J., Vale, W., 
Tsien, R. and Montminy, M. R. (1993). Molecular Cell Biology 13, 4852-4859.
89. Hanoune, J. , Pouille, Y., Tzavara, E., Shen, T. S., Lipskaya, L., Miyamoto, N., 
Suzuld, Y. and Defer, N. (1997). Molecular and Cellular Endocrinology 128, 179-
194.
90. Han, P., Zhu, X. and Michaeli, T. (1997). Journal o f Biological Chemistry 272, 
16152-16157.
25 6
91. Harhammer, R., Gohla, A. and Schultz, G, (1996). FEBS Letters 399, 211-214.
92. Harrison, S. A , Reifsnyder, D. H., Gallis, B., Cadd, G. G. and Beavo, J. A. (1986). 
Molecular Pharmacology 29, 506-514.
93. Hausken, Z. E., Coglilan, V, M., Hasting, C. A. S., Reimann, E. M. and Scott, J. D.
(1994). Journal o f  Biological Chemistry 269, 24245-24251.
94. Hausken, Z. E., DellAcqua, M. L., Coghlan, V, M. and Scott, J. D. (1996). 
Journal o f  Biological Chemistry 271, 29016-29022.
95. Hausken, Z. E., Coghlan, V. M. and Scott, J. D. (1997). In Protein Targeting 
Protocols (R. A. Clegg, ed.) 47-64, Humana Press, Totowa, NJ.
96. Hayshi, M., Matsushima, K., Ohashi, H., Tsimoda, H., Murase, S., Kawarada, Y. 
and Tanaka, T. (1998). Biochemical and Biophysical Research Communications 
250,751-756.
97. Henkel-Tigges, J. and Davies, R. L. (1990). Molecular Pharmacology 37, 7-10.
98. Herbert, T. E., Moffett, S., Morello, J. P., Loisel, T. P., Bichet, D. G., Barret, C. 
and Bouvier, M. (1996). Journal o f  Biological Chemistry 271, 16384-1639.
257
99. Hirsch, A. H., Glantz, S. B., Li, Y., You, Y. and Rubin, C. S. (1992). Journal o f  
Biological Chemistry 267, 2131-2134.
100. Hoffinan, R., Wilkinson, I. R., McCallmn, J. F., Engels, P. and Houslay, M. D. 
(1998). Biochemical Journal 333, 139-149.
101. Horton, Y. M., Sullivan, M, and Houslay, M. D. (1995). Biochemical Journal 308, 
683-691.
102. Houslay, M. D. (1996). Biochemical Society Transactions 24, 980-986.
103. Houslay, M. D and Kilgour, E. (1990). Cylcic Nucleotide Phosphodiesterases ed. 
J. A. Beavo and M. D. Houslay, 2, 185-226. Chichester, uk, John Wiley & Sons 
Ltd.
104. Houslay, M. D. and Marchmont, R. J. (1981). Biochemical Journal 198, 703-706.
105. Houslay, M. D. and Milligan, G. (1997). Trends in Biochemistry 22, 6, 217-224.
106. Houslay, M. D., Scotland, G., Pooley, L., Spence, S., Wilkinson, I., McCallmn, F., 
Juhen, P., Rena, N. G., Michie, A. M., Erdogan, S., Zeng, L., O'Connell, J. C., 
Tobias, E. S. and McPhee, I. (1995). Biochemical Society Transactions 23, 393- 
398.
258
107. Houslay, M. D., Sullivan, M. and Bolger, G. B. (1998). Advances in 
Pharmacology 44, 225-342,
108. Hurley, J. H. (1999). Structure, mechanism and regulation of mammalian adenylyl 
cyclase. The Journal o f  Biological Chemistry 274, 12, 7599-7602.
109. Huston, E., Pooley, L., Mien, J., Scotland, G., McPhee, I., Sullivan, M., Bolger,
G. and Houslay, M. D. (1996). Journal o f  Biological Chemistry 271, 31334-31344.
110. Ichimura, M. and Kase, H. (1993). Biochemical and Biophysical Research 
Communications 193, 985-990.
111. Jacobitz, S., McLaughlin, M. M., Livi, G. P., Burman, M. and Torphy, T. J. 
{1996). Molecular Pharmacology 50, 891-899.
112. Jacobitz, S., Ryan, M. D., McLaughlin, M. M., Livi, G. P., De Wo If, W. E. and 
Torphy, T. J. (1997). Molecular Pharmacology 51, 999-1006.
113. Ji, T. H., Grossmann, M. and Ji, I, (1998). The Journal o f Biological Chemistry 
273,28, 17299-17302.
114. Ji, T. H., Murdoch, W. J. and Ji, I. (1995). Endocrine 3, 187-194.
2 5 9
115. Jin, S. L. C., Swinnen, J. V. and Conti, M. (1992). Journal o f  Biological Chemistry 
267,18292-18939.
116. Kayusa, J., Goko, and Fujita-Yamagiichi (1995). Journal o f Biological Chemistry 
270,14305-14312.
117. Kemp, B. E., Bylimd, D. B., Huang, T. S., and Krebs, E. G. (1975). Proceedings o f  
the National Academy o f Science USA 72, 3448-3452.
118. Kemp, B. E., Graves, D. J., Benjamini, E. and Krebs, E. G. (1977). Journal o f  
Biological Chemistry 252, 4888-4894.
119. Kemp, B. E. and Pearson, R. B. (1990). Trends in Biochemical Sciences 15, 342- 
346.
120. Kenakin, T. (1997). Trends in Pharmacological Sciences 18, 416-417.
121. Khramtsov, N. V., Feshchenko, E. A., Suslova, V. A., Sclimukler, B. E., 
Terpugov, B. E., Rakitina, T. V., Atabekova, N. V. and Lipkin, V. M. (1993). 
FEBS Letters 327, 275-278.
122. Kiefer, J. R., Mao, C., Braman, J. C. and Beese, L. S. (1998). Nature 392, 304-
26 0
307.
123. Kincaid, R. L., Stith-Coleman, I. E. and Vaughn, M. (1985). Journal o f  Biological 
Chemistry 260, 9009-9015.
124. Kisselev, O., Pronin, A., Ermolaeva, M. and Gautam, N. (1995). Proceedings o f  
the National Academy o f Science USA 92, 9102-9106.
125. Kovala, T., Sanwal, B. D. and Bail, E. H. (1997). Biochemistry 36, 2968-2976.
126. Kozak, M (1987a). Journal o f Molecular Biology 196 (4), 947-950.
127. Kozak, M (1987b). Nucleic Acids Research 15 (20), 8125-8148.
128. Krause, W., Kuhne, G. and Sauerbrey, N. (1990). European Journal o f Clinical 
Pharmacology 38, 71-75.
129. Kmpinski, J., Coussen, F., Bakalyar, H., Tang, W, J., Feinstein, P. G., Orth, K., 
Slaughter, C., Reed, R. R. and Gilman, A. G. (1989). Science 244, 1558-1564.
130. Lambriglit, D. G., Noel, J. P., Hamm, H. E. and Sigler, P. B. (1994). Nature 369, 
621-628.
251
131. Lambright, D., Sondek, J., Bolnn, A., Skiba, N., Hamm, H. and Sigler, P. (1996).
379, 311-319.
132. Lavan, B. E., Lakey, T. and Houslay, M. D. (1989). Biochemical Pharmacology 
38,4123-4136.
133. Lefkowitz, R. (1998). Journal o f  Biological Chemistry 273, 18677-18680.
134. Lefkowitz, R. J., Cotecchia, S., Samama, P. and Costa, T. (1993). Trends in 
Pharmacological Science 14, 303-307.
135. Leiser, M., Rubin, C. S. and Erlichman, J. (1986). Journal o f  Biological Chemistry 
261, 1904-1908.
136. Levin, L. R. and Reed, R. R. (1995). Journal o f Biological Chemistry 270, 7573- 
7579.
137. Li, T. S., Volpp, K and Applebury, M. L. (1990). Proceedings o f  the National 
Academy o f Science USA 87, 293-297.
138. Li, Y. and Rubin, C. S. (1995). Journal o f Biological Chemistry 270, 1935-1944.
139. Lipkin, V. M., Khramtsov, N. V., Vasilevskaya, 1. A., Atabekova, N. V., Muradov,
262
K. G., Gubanov, V. V., Li, T., Jolinston, J. P., Volpp, K. J. and Applebury, M. L. 
{\990i). Journal o f Biological Chemistry 265, 12955-12959.
140. Liu, Y., Ruoho, A. E., Rao, V. D. and Hurley, J. H. (1997). Proceedings o f  the 
National Acadamy o f Science USA 94, 13414-13419.
141. Livi, G. P., Kinetz, P., McHale, M. M., CiesUnski, L. B., Sathe, G. M., Taylor, D. 
P., Davis, R. L., Torphy, T. J. and Balcarek, J. M. (1990). Molecular and Cellular 
Biology 10, 2678-2686.
142. Lobban, M., Shakur, Y., Beattie, J. and Houslay, M. D. (1994). Biochemical 
Journal 304, 399-406.
143. Lochhead, A., Nekrasova, E., R., Arshavsky, V. Y. and Pyne, N. J. (1997). Journal 
o f Biological Chemistry 272, 18397-18403.
144. Lolnnann, S. M., DeCamih, P., Enig, I. and Walter, U. (1984). Proceedings o f the 
National Academy o f Science USA 81, 6723-6727.
145. Loughney, K., Snyder, P. B., Ulier, L., Rosman, G. J., Ferguson, K. and Florio, V. 
A  (1999). Gene 234, 109-117.
146. Luo, Z., Shafit-Zagardo, B. and Erlichman, J. (1990). Journal o f Biological
263
Chemistry 265 ,21804-21810.
147. MacPhee, C. H., Harrison, S. A. and Beavo, J. A. (1986). Proceedings o f the 
National Academy o f Science USA 83, 6660-6663.
148. Manganiello, V. C., Murata, T., Taira, M., Belffage, P. and Degerman, E. (1995a). 
Archives o f Biochemistry and Biophysics 322, 1-13.
149. Manganiello, V. C., Taira, M., Degerman, E. and Belfrage, P. (1995b). Cellular 
Signalling 7, 445-455,
150. Marchmont, R. J., Ayad, S. R. and Houslay, M. D. (1981). Biochemical Journal 
195,645-6652.
151. Marchmont, R. J. and Houslay, M. D. (1980). Biochemical Journal 187, 381-392.
152. Martin, E. L., Rens-Domiano, S., Schatz, P. J. and Hamm, H. E. (1996). Journal o f  
Biological Chemistry 271, 361-366.
153. McAUister-Lucas, L. M., Haik, T. L., Colbran, J. L., Sonnenburg, W. K., Seger, 
D., Turko, I. V., Beavo, J. A., Francis, S. H. and Corbin, J. D. (1995). Journal o f  
Biological Chemistry 270, 30671-30679.
264
154. McAllister-Lucas, L. M., Sonnenburg, W. K., Kadlecek, A., Seger, D., Trong, H. 
L., Colbran, J. L., Thomas, M. K., Walsh, K. A., Francis, S. H., Corbin, J. D. 
{1993). Journal o f  Biological Chemistry 268, 22863-22873.
155. McHale, M. M., Cieslinski, L. B., Eng, W. K., Jolmson, R. K., Torphy, T. J. and 
Livi, G. P. {\99\). Molecular Pharmacology 3 9 ,109-113.
156. McLaughlin, M. M., Cieslinski, L. B., Burman, M., Torphy, T. J. and Livi, G. P.
(1993). Journal o f  Biological Chemistry 268, 6470-6476.
157. McPhee, L, Pooley, L., Lobban, M., Bolger, G. and Houslay, M. D. (1995). 
Biochemical Journal 3\Q, 965-974.
158. Meacci, E., Taira, M., Moos, M. J., Smitli, C. J., Movsesian, M. A., Degennan, E., 
Belfrage, P. and Manganiello, V. (1992). Proceedings o f the National Academy o f  
Science USA 89, 3721-3725.
159. Meinkoth, J. L., Ji, Y., Taylor, S. S. and Feramisco, J. R. (1990). Proceedings o f  
the National Academy o f Science USA 87, 9595-9599.
160. Michaeli, T., Bloom, T. J., Martins, T., Loughney, K., Ferguson, K. Riggs, M., 
Rodgers, L., Beavo, J. A. and Wigler, M. (1993). Journal o f Biological Chemistry 
268, 12925-12932.
265
161. Milatovich, A., Bolger, G., Michaeli, T and Franche, U. (1994). Somatic Cell and 
MolecularGenetics 20, 75-86.
162. Mizobe, T., Mervyn Maze, M., Lam, V., Siiryanaiayana, S., and Kobilka, B. 
(1996). Journal o f  Biological Chemistry 271, 2387-2389.
163. Monaco, L., Vichii, E. and Conti, M. (1994). Journal o f  Biological Chemistry 269, 
347-357.
164. Mons, N., Harry, A., Dubourg, P., Fremont, R. T., Iyengar, R. and Cooper, D. M. 
F. (1995). Proceedings o f the National Academy o f Science USA 92, 8473-8477.
165. Morris, A. and Scarlata, S. (1997). BiochemicalPharmacolog)’ 54, 429-435.
166. Muller, T., Engles, P. and Fozard J. R. (1996). Trends in Pharmacological 
Sciences 17 (8), 294-8.
167. Mumby, M. C., Prigent, A. F,, Moueqqit, M., Fougier, S., Mascovischi, O. and 
Pacheco, H. (1985). Biochemical Pharmacology 34, 2997-3000.
168. Nemoz, G., Prigent, A. F., Moueqqit, M., Fougier, S., Mascovsclii, O. and 
Pacheco, H. (1985). Biochemical Pharmacology 34, 2997-3000.
26 6
169. Nemoz, G., Zhang, R., Sette, C. and Conti, M. (1996). FBESLetters 384, 97-102.
170. Obemotle, R., Bhakta, S., Alvarez, R., Bach, G., Zuppan, P., MuUdns, M., 
Jamagin, K., Shelton, E. R. (1993). Gene 129, 239-247.
171. O’Connell, J. C., McCallum, J. F., McPhee, L, Wakefield, J., Houslay, E. S., 
Wishart, W., Bolger, G., Frame, M. and Houslay, M. D. (1996). Biochemical 
Journal 318,255-262.
172. Ovcliinnikov, Y. A., Gubanov, V. V., Khramtsov, N. V., Ischenko, K. A., 
Zagranichny, V. E. (1987). FEBS Letters 223, 169-173.
173. Owens, R. J., Catterall, C., Batty, D., Jappy, J., Russell, A., Smitli, B., O'Connell, 
J. and Perry, M. J. (1997). Biochemical Journal 326, 53-60.
174. Pan, X., Arauz, E., Krzanowski, J. J., Fitzpatrick, D. F. and Poison, J. B. (1994). 
Biochemical Pharmacology 48, 827-835.
175. Parma, J., Van Sande. J., Swillens, S., Tonacchera, M., Dumont, J. and Vassart. G. 
(1995). Molecular Endocrinology 9, 725-733.
176. Pawson, T. and Scott, J. D. (1997). Science 278, 2075-2080.
267
177. Pellegrino, S., Zhang, S., Garritsen, A. and Simonds, W. F. (1997). Journal o f  
Biological Chemistry 272, 25360-25366.
178. Pieroni, J. P., Harry, A., Chen, J., Jacobwitz, O., Magnusson, R. P. and Iyengar, R.
(1995). Journal o f  Biological Chemistry 270, 21368-21373.
179. Pillai, R., Kytle, A., Reyes, A. and Colicelli, J. (1993). Proceedings o f the 
National Academy o f Science 90, 11970-11974.
180. Pillai, R., Staub, S. F. and Colicelli, J. (1994). Journal o f Biological Chemistry 
269,30676-30681.
181. Poison, J. B. and Strada, S. J. (1996). Annual Review o f Pharmacology and 
Toxicology 36,403-427.
182. Potter, R. L., Stafford, P. H. and Taylor, S. (1978). Archives o f Biochemistry and 
Biophysics 190, 174-180.
183. Potter, R. L. and Taylor, S. S. (1979). Journal o f Biological Chemistry 254, 2413- 
2418.
184. Probst, W. C., Snyder, L. A., Schuster, D. I., Brosius, J. and Sealfon, S. C. (1992).
268
DNA Cell Biology u, 1-20 .
185. Pyne, N. J., Anderson, N., Lavan, B. E., Milligan, G., Niinmo, H. G. and Houslay, 
M. D. (1987). BiochemicalJoumal 248, 897-901.
186. Qui, Y. and Davis, R. L. (1993). Genes and Development 7, 1447-1458.
187. Raine, C. S. (1995). Nature Medicine 1, 244-248.
188. Reeves, M. L., Leigh, B. K. and England, P. J. (1987). Biochemical Journal 241, 
535-541.
189. Reiny, J. J., Couture, L., Pantel, J., Haertle, T., Rabesona, H., Bozon, V., Pajot- 
Augy, E., Robert, P., Troalen, F., Salesse, R. and Bidart, J. M. (1996). Molecular 
and Cellular Endocrinology 125, 79-91.
190. Resh, M. (1996). Cell Signal 8, 403-412.
191. Romano, C., Yang, W. L. and OMalley, K. L. (1996). Journal o f Biological 
Chemistry 271, 28612-28616.
192. Rossi. P., Giorgi, M., Geremia, R. and Kincaid, R. L. (1988). Journal o f Biological 
Chemistry 263, 15521-15527.
269
193. Rubin, C. S. (1994). Biochimica et Biophysica Acta 1224, 467-479.
194. Ryu, K., Lee, H., Kim, S., Beauchamp, J., Tung, C., Isaacs, N. W., Ji, I., and Ji, T.
H. (1998). Journal o f  Biological Chemistry 273, 6285-6291.
195. Samama, P., Cotecchia, S., Costa, T. and Lefkovitz, R. J. (1993). Journal o f  
Biological Chemistry 268, 4625-4636.
196. Sarkar, D., Erlichman, J. and Rubin, C. S. (1986). Journal o f  Biological Chemistry 
259, 9840-9846.
197. Sass, P., Field, J., Nikawa, J., Toda, T. and Wigler, M. (1986). Proceedings o f the 
National Academy o f Science USA 83, 9303-9307.
198. Sawaya, M. R., Prasad, R., Wilson, S. H, Kiaiit, J. and Pelletier, H. (1997). 
Biochemistry 36, 11205-11215.
199. Schneider, T., Igelmund, P. and Herscheler, J. (1997). Trends in Pharmacological 
Sciences 18, 8-11.
200. Scotland, G. and Houslay, M. D. (1995). Biochemical Journal 308, 673-681.
270
201. Scott, A. I., Pierini, A. F., Shering, P. A  and Wlialley, L. J. (1991). European 
Journal o f  Pharmacology 40, 127-129.
202. Scott, J. D., Stofko, R. E., McDonald, J. R., Corner, J. D., Vitalis, E. A. and
Mangeli, J. (1990). Journal o f  Biological Chemistry 265, 21561-21566.
203. Scott, J. D. (1991). Pharmacological Therapeutics 50, 123-145.
204. Scott, J. D., DellAcqua, M. L., Fraser, I. D. C., Tavalin, S. J. and Lester, L. B.
(fOOO). Advances in Pharmacology 175-207.
205. Sealfon, S., Weinstein, H. and Miller, R. (1997). Endocrinology Review 18, 180-
205.
206. Sette, C. and Conti, M. (1996). Journal o f Biological Chemistry 271, 16526- 
16534.
207. Sette, C. Iona, S. and Conti, M. (1994). Journal o f Biological Chemistry 269, 
9245-9252.
208. Sette, C., Vicini, E. and Conti, M. (1994). Journal o f Biological Chemistry 269, 
18271-18724.
271
209. Shabb, J. B. and Corbin, J. D. (1992). Journal o f Biological Chemistry 267, 5723- 
5726.
210. Shakiir, Y., Pryde, J. G. and Houslay, M. D. (1993). Biochemical Journal 292, 
677-686.
211. Shakur, Y., Wilson, M., Pooley, L., Lobban, M., Griffiths, S. L., Campbell, A. M., 
Beattie, J., Daly, C. and Houslay, M. D. (1995). Biochemical Journal 306, 801- 
809.
212. Shaulsky, G., Escalante, R. and Loomis, W. F. (1996). Proceedings o f  the 
National Academy o f Science 93, 15260-15265.
213. Shenohkar, S., Thompson, W. J. and Strada, S. J. (1985). Biochemistry 24, 672- 
678.
214. Skiba, N. P., Bae, H. and Hamm, H. E. (1996). Journal o f Biological Chenistry 
271,413-424.
215. Smith, J. K., Scotland, G., Beattie, J., Trayer, I. P., and Houslay, M. D. (1996). 
Journal o f Biological Chemistry 271, 16703-16711.
216. Soderling, S. H., Bayuga, S. J. and Beavo, J. (1998). Journal o f Biological
272
Chemistry 213, 15553-15558.
217. Soderling, S. H., Bayagu, S. J. and Beavo, J. A. (1999). Proceedings o f the 
National Academy o f Science USA 96 (2), 7071-7076.
218. Sommer, N., Loschman, P.-A., Nortiioff, G. H., Weller, M., Steinbrecher, A., 
Steinbach, J. P., Lichtenfels, R., Meyermann, R., Reithmuller, A., Fontana, A., 
Dichgans, J. and Martin, R. (1995). Nature Medicine 1, 244-248.
219. Sondek, J., Bohm, A., Lambright, D., Hamm, H. and Sigler, P. (1996). Nature 379, 
369-374.
220. Sparks, A. B., Rider, J. E., G., H. N., Fowlkes, D. M., Quilliam, L. A. and Kay, B. 
K. (1996). Proceedings o f the National Academy o f Science 93, 1540-1544.
221. Sprang, S. R. (1997). Annual Review o f Biochemistry 66, 639-678.
222. Steitz, T. A. (1998). Nature 391, 231-232.
223. Strada, S. J., Martin, M. W. and Thompson, W. J. (1984). Advances in Cyclic 
Nucleotide Research 16, 13-29.
224. Stroop, S. D. and Beavo, J. A. (1991). Journal o f Biological Chemistry 266,
273
23803-23809.
225. Stroop, S. D., Charbonneau, H. and Beavo, J. A. (1989). Journal o f Biological 
Chemistry 264, 13718-13725.
226. Su, Y., Dostinann, W. R. G., Herberg, F. W., Diirick. K., Xuong, N. H., Ten Eyck, 
L.,Taylor, S. S. and Varughese, K. I. (1995). Science 69, 807-813.
227. Su, Y., Taylor, S. S., Dostmann, W. R. G., Xuong, N. H. and Varughese, K. I. 
{\993). Journal o f  Molecular Biology 230,1091-1093.
228. Sulhvan, M., Egerton, M., Shakur, Y., Marquarsdon, A. and Houslay, M. D.
(1994). Cellular Siganlling 6, 793-812.
229. Sullivan, M., Rena, G., Begg, F., Gordon, L., Olsen, A. S. and Houslay, M. D. 
(\99S). Journal o f Biological Chemistry 333, 693-703.
230. Sunahara, R. K., Dessauer, C. W. and Gihnan, A. G. (1996). Annual Review o f  
Pharmacological Toxicology 36, 461-480.
231. Sutherland, E. W. and Rail, T. W. (1957). Journal o f the American Chemistry 
Society 79, 3608-3610.
274
232. Swinnen, J. V., Joseph, D. R. and Conti, M. (1989). Proceedings o f  the National 
Academy o f  Sciences USA 86, 5325-5329.
233. Szpirer, C., Szpirer, J., Riviere, M., Swinnen, J., Vicini, E. and Conti, M. (1995). 
Cytogenetics and Cell Genetics. 69, I I -14.
234. Taira, M., Hockman, S. C., Calvo, J. C., Belfrage, P. and Manganiello, V. C. 
(1993). Journal o f  Biological Chemistry 268,18573-18579.
235. Takemoto, D. J., Hansen, J., Takemoto, L. J. and Houslay, M. D. (1982). Journal 
o f Biological Chemistry 251, 14597-14599.
236. Takio, K., Wade, R. D., Smith, S. B., Krebs, E. G., Walsh, K. A. and Titani, K. 
(1984). Biochemistry 23, 4207-4218.
237. Tang, W. J. and Gilman, A. G. (1992). Cell 70, 869-872.
238. Tang, W. J. and Gilman, A. G. (1995). Science 268, 1769-1772.
239. Tang, W. J. and Hurley, J. H. (1998). Molecular Pharmacology 54, 231-240.
240. Tang, W. J., Stanzel, M. and Gilman, A. G. (1995). Biochemistry 34, 14563- 
14572.
27 5
241. Tang, X. and Downes, C. (1997). Journal o f  Biological Chemistry 272, 14193- 
14199.
242. Taussig, R. and Gilman, A. G. (1995). Journal o f  Biological Chemistry 270,1-4.
243. Taylor, S. S., Buechler, J. A. and Yonemoto, Y. (1990). Annual Review o f  
Biochemistry 59, 971-1005.
244. Tempel, B. L., Bonini, N., Dawson, D. R. and Quinn, W. G. (1983). Proceedings 
o f the National Academy o f Science 80, 1482-1486.
245. Tesmer, J. J. G., Sunahara, R. K., Gilman, A. G. and Sprang, S. R. (1997). Science 
278, 1907-1916.
246. Thomas, M. K., Francis, S. H. and Corbin, J. D. (1990). Journal o f Biological 
Chemistry 265, 14964-14970.
247. Thomas, M. K., Francis, S. H. and Corbin, J. D. (1990). Journal o f  Biological 
Chemistry 265, 14971-14978.
248. Thompson, W. J. and Appleman, M. M. (1971). Biochemistry 10, 311-316.
276
249. Thompson, W. J., Lavis, V. R., Whalm, M. E. and Strada, S. J. (1992). Advances 
in Second Messenger Phosphoprotein Research 25, 165-184.
250. Torphy, T. J., Bamette, M. S., Hay, D. W. P. and Underwood, D. C. (1994). 
Environmental Health Perspectives 102, 79-84.
251. Torphy, T. J., Dewolf, W., Green, D. W. and Livi, G. P. (1993). Agents and 
Actions 43, 51-71.
252. Torphy, T. J., Livi, G. P. and Cluistensen, S. B. (1993). Drug News and 
Perspectives 5,.
253. Torphy, T. J. and Undem, B. J. (1991). Thorax 149, 512-524.
254. Trong, H. L., Beier, N., Sonnenbing, W. K., S troop, S. D., Walsh, K. A., Beavo, J. 
A. and Charbonneau, H. (1990). Biochemistry 29, 10280-10288.
255. Tucker, M. M., Robinson, J. B. J. and Stellwagen, J. (1981). Journal o f Biological 
Chemistry 256, 9051-9058.
256. Unger, V., Hargrave, P., Baldwin, J. and Schertler, G. (1997). Nature 389, 203-
206.
277
257. Vorherr, T., Knopfel, L., Hofinann, F., Mollner. S., Pfeuffer, T. and Carafoli, E. 
(1993). Biochemistry 32, 6081-6088.
258. Wachtel, H. (1983). Neuropharmacology 22, 267-272.
259. Walsh, D. A. and Van Patten, S. M. (1994). The FASEB Journal 8, 1227-1236.
260. Wang, Y., Scott, J. D., McKnight, G. S. and Krebs, E. G. (1991). Proceedings o f  
the National Academy o f Science USA 88, 2446-2450.
261. Wayman, G. A., Wei, J., Wong, S. and Storm, D. R. (1996). Molecular Cell
Biology 16, 6075-6082.
262. Weber, I. T., Takio, K., Titani, K. and Steitz, T. A. (1982). Proceedings o f  the 
National Academy o f Science USA 79, 7679-7683.
263. Wei, J., Wayman, G. and Storm, D. R. (1996). Journal o f Biological Chemistry
271,24231-24235,
264. Wells, J. A. (1996). Proceedings o f the National Academy o f Science USA 93, 1-6.
265. Wells, J. N. and Hardman, J. G. (1977). Advances in Cyclic Nucleotide Research 
8, 119-143.
278
266. Wess, J. (1997). The FASEB Journal \ l ,  346-354.
267. Whisnaut, R. E., Gilman, A. G. and Dessauer, C. W. (1996). Proceedings o f the 
National Academy o f Science USA 93, 6621-6625.
268. Woodford, T. A,, Correll, L. A., McKnight, G. S. and Corbin, J. D. (1989). 
Journal o f  Biological Chemistry 264, 13321-13328.
269. Wu, H. and Parsons, J. (1993). Journal o f  Cell Biology 120, 1417-1426.
270. Wu, Z., Wong, S. T, and Storm, D. R. (1993). Journal o f  Biological Chemistry 
268,23766-23768.
271. Wyatt, T. A., Naftilan, A. J., Francis, S. H. and Corbin, J. D. (1998). American 
Journal o f Physiology 274, H448-H55.
272. Xia, Z. G. and Storm, D. R. (1997). Current Opinions in Neurohiology 7, 391-396.
273. Yan, C., Zhao, A. Z., Bentley, J. K. and Beavo, J. A. (1996). The Journal o f 
Biological Chemistry 271 (41), 25699-25706.
274. Yan, C., Zhao, A. Z , Bentley, J. K., Loughney, K., Ferguson, K. and Beavo, J. A.
279
(1995). Proceedings o f  the National Academy o f Science USA 92, 9677-9681.
275. Yan, S. Z., Hahn, D., Huang, Z. H. and Tang, W. J. (1996). Journal o f  Biological 
Chemistry 111, 10941-10945.
276. Yan, S. Z., Huang, Z. H., Andrews, R. K. and Tang, W. J. (1998). Molecular 
Pharmacology 53, 182-187.
277. Yan, S. Z., Huang, Z. H., Rao, V. D., Hurley, J. H. and Tang, W. J. (1997). 
Journal o f  Biological Chemistry 272, 18849-18854.
278. Yan, S. Z., Huang, Z. H, Shaw, R. S, and Tang, W. J. (1997). Journal o f  
Biological Chemistry 272, 12342-12349.
279. Yang, Q., Paskind, M., Bolger, G., Thompson, W. J., Repaske, D. R., Cutter, L. S. 
and Epstein, P. M. (1994). Biochemical and Biophysical Research 
Communications 205, 3, 1850-1858.
280. Yasuda, H., Lindorfer, M., Woodfork, K., Fletcher, J. and Garrison, J. (1996). 
Journal o f  Biological Chemistry 271,18588-18595.
281. Yoshimui’a, M. and Cooper, D. M. (1992). Proceedings o f the National Academy 
o f Science USA 89, 6716-6720.
280
282. Zhang, G., Liu, Y., Ruoho, A. E. and Hurley, J. H. (1997). Nature 386, 247-253.
283. Zhnmennann, G., Zhou, D. and Taussig, R. (1998). Journal o f Biological 
Chemistry 213, 19650-19655,
281
